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ABSTRACT 
 The dopamine (DAT) and serotonin (SERT) transporters are monoamine 
neurotransmitter transporters (MATs) responsible for the reuptake of dopamine (DA) or 
serotonin (5-HT) from the synapse following vesicular release, effectively regulating synaptic 
neurotransmission. Blockade of these transporters by antagonists such as psychostimulant drugs 
or transporter mutations that affect function can compromise DA or 5-HT homeostasis and 
impact fundamental brain processes including movement, emotion, behavior, motivation, and 
memory. To address these issues, my dissertation research focused on: (1) identifying and 
characterizing the cocaine binding site in DAT, (2) determining the influence of membrane 
depolarization on DAT trafficking, (3) investigating antidepressant metabolite action in an 
antidepressant-insensitive mouse model, and (4) understanding the link between the structural 
and functional changes induced by mutations in SERT associated with autism spectrum disorder.   
 Cocaine binding site in DAT – Through the development and utilization of several high 
affinity, photoactivatable cocaine ligands we identified a cocaine binding site in the core of 
DAT, a site that overlaps with the putative DA binding site, supporting a competitive mechanism 
for cocaine inhibition of DA uptake. (Chapters II-IV) 
 Influence of membrane depolarization on DAT trafficking – Trafficking of mature DAT 
to and from the cell membrane is a highly regulated process. Within this process, we 
demonstrated that membrane depolarization alone could induce a CaMKIIα- and dynamin-
dependent rapid reversible reduction in membrane DAT. (Chapter V)  
!xviii 
 Characterization of antidepressant metabolites in the blockade of 5-HT reuptake – As 
studies of the antidepressant selective serotonin reuptake inhibitors (SSRIs) have revealed 
discrepancies between acute and chronic dosing treatments, we evaluated the sensitivity of SSRI 
metabolites in a mouse model of depression and identified a role for metabolites in 
antidepressant administration that may confound study conclusions. (Chapter VI) 
 Autism-associated SERT mutations – Previously, several rare SERT coding variants were 
identified in humans with autism spectrum disorder that augment 5-HT transport function. We 
studied the structure of these variants and discovered alterations in SERT tertiary structure, 
which likely impact the catalytic activity or surface expression of SERT. (Chapter VII)   
 
!!1 
CHAPTER I 
INTRODUCTION 
Solute Carrier Superfamily of Transporters 
 Transporters are membrane-bound proteins that mediate the translocation of impermeant 
solutes across cellular membranes (Kristensen et al. 2011; Lin et al. 2015) either through passive, 
also known as facilitated, transport, where solutes move down their concentration gradient, or 
active transport, in which an ion/solute gradient is created with the help of ATP (primary active) 
or used (secondary-active) to drive transport of solutes against their concentration gradient 
(Hediger et al. 2003). Of the major transporter superfamilies, the solute carrier (SLC) 
superfamily consists of approximately 350-400 membrane-spanning transporters organized 
according to 20-25% sequence identity into 43-55 families (Hediger et al. 2003; He, Vasiliou, 
and Nebert 2009; Lin et al. 2015). This superfamily is responsible for transporting a diverse 
range of substrates including inorganic ions, amino acids, sugars, metals, neurotransmitters, 
vitamins, and fatty acids (He, Vasiliou, and Nebert 2009; Hediger 2013). Despite distinct 
substrates, SLC transporters have remarkably similar tertiary structures, as all the solved crystal 
structures reveal a 5 + 5 α-helical arrangement where transmembrane domains (TMs) 1-5 are 
aligned antiparallel to TMs 6-10 suggesting a conserved structural mechanism within the SLC 
superfamily (Forrest and Rudnick 2009; Krishnamurthy, Piscitelli, and Gouaux 2009; Abramson 
and Wright 2009; Boudker and Verdon 2010).   
The solute carrier 6 (SLC6) family of secondary active transporters is one of the largest 
SLC families and is responsible for transport of amino acids and amino acid derivatives into cells 
!!2 
by utilizing the electrochemical potential difference of Na+ across the cell membrane to couple 
‘downhill’ movement of Na+ to ‘uphill’ movement of substrate (Chen, Reith, and Quick 2004; 
Kristensen et al. 2011; Pramod et al. 2013). As this coupled transport of Na+ and substrate occurs 
in the same direction and, in some cases, is accompanied by co-transport of Cl-, the SLC6 family 
is also referred to as symporters or Na+/Cl--dependent transporters, even though some members 
exhibit counter-transport of K+ (Rudnick and Clark 1993; Rudnick 1998). This family encodes 
for a group of 20 highly similar transporter proteins that are divided into four subgroups based on 
substrate specificity and sequence similarity, namely the monoamine neurotransmitter 
transporters, the γ-aminobutyric acid (GABA) transporters, and two amino acid transporter 
branches that, in several instances, have been further subdivided into either orphan, 
neurotransmitter, or nutrient transporters (Bröer 2006; Kristensen et al. 2011; Bröer and Gether 
2012; Pramod et al. 2013). This dissertation is concerned with the subset of the SLC6 family 
known as the neurotransmitter transporters (NTT) with primary focus on the SLC6A family of 
monoamine neurotransmitter transporters (MATs), including the serotonin (SERT), 
norepinephrine (NET), and dopamine (DAT) transporters, which are responsible for reuptake of 
the biogenic monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE), or dopamine 
(DA), respectively.  
Physiological Functions and Molecular Characteristics of MATs 
MATs have an important role in the central nervous system (CNS), as their primary 
physiological function is regulation of neurotransmitter homeostasis, which is associated with 
modulation of mood, motor function, aggression, anxiety, depression, addiction, appetite, 
attention, etc. (Hahn and Blakely 2007; Ramamoorthy, Shippenberg, and Jayanthi 2011). 
Expressed in both dendrites and axons of their respective monoaminergic neurons, MATs 
!!3 
regulate neurotransmission through the reuptake of neurotransmitters from the synapse following 
vesicular release (Fig. 1a) (Torres, Gainetdinov, and Caron 2003) as well as contribute to 
neurotransmitter recycling; return of the neurotransmitter to the presynaptic neuron allows the 
secondary-active, proton-coupled vesicular monoamine antiporters, VMAT1 and VMAT2, 
which are integral membrane proteins in vesicles, to sequester neurotransmitter not yet 
enzymatically degraded by monoamine oxidases (MAOA and MAOB) (Iversen 1971; Shih, 
Chen, and Ridd 1998; Eiden et al. 2003; Blakely and Edwards 2012; Lawal and Krantz 2013). 
Importantly, as regulators of synaptic signaling, altered MAT expression and/or catalytic activity 
impact the plasticity of synaptic signaling due to dynamic changes in the number and function of 
transporters.   
 
 
Figure 1. Role of MATs in synaptic transmission. (a) Schematic representation of 
monoaminergic synaptic terminals. VMATs sequester 5-HT, DA, or NE into synaptic vesicles, 
which fuse with the membrane upon synaptic transmission releasing neurotransmitters into the 
synaptic cleft to act on post- and presynaptic receptors. MATs are crucial for termination of 
neurotransmission through rapid reuptake of neurotransmitters into the presynaptic neuron and 
are important for maintaining low neurotransmitter concentrations outside synapses. (b) 
Chemical structures of the endogenous substrates for MATs and ion coupling stoichiometry for 
neurotransmitter reuptake. (Reprinted by permission from Kristensen, Andersen, Jørgensen, 
Sørensen, Eriksen, Loland, Strømgaard, and Gether, SLC6 Neurotransmitter Transporters: 
Structure, Function, and Regulation, Pharmacol Rev 63(3): 585-640, 2011.) 
!!4 
NET 
 SLC6A2 encodes for NET, a MAT with KM values of 0.4 µM for NE and 0.7 µM for DA, 
indicating a high affinity not only for the endogenous substrate, but for DA as well (Gether et al. 
2006), which transports one substrate molecule in symport with one Na+ and one Cl- ion (Gu, 
Wall, and Rudnick 1996; Bröer and Gether 2012) (Fig. 1b). It is distributed throughout the brain, 
adrenal gland, intestine, kidney, testis, and placenta with ties to ADHD (Kim et al. 2006), 
depression (Hahn and Blakely 2007), and blood pressure regulation (Halushka et al. 1999). In 
NET knockout mice, the synaptic lifetime of NE is prolonged and the mice themselves have 
lower body weight and a decreased locomotor response to novelty (Xu et al. 2000). Furthermore, 
these mice display lower body temperature as a result of the thermoregulatory role of NE as well 
as enhanced morphine analgesia due to increased stimulation of α2-adrenoreceptors (Bohn et al. 
2000).    
DAT 
 SLC6A3 encodes for DAT, a MAT with KM values of 2.5 µM for DA and a lower affinity 
for NE, 20 µM, which transports one molecule of substrate coupled to two Na+ ions and one Cl- 
ion (Gu, Wall, and Rudnick 1994; Sonders et al. 1997; Bröer and Gether 2012) (Fig. 1b). It is 
distributed throughout the brain and has a role in ADHD (Hahn and Blakely 2007), bipolar 
disorder (Grunhage et al. 2000), Tourette syndrome (Tarnok et al. 2007), and addiction 
(Kristensen et al. 2011; Pramod et al. 2013). DAT knockout mice are dwarf (Bossé et al. 1997), 
hyperactive (Giros et al. 1996; Gainetdinov et al. 1999; Spielewoy et al. 2000), and exhibit 
cognitive deficits including disrupted sensorimotor gating (Ralph et al. 2001) and sleep 
dysregulation (Wisor et al. 2001). These physiological changes are a result of the neurochemical 
changes in which DA persists up to 300-fold longer in the extracellular space, a rate that is 
!!5 
synonymous with diffusion mediated clearance (Giros et al. 1996), thereby increasing the steady-
state extracellular DA concentration 5-fold (Giros et al. 1996; Jones et al. 1998; Gainetdinov, 
Sotnikova, and Caron 2002; Chen, Reith, and Quick 2004). Furthermore, despite normal social 
interactions in adult animals, female mice without DAT have an impaired capacity to care for 
their offspring (Giros et al. 1996). 
SERT 
 SLC6A4 encodes for SERT, a MAT with KM values of 0.45 µM for 5-HT. Furthermore, 
recent evidence suggests that SERT is also capable of transporting DA, but with lower substrate 
affinity, higher maximum velocity, and the requirement for higher Na+ and Cl- (~10- and 100-
fold, respectively) to drive transport (Larsen et al. 2011; Bröer and Gether 2012). One molecule 
of substrate is transported in symport with one Na+ and one Cl- ion followed by antiport of one 
K+ ion, which is thought to be important in outwardly rectifying the transporter (Fig. 1b) (Gu, 
Wall, and Rudnick 1996; Rudnick 1998). It is distributed throughout the brain, intestine, 
placenta, epithelium, and platelets and is linked to autism (Cook et al. 1997; Sutcliffe et al. 
2005), obsessive-compulsive disorder (Ozaki et al. 2003), anxiety (Lesch et al. 1996), and 
depression (Stahl 1998). In SERT knockout mice, the extracellular concentration of 5-HT is 
increased 6-fold while the intracellular concentration is reduced by 60-80% (Bengel et al. 1998; 
Murphy et al. 1999; Fabre et al. 2000), which leads to increased anxiety-related behaviors, 
reduced locomotor activity, and exaggerated stress responsiveness (Rudnick et al. 2013).  
MAT Structure and Mechanism of Transport 
 After cloning of MATs (Pacholczyk, Blakely, and Amara 1991; Giros et al. 1992; 
Ramamoorthy et al. 1993), but prior to solved SLC crystal structures, each MAT structure was 
probed intensively using site-directed mutagenesis, alanine scanning, cysteine accessibility, 
!!6 
hydropathy analysis, and other biochemical approaches. These techniques predicted a transporter 
topology of 12 membrane spanning domains connected by alternating extracellular and 
intracellular loops with both N- and C-termini located intracellularly (Fig. 2), but lacked the 
resolution needed to define tertiary structure. Attempts to crystallize members of the SLC6 
family were, up until very recently, stunted due to problems in obtaining pure and stable 
transporters in the large quantities needed for protein crystallization (Tate et al. 2003; Rasmussen 
and Gether 2005; Kristensen et al. 2011; Caron and Gether 2016). However, over a decade ago, 
with the advent of the first reported high-resolution X-ray crystallographic structure of a SLC6 
bacterial homolog came a much-anticipated surge in our understanding of MAT structure.  
 
 
Figure 2. Structure and topology of MATs. MATs are composed of twelve membrane 
spanning domains that are connected by alternating extracellular and intracellular loops with 
both amino (N) and carboxyl (C) termini located intracellularly.  
 
 The leucine transporter (LeuT), from the thermophile bacterium Aquifex aeolicus, is a 
prokaryotic homolog of SLC6 transporters with an overall sequence identity of roughly 20-25% 
compared to MATs, a number that increases to 50-67% when considering the core domains 
2" 3" 4" 5" 7" 8" 9" 10" 11" 12"
1a"
1b"
6a"
6b"
N""" """"""""""""""""""""""""""""""""""""C"
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involved in substrate binding (Yamashita et al. 2005; Kristensen et al. 2011). LeuT is an amino 
acid Na+-dependent symporter with specificity for the hydrophobic amino acids alanine, leucine, 
methionine, and glycine (Singh et al. 2008). Since 2005, LeuT has been crystallized in multiple 
conformations corresponding to occluded (Yamashita et al. 2005), extracellularly-facing (Singh 
et al. 2008), intracellularly-facing (Krishnamurthy and Gouaux 2012), and inhibitor-bound forms 
(Singh, Yamashita, and Gouaux 2007; Zhou et al. 2007; Zhou et al. 2009). These crystals 
provided a template from which MAT homology models were constructed, a method often put 
into practice to investigate ligand binding sites through small molecule docking and molecular 
dynamics (Beuming et al. 2008; Andersen et al. 2009; Dahal et al. 2014). However, another 
surge in structural understanding of MATs has developed in the last few years with the 
crystallization of the eukaryotic Drosophila melanogaster DAT (dDAT) (Penmatsa, Wang, and 
Gouaux 2013; Wang, Penmatsa, and Gouaux 2015; Penmatsa, Wang, and Gouaux 2015), with 
greater than 50% sequence identity to its mammalian counterparts, and, more significantly, the 
first high-resolution crystallographic MAT structure of hSERT (Coleman, Green, and Gouaux 
2016). 
 Crystal structures and biochemical data support a MAT architecture that is composed of 
an inverted-topological repeat of the first ten TMs, known as the LeuT fold, in which TMs 1-5 
and TMs 6-10 have the same overall arrangement, but are aligned antiparallel to one another 
(Fig. 3) (Yamashita et al. 2005; Forrest et al. 2008). TMs 11 and 12 however are located on the 
periphery of the 5 + 5 core, suggestive of a specific role in structure, regulation, or dimerization 
(Just et al. 2004), as 70% of prokaryotic SLC6 members lack TM12 altogether (Quick et al. 
2006). The TMs are connected by 6 extracellular and 5 intracellular loops (ELs 1-6 and ILs 1-5) 
with N- and C-termini located in the cytosol. Except for short, unwound segments in the middle
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Figure 3. Architecture of the LeuT fold. View of the 5 + 5 α-helical architecture composed of 
an inverted-topological repeat of TMs 1-5 aligned antiparallel to TMs 6-10. The central, or 
primary (S1) substrate and ion binding site is formed by TMs 1, 3, 6, and 8. Substrate and ions 
are depicted as a yellow triangle and yellow circles, respectively. (Reprinted by permission from 
Macmillan Publishers Ltd: Nature – Krishnamurthy, Piscitelli, and Gouaux 2009.)!
 
of TMs 1 and 6, the TMs are exclusively α-helical and packed into a cylindrical bundle. TMs 1, 
3, 6, and 8 form a central, or primary, substrate and ion binding site (S1) that is occluded from 
the extracellular and intracellular milieu by external and internal gates formed from side chains 
of TMs 1, 3, 6, 8, and 10 (Yamashita et al. 2005; Krishnamurthy and Gouaux 2012; Wang, 
Penmatsa, and Gouaux 2015). Two Na+ ion coordination sites lie proximal to the S1 binding site 
while Cl- binds near the Na1 site, which is consistent with coupling of these ions to substrate 
transport (Forrest et al. 2007; Zomot et al. 2007; Penmatsa, Wang, and Gouaux 2013; Coleman, 
Green, and Gouaux 2016). SERT also exhibits antiport of K+ though, to date, the K+ binding site 
is not yet elucidated. A secondary substrate, or S2, binding site, whose existence and role are 
much debated, is located above the external gate in the large extracellular vestibule (Coleman, 
Green, and Gouaux 2016).  
As LeuT has been the focus of crystallization in the past decade, for the purpose of 
deciphering MAT tertiary structure, multiple crystals have been obtained in conformations 
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corresponding to various stages of substrate translocation or those adopted upon inhibitor 
binding. For this reason, the following sections will focus primarily on LeuT crystal structure 
findings and biochemical evidence while also considering the more recent crystallization of 
dDAT and hSERT.  
S1 Binding Site 
LeuT. The substrate, or S1, binding site in LeuT is divided into a polar region that is 
formed exclusively by the unwound regions of TMs 1 and 6 and a hydrophobic pocket formed by 
the side chains of TMs 1, 3, 6, and 8 (Yamashita et al. 2005; Singh et al. 2008). The polar region 
accommodates the α-amino and α-carboxylate groups of the amino acid substrates by forming 
hydrogen bonds with the exposed main carbonyl oxygen and nitrogen atoms in the unwound 
sections of TMs 1 and 6. Furthermore, the two Na+ ions interact with these unwound regions and 
are proposed to stabilize the leucine binding site as well as the overall structure itself (Gether et 
al. 2006). The α-carboxyl group of leucine interacts with the sodium at Na1, an interaction that 
does not occur in MATs as DA, NE, and 5-HT lack a carboxyl group; however, a glycine at 
position 24 in LeuT, which is replaced by an aspartate at the corresponding position in MATs, is 
predicted to be in immediate proximity of Na1, thus likely substituting for the missing substrate 
carboxyl group. 
Of the 11 S1 residues in LeuT that coordinate leucine, 7 are conserved across all MATs 
(Kristensen et al. 2011) indicating a conserved S1 site between LeuT and MATs, consistent with 
experimental evidence where several S1 residues were identified as major determinants for 
substrate affinity (Henry et al. 2003; Beuming et al. 2006; Rudnick 2006; Henry, Meiler, and 
Blakely 2007; Kanner and Zomot 2008). 
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 MATs. As mentioned previously, attempts to crystallize MATs were unsuccessful due to 
a proposed loss in ligand binding after detergent extraction and a general resistance to 
crystallization (Penmatsa, Wang, and Gouaux 2013; Coleman, Green, and Gouaux 2016). 
However, after a thorough process of identifying and engineering thermostabilizing mutations in 
dDAT and hSERT, the lab of Eric Gouaux has identified several MAT crystal structures with 
substrate bound (Wang, Penmatsa, and Gouaux 2015) or in complex with antagonists (Penmatsa, 
Wang, and Gouaux 2013; Wang, Penmatsa, and Gouaux 2015; Penmatsa, Wang, and Gouaux 
2015; Coleman, Green, and Gouaux 2016). For the purpose of discussing the S1 binding site in 
MATs, the following will review the structures of dDAT with DA and antagonists bound in S1 
(Wang, Penmatsa, and Gouaux 2015). 
 As predicted by previous biochemical analyses and consistent with LeuT crystal 
structures (Huang and Zhan 2007; Beuming et al. 2008; Bisgaard et al. 2011; Koldsø et al. 2013), 
DA binds to a central substrate binding pocket surrounded by TMs 1, 3, 6, and 8 (Fig. 4a,b and 
5a,e). The positively charged amine group of DA interacts with the negatively charged aspartate 
on TM1 corresponding to G24 in LeuT while the catechol group interacts with residues from 
TMs 3, 6, and 8. Unlike in simulations where the DA binding site was dehydrated (Huang and 
Zhan 2007), this dDAT crystal structure elucidated a hydrogen bond network formed by two 
water molecules that link DA to Na1 (Fig. 4b), an interaction that is not duplicated in LeuT as 
the carboxylate of leucine directly coordinates Na+ at this site. However, this crystal is a 
snapshot of the transporter in an extracellularly-facing conformation; upon shifting to an 
occluded conformation, as identified by the isosteric DA analogue 3,4-dichlorophenethylamine 
(DCP) (Fig. 5b,e), there is no evidence of water molecules associating with DCP, suggesting that 
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dehydration of the binding pocket occurs with formation of an occluded state (Wang, Penmatsa, 
and Gouaux 2015).  
 
 
Figure 4. DA occupies the central, S1 binding site. (a) Surface representation of the dDAT/DA 
crystal complex viewed parallel to the membrane. DA is depicted as cyan spheres and residues 
Y124 and F319, which form an aromatic extracellular lid during translocation, are shown as cyan 
sticks on the left and right sides of DA, respectively. (b) Close-up view of the S1 binding pocket 
with DA bound. Hydrogen bonds are shown as dashed lines while sodium ions and water are 
shown as purple and red spheres, respectively. (Reprinted by permission from Macmillan 
Publishers Ltd: Nature – Wang, Penmatsa, and Gouaux 2015.) 
 
 dDAT has also been crystallized in complex with antagonists bound to S1, including 
amphetamines and cocaine (Wang, Penmatsa, and Gouaux 2015) as well as the antidepressants 
nortriptyline, (Penmatsa, Wang, and Gouaux 2013), nisoxetine, and reboxetine (Penmatsa, 
Wang, and Gouaux 2015). By comparing these structures, it is clear that S1 can accommodate 
ligands of various sizes through structural rearrangement in the unwound region of TM6 and 
positional changes of the side chains of residues F319 and F325 (Fig. 5). In the case of the 
substrates DA and amphetamine, the functional amine and aromatic groups at opposite ends 
allow for multiple interactions with residues from TMs 1, 3, 6, and 8, ultimately stabilizing the 
several conformations that occur with substrate translocation. Conversely, antagonists with 
A B 
!!12 
tropane moieties, such as cocaine, and antidepressants, which have bulky aromatic moieties, 
appear to prevent formation of an occluded structure by hindering the movement of the 
extracellular gate (Fig. 5c,f) or by blocking the overall transporter flexibility required for 
conformational changes (Fig. 5d,f). 
 
 
Figure 5. S1 accommodates high- and low-affinity interactions with various ligands. (a-d) 
Transverse sections of the S1 binding site in dDAT with DA (a), DCP (b), cocaine (c), or 
nortriptyline (d) bound. (e-f) Schematic representing the plasticity of the binding pocket in the 
presence of DCP (e), which adopts an occluded conformation as seen by the inward rotation of 
F319, cocaine (f), which binds to S1 in a manner similar to the extracellularly-facing DA bound 
structure, and nortriptyline (f), where accommodation of multiple aromatic rings is accomplished 
by orienting F319 and F325 outward. (Reprinted by permission from Macmillan Publishers Ltd: 
Nature – Wang, Penmatsa, and Gouaux 2015.) 
 
S2 Binding Site 
LeuT. The extracellular pathway, or extracellular vestibule, which forms the solvent 
accessible path from the extracellular space to the S1 site, has been argued to possess a second 
substrate binding site, designated S2 (Shi et al. 2008). S2 is separated from S1 by a hydrophobic 
lid, formed by the aromatic residues Y108 on TM3 and F253 on TM6, as well as a salt bridge, 
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Figure 6. Location of the LeuT S2 binding site in relation to S1. TMs 1, 3, 6, 8, and 10 line 
the extracellular vestibule S2 binding site which is separated from S1 via an extracellular gate, a 
water-mediated salt bridge between R30 and D404, and an aromatic lid, Y108 and F253. 
(Reprinted by permission from Kristensen, Andersen, Jørgensen, Sørensen, Eriksen, Loland, 
Strømgaard, and Gether, SLC6 Neurotransmitter Transporters: Structure, Function, and 
Regulation, Pharmacol Rev 63(3): 585-640, 2011.) 
 
created by the side chains of R30 on TM1 and D404 on TM10 (Fig. 6). Occupancy of the S2 
pocket by a second substrate molecule has been proposed to trigger conformational changes 
necessary for release of substrate from S1 into the cytosol (Shi et al. 2008; Zhao et al. 2011), a 
result that is refuted by others (Piscitelli, Krishnamurthy, and Gouaux 2010). Though no 
structures have been crystallized with a substrate molecule bound to S2, several inhibitors and 
detergents have been crystallized in this extracellular space, which allows for inhibition of 
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substrate translocation and suggests a mechanism of action for MAT inhibitors (Zhou et al. 2007; 
Singh et al. 2008; Zhou et al. 2009; Quick et al. 2009; Coleman, Green, and Gouaux 2016). 
MATs. Prior to crystallization of the first human MAT structure, biochemical evidence 
and computational studies based on LeuT co-crystallized with antagonists bound in the outer 
vestibule identified a binding site in S2 for selective serotonin reuptake inhibitors (SSRIs) (Chen 
et al. 2005; Plenge, Gether, and Rasmussen 2007) and tricyclic antidepressants (TCAs) (Sarker et 
al. 2010), both of which primarily act on SERT to block reuptake of 5-HT. Binding of an 
antagonist to the S2 site results in allosteric modulation by acting as a functional lid and 
attenuating dissociation of the inhibitor in S1, which enhances its dwell time to antagonize 
transporter function (Fig. 7) (Chen et al. 2005; Neubauer, Hansen, and Wiborg 2006; Plenge et 
al. 2012). These results were recently supported by the hSERT crystal structure (Coleman, 
Green, and Gouaux 2016). However, the S2 site may actually represent many binding sites in the 
 
Figure 7. Allosteric modulation of inhibitor binding. (a) Citalopram (dark green) binds to S1 
while a second molecule binds to S2 (b) acting as a functional lid, which slows the dissociation 
of the S1 bound inhibitor. (Reprinted by permission from Macmillan Publishers Ltd: Nature – 
Coleman, Green, and Gouaux 2016.) 
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outer vestibule that can accommodate multiple ligands, as several analogs developed recently 
appear to bind to distinct locations in S2 (Banala et al. 2013; Kumar et al. 2015; Tomlinson et al. 
in preparation). Further evaluation of these ligands should help to elucidate critical S2 residues 
involved in antagonist binding  
Debate regarding the existence of a S2 site in MATs is likely stunted due to the very 
recent crystallization of two hSERT structures: a citalopram-bound transporter with citalopram 
molecules bound in both S1 and S2 and a paroxetine-bound structure in which paroxetine is 
bound in S1 and maltose, derived from a detergent molecule, is bound in S2 (Fig. 8) (Coleman, 
Green, and Gouaux 2016). In these structures, the secondary site is defined by residues in TMs 1, 
6, 10, and 11 as well as ELs 4 and 6, regions that when mutated alter allosteric potency 
(Neubauer, Hansen, and Wiborg 2006; Zhong et al. 2009; Plenge et al. 2012) though the 
 
Figure 8. hSERT allosteric binding site. Sagittal slice through hSERT crystal structures in 
complex with citalopram (a), bound not only in S1, but in the allosteric, S2 site as well, and 
paroxetine (b), where paroxetine is bound in S1 and maltose, a sugar derivative, is bound in S2. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature – Coleman, Green, and 
Gouaux 2016.) 
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physiological mechanism is not well established (Jacobsen et al. 2014). Comparison of these two 
structures suggests that S2 is plastic, as it appears to adopt different conformations based on the 
composition of the bound molecule. This finding suggests that occupancy of S2 may inhibit or 
support transport activity depending on the size and shape of the allosteric ligand. Furthermore, 
by superimposing the S2 site identified in hSERT crystals onto the same region in dDAT, it is 
apparent that these sites are distinct, even though the S1 sites in hSERT and dDAT are 
structurally similar (Fig. 9). For instance, EL6, which was shown to contribute to the S2 site in 
 
Figure 9. Alignment of SERT and DAT. (a) Overall alignment of SERT (pink) and dDAT 
(grey) with citalopram bound to the central (green) and allosteric (cyan) sites. Regions that differ 
structurally include EL2 (b), EL4 (c), the allosteric site (d) and the C-terminus (e). (Reprinted by 
permission from Macmillan Publishers Ltd: Nature – Coleman, Green, and Gouaux 2016.) 
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hSERT, is the most diverse when comparing amino acid sequences and adopts a conformation 
unique to hSERT, consistent with SERT selective allosteric ligands that do not impact DAT or 
NET (Coleman, Green, and Gouaux 2016).  
Alternating Access Mechanism of Transport 
A transport mechanism was envisioned in the late 1950s in which substrate translocation 
was mediated by several conformations that either allowed access to the substrate binding site, 
through an outward-facing conformation or an inward-facing conformation, or occluded the 
substrate from the external or internal medium (Mitchell 1957; Wilbrandt and Rosenberg 1961). 
This model was later refined and is now widely accepted as the alternating access mechanism 
(Jardetzky 1966; Mitchell 1990) though there are several variations. One of the proposed models 
is the rocking bundle model (Forrest et al. 2008; Forrest and Rudnick 2009), which suggests that 
TMs 1, 2, 6, and 7 form a bundle that rocks in relation to the scaffold TMs 3, 4, 5, 8, and 9. 
Conversely, the hinge model (Krishnamurthy, Piscitelli, and Gouaux 2009) proposes that flexing 
movements of TMs 1 and 6 is sufficient for substrate translocation and is supported by the 
conformational rigidity of TMs 2 and 7 preventing both the external and internal gates from 
being open at the same time. The rocking bundle model, which was proposed prior to the 
crystallization of an intracellularly-facing conformation, suggested that the core TMs 1, 2, 6, and 
7 moved as a unit, but analysis of LeuT crystallized facing inward (Krishnamurthy and Gouaux 
2012), however, indicates that only a portion of the core helices move as a unit. Therefore, the 
actual mechanism may consist of some of the components proposed in each model as opening 
and closing of the extracellular and intracellular gates depends on hinge-like bending of the 
unwound regions of TMs 1 and 6 together with multiple adjustments of TMs 1, 2, 6, and 7 and 
movements of extracellular loops, particularly EL4 (Fig. 10) (Krishnamurthy and Gouaux 2012). 
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Figure 10. LeuT alternating access mechanism. Depicted are the conformational changes 
associated with substrate translocation from outward-open (a) to outward-occluded (b) followed 
by inward-open (c). TMs 1, 2, 6, and 7 as well as EL4 in particular undergo multiple adjustments 
when transitioning from an extracellularly-facing conformation to an intracellularly-facing 
conformation. (Reprinted by permission from Macmillan Publishers Ltd: Nature – 
Krishnamurthy and Gouaux 2012.) 
 
MAT Pathophysiology and Polymorphisms 
 The crystal structures and biochemical evidence detailed above allow us to understand 
more about transporter structure and function as well as provide insight into pathophysiology. 
For example, genetic variation in MATs, either through single nucleotide polymorphisms (SNPs) 
or variable number of tandem repeats (VNTRs), has been implicated in a wide spectrum of 
neurological and neuropsychiatric disorders due to the identification of human SLC6 MAT 
polymorphisms that lead to altered transporter expression, function, or regulation. Understanding 
the correlation between genetic perturbation of MATs and phenotypes in physiology and 
pathophysiology has the potential to elucidate improved pharmacotherapies. Therefore, the 
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following sections will highlight the predominant genetic changes in MATs identified in disease 
states.      
NET 
 Depression is thought to involve the noradrenergic, dopaminergic, and serotonergic 
systems. NET has been implicated because levels of NET are decreased in individuals with 
major depressive disorder (Klimek et al. 1997). NET is also the target of amphetamines used to 
treat ADHD and is important in attention, vigilance, learning, memory, and stress (Biederman 
and Spencer 1999; Heim and Nemeroff 2001; Hahn et al. 2009). SNPs have been identified in 
non-coding, promoter, and coding regions of the SLC6A2 gene (Hahn and Blakely 2007; Pramod 
et al. 2013) and are linked to several disorders and disease states.  
 Orthostatic intolerance (OI), a disorder characterized by an increase in resting heart rate 
not accompanied by hypotension (Robertson 1999), was linked to NET dysfunction after a 
patient with OI demonstrated standing-induced decreased NE clearance and decreased 
intraneuronal metabolism of NE (Jacob et al. 1999). Genetic analysis revealed an individual 
heterozygous for a nonsynonymous SNP, in which a highly conserved Ala in TM9 was 
converted into a Pro (A457P) (Shannon et al. 2000), a mutation that was significantly correlated 
with increased standing-induced heart rate and plasma NE. Co-expression of NET with the NET 
A457P mutant resulted in loss of NE transport likely due, in part, to decreased surface expression 
exerted by the dominant-negative effect of A457P NET in complex with wild-type NET 
(Shannon et al. 2000; Hahn, Robertson, and Blakely 2003). These findings suggest that 
heterozygous mutations may have a broader impact than homozygous mutations due to the 
additional dominant-negative effect (Hahn and Blakely 2007) and that the phenotype of elevated 
standing heart rate may be linked to NET dysfunction. 
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In studies of populations with altered cardiovascular phenotypes, including extreme 
blood pressure or long QT syndrome (Halushka et al. 1999; Iwasa et al. 2001), NET variants 
A369P in EL4 and N292T in EL3 were identified. The A369P mutant generated a total loss of 
DA and NE transport associated to its complete loss of surface expression whereas N292T 
resulted in a 50% loss of transport matched by a similar reduction in expression (Hahn, Mazei-
Robison, and Blakely 2005; Hahn and Blakely 2007). As both mutants altered total and surface 
levels of hNET when coexpressed, these findings support that intracellularly retained or 
mistargeted mutant transporters exert dominant-negative effects on the expression and activity of 
wild-type transporters through the formation of oligomers (Hahn, Robertson, and Blakely 2003; 
Sitte, Farhan, and Javitch 2004). 
DAT 
As dopaminergic systems mediate motor activity, cognition, reward, attention, 
motivation, and mood (Giros and Caron 1993; Carlsson 1987; Koob, Sanna, and Bloom 1998; 
Björklund and Dunnett 2007; Palmiter 2008), DAT polymorphisms within coding, non-coding, 
and promoter regions of the SLC6A3 gene have been implicated in ADHD, ASD, bipolar 
disorder, drug abuse, schizophrenia, Parkinson disease, and Tourette syndrome (Nieoullon 2002; 
Thapar, O’Donovan, and Owen 2005). Genetic variation in DAT was recently shown to increase 
connections between frontal, parietal, and striatal nodes in a manner that correlated with 
elevations in impulsivity and inattention, two prominent traits of both ADHD and ASD (Gordon 
et al. 2012). Furthermore, identification of mutation A559V, located in TM12 of DAT, in two 
male siblings with ADHD (Mazei-Robison et al. 2005; Mazei-Robison et al. 2008), in a patient 
with bipolar disorder (Grunhage et al. 2000), and in two subjects with ASD (Bowton et al. 2014), 
supports a shared pathophysiology in these disorders.  
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A559V was found to decrease DAT-mediated, amphetamine-induced DA efflux without 
impacting normal DAT transport function (Mazei-Robison et al. 2005), though under basal 
conditions A559V supports anomalous DA efflux (Mazei-Robison et al. 2008). It was later 
discovered that the efflux properties of this mutant might be regulated through the D2 
autoreceptor (Bowton et al. 2010). Interestingly, though the DAT substrate amphetamine 
(AMPH) binds hDAT A559V (Mazei-Robison et al. 2008; Bowton et al. 2010), it is not an 
efficiently transported substrate in relation to the wild-type transporter (Bowton et al. 2014). 
AMPH also causes reduced DAT surface expression (see chapter five) (Saunders et al. 2000; 
Kahlig et al. 2006), a mechanism that is not apparent in A559V likely due to the lack of 
intracellular accumulation of AMPH (Bowton et al. 2014), as this is required to cause DAT 
redistribution from the membrane (Kahlig et al. 2006). Finally, DAT trafficking is modulated by 
PKCβ-dependent D2 activation (Chen et al. 2013) and, in A559V, inhibition of PKCβ restored 
AMPH-induced trafficking suggestive of a role for PKCβ activity in the A559V trafficking 
deficits (Bowton et al. 2014). In combination, these insights could shed light on the underlying 
dysregulations that are shared by ADHD, bipolar disorder, and ASD.  
SERT 
The role of SERT and 5-HT is broad, contributing to sleep, cognition, mood, aggression, 
appetite, and sexual and motor activity (Coccaro 1989; Hahn and Blakely 2007). Disturbances in 
serotonergic signaling by non-coding VNTRs as well as rare coding variants have been 
implicated in anxiety, depression, ASD, gastrointestinal disorders, ejaculatory disorders, obesity, 
and OCD (Owens and Nemeroff 1994; Gershon 2005; Wolters and Hellstrom 2006; Kristensen 
et al. 2011).  
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Located in the SLC6A4 promoter, 5-HTTLPR is an insertion/deletion polymorphism of 
two 22-base pair repeat elements located approximately 1 kb upstream of transcription initiation 
that gives rise to what has been termed the short (S) allele consisting of 14 repeats or the long (L) 
allele consisting of 16 repeats (Lesch et al. 1996; Kristensen et al. 2011; Kenna et al. 2012). 
SERT expression is modulated by variation in the length of this promoter region with the L allele 
conferring threefold greater basal transcriptional activity (Heils et al. 1996; Heils, Mössner, and 
Lesch 1997; Nakamura et al. 2000). Due to decreased transcription, the S allele of 5-HTTLPR, 
also known as the “risk allele”, has been associated with anxiety-related personality traits (Lesch 
et al. 1996; Holmes, Murphy, and Crawley 2003), major depressive disorder (Clarke et al. 2010; 
Kiyohara and Yoshimasu 2010), bipolar disorder (Anguelova, Benkelfat, and Turecki 2003; Cho 
et al. 2005), and a predisposition for poor response to treatment with SSRIs (Serretti et al. 2007). 
Conversely, the L allele is linked to OCD (Bloch et al. 2008), completed suicide (Du et al. 1999; 
Du et al. 2001), and ADHD (Seeger, Schloss, and Schmidt 2001; Retz et al. 2008; Thakur et al. 
2010). In combination, it is apparent that the 5-HTTLPR polymorphism and its effects on 
expression predisposes individuals to several disorders, though it is important to consider 
epigenetic factors as well as how the influence of the S and L alleles may vary based on stimulus 
intensity and previous experience (Hahn and Blakely 2007; Kenna et al. 2012).  
Several studies have identified rare, nonsynonymous genetic variants in the SERT gene 
that affect transport function. A screen of 450 individuals discovered the SNP I425V (Glatt et al. 
2001) that was later linked to OCD by identification in seven subjects from two families, 
tracking the allele (as well as the 5-HTTLPR L allele) with diagnoses of OCD or OC personality 
disorder in six out of the seven individuals (Ozaki et al. 2003). Heterologous expression of this 
mutation showed enhanced 5-HT transport either through constitutive activation normally 
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supported by PKG stimulation (Kilic, Murphy, and Rudnick 2003) or elevated surface SERT 
density (Prasad et al. 2005). Relatedly, a genetic study of 341 ASD-associated families in 2005 
identified five SNPs located in the coding region of SERT that, similar to I425V, resulted in 
elevated transport relative to wild-type SERT (Sutcliffe et al. 2005). The two mutations located 
on the N- and C-termini, G56A and K605N respectively, are insensitive to regulation through the 
PKG and p38 MAPK pathways suggesting that transport is elevated due to enhanced catalytic 
activity (Sutcliffe et al. 2005; Prasad et al. 2005). Conversely, the three transmembrane domain 
variants, I425L, F465L, and L550V, affect 5-HT transport as a result of elevated surface SERT 
density (Prasad et al. 2009). All mutants, but K605N, had a significant association with rigid 
compulsive behaviors in 120 autistic families with linkage at 17q11.2, the SLC6A4 locus, 
suggesting a link between a gain-of-function SERT phenotype and ASD. The functional and 
structural impact of these SNPs will be discussed further in chapter seven.        
MAT Pharmacology and Therapeutic Intervention  
 The association of MATs with the disorders and diseases discussed above has made them 
important pharmacotherapeutic drug targets for decades. In addition, MATs are the primary 
targets for several psychostimulant drugs of abuse.  
Antidepressants 
 The development of the TCA imipramine in the early 1950s (Azima and Vispo 1958; 
Kuhn 1958) provided a breakthrough in treatment of depression and an understanding of the 
underlying mechanism of action of antagonism of SERT and NET function (Pacholczyk, 
Blakely, and Amara 1991; Ramamoorthy et al. 1993). However, severe side effects resulting 
from the broad action of TCAs on SERT, NET, and several other classes of receptors, including 
muscarinic, histaminergic, and α-adrenergic receptors (Owens et al. 1997; Iversen 2000; Gillman 
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2007), spurred the development of a new generation of antidepressants with improved selectivity 
(Kaiser and Setler 1981). These include compounds selectively targeting SERT (SSRIs) such as 
citalopram, fluoxetine, and paroxetine (Wong and Bymaster 1995), compounds selectively 
targeting NET (selective norepinephrine reuptake inhibitors, NRIs) such as reboxetine (Andersen 
et al. 2009), and compounds targeting both SERT and NET (serotonin-norepinephrine reuptake 
inhibitors, SNRIs) such as venlafaxine (Wong and Bymaster 2002). Though originally designed 
to treat major depressive disorder, antidepressants have also been efficacious for treatment of 
anxiety, OCD, ASD, and eating disorders (Cook and Leventhal 1996; Hollander et al. 2004; 
Bröer and Gether 2012).  
Several antidepressants require molecular recognition in hSERT by the S1 residues Tyr-
95 in TM1 and Ile-172 in TM3 to bind with high affinity (see chapter six) (Barker et al. 1998; 
Henry et al. 2006; Thompson et al. 2011). For example, by using human and drosophila SERT 
chimeras (Barker et al. 1998), the combined mutation of Y95F and I172M decreased the potency 
of racemic citalopram (a mix of both R- and S-isomers of citalopram) by ~10,000 fold (Henry et 
al. 2006), suggestive of a high affinity antidepressant binding site in S1. However, as affinity of 
citalopram for SERT is not completely abolished by these mutations, it was proposed that an 
additional binding site exists. This hypothesis was recently confirmed by the crystallization of 
hSERT in complex with citalopram bound in S1 as well as in an allosteric S2 site (Coleman, 
Green, and Gouaux 2016).  
Cocaine 
 The recreational drug cocaine is a rapidly acting, non-selective, and moderate affinity 
inhibitor of all three MATs (Eshleman et al. 1999). However, the stimulatory and rewarding 
properties of cocaine result from binding to DAT and inhibiting DA reuptake (Giros et al. 1996; 
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Chen et al. 2006). This cocaine-mediated inhibition of DA reuptake has been proposed to occur 
by both competitive (see chapters two, three, and four) (Beuming et al. 2008; Bisgaard et al. 
2011; Dahal et al. 2014) and noncompetitive mechanisms (Huang, Gu, and Zhan 2009; Hill et al. 
2011; Merchant and Madura 2012; Schmitt, Rothman, and Reith 2013). More specifically, the 
abuse liability of cocaine and cocaine-like antagonists is related to binding affinity and 
selectivity (Heikkila, Cabbat, and Duvoisin 1979; Kuhar, Ritz, and Boja 1991; Newman and 
Kulkarni 2002; Newman and Katz 2009) as well as rate of drug entry into brain (Kimmel et al. 
2008) and occupancy of DAT (Lindsey et al. 2004).  
 Because of the increase in synaptic dopamine levels, it was originally assumed that all 
DAT antagonists would elicit behavioral effects similar to those of cocaine; that is, besides a 
difference in potency, each drug would be readily self-administered, produce strong 
psychomotor stimulation, and be highly addictive (Ritz et al. 1987; Bergman et al. 1989; Cline et 
al. 1992; Katz, Izenwasser, and Terry 2000). However, several atypical DAT antagonists do not 
produce the same increase in self-administration or locomotor stimulation as most DAT 
inhibitors (Carroll et al. 2009; Vosburg et al. 2010). In particular, the piperazine-based 
compound GBR12909 in comparison to cocaine exhibits increased affinity for and slower 
dissociation from DAT resulting in prolonged duration of DAT inhibition (Rothman et al. 1991). 
However, the drug has a slower onset to block DAT and mice pre-treated with GBR12909 
displayed decreased self-administration of cocaine (Baumann et al. 1994; Glowa et al. 1995; 
Tella 1995) likely due to the reduced ability of cocaine to increase extracellular DA (Rothman et 
al. 1991). Though originally a promising cocaine-abuse pharmacotherapy, it prolonged the QTc 
interval in Phase II clinical trials of cocaine-experienced subjects (Vocci, Acri, and Elkashef 
2005), suggestive of inhibition of a voltage-gated potassium channel (Tang et al. 2001). Analysis 
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of several benztropine analogs, a related class of atypical DAT antagonists, identified 
compounds with high affinity and selectivity for DAT though treatment attenuated 
hyperlocomotor activity and decreased drug discrimination in rats trained to recognize cocaine 
from saline (Rothman et al. 2008), indicating their potential as cocaine-abuse therapeutics. 
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CHAPTER II 
COMPUTATIONAL AND BIOCHEMICAL DOCKING OF THE IRREVERSIBLE 
COCAINE ANALOG RTI 82 DIRECTLY DEMONSTRATES LIGAND POSITIONING 
IN THE DOPAMINE TRANSPORTER CENTRAL SUBSTRATE-BINDING SITE 
  
Introduction 
         The dopamine transporter (DAT) is a presynaptic plasma membrane protein that is 
responsible for driving the reuptake of dopamine (DA) from the synapse following its vesicular 
release. This activity controls the magnitude and duration of dopaminergic neurotransmission by 
maintaining synaptic DA homeostasis (Nianhang Chen and Reith 2004; Gether et al. 2006; 
Torres and Amara 2007) and is critical for proper functioning of the nervous system (Giros et al. 
1996). Dysfunction of DAT is hypothesized to contribute to dopaminergic disorders such as 
schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum 
disorder, Tourette syndrome, Parkinson disease, and hereditary DAT deficiency syndrome 
(Gether et al. 2006; Torres and Amara 2007; Hahn and Blakely 2007; Pramod et al. 2013; 
Gainetdinov and Caron 2003; Kurian et al. 2011). Many drugs such as bupropion and 
methylphenidate that bind to DAT and inhibit transport are used therapeutically to regulate 
dopaminergic signaling in disease states, whereas others such as cocaine induce psychomotor 
stimulation and addiction. Many but not all uptake blockers are reinforcing, and some such as the 
benztropines can counteract a number of cocaine's behavioral effects (Desai et al. 2005; 
Velázquez-Sánchez et al. 2010; Loland et al. 2008). This suggests the potential for development 
of improved pharmacotherapies for drug abuse and other DA disorders, but despite years of 
!!28 
research, the molecular basis by which structurally distinct inhibitors interact with DAT and 
induce differential neurochemical and behavioral outcomes remains incompletely understood. 
DAT and the related cocaine-sensitive norepinephrine and serotonin transporters (NET 
and SERT) belong to the neurotransmitter sodium symporter (NSS) subfamily of solute carrier 6 
transporters (SLC6A) that share a common topology of 12 transmembrane (TM) domains 
connected by extracellular (EL) and intracellular (IL) loops (Pramod et al. 2013; Kristensen et al. 
2011; Bröer and Gether 2012). Solute translocation is driven by a Na+- and Cl−-dependent 
alternating access mechanism in which the proteins cycle through outwardly and inwardly facing 
conformations that bind and release substrates on opposite sides of the membrane (Forrest et al. 
2008). Major insights into structural mechanisms of NSS proteins have come from the 
homologous prokaryotic leucine transporter (LeuT) from Aquifex aeolicus, which has been 
crystallized in conformations corresponding to outwardly facing, occluded, inwardly facing, and 
inhibitor-bound forms (Yamashita et al. 2005; Zhou et al. 2007; Zhou et al. 2009; Singh, 
Yamashita, and Gouaux 2007; Singh et al. 2008; Krishnamurthy and Gouaux 2012). These 
structures reveal that outwardly facing transporters possess an aqueously accessible external 
vestibule that opens to a compact central/primary substrate-binding site (S1) composed of 
residues from TM domains 1, 3, 6, and 8 (Yamashita et al. 2005). Binding of substrate, two Na+ 
(Na1 and Na2) ions, and one Cl− ion to their respective sites triggers conformational changes 
leading to closure of an extracellular gate that occludes S1, followed by opening of the 
intracellular gate and generation of an inwardly facing form that releases solutes to the cytoplasm 
(Forrest et al. 2008; Watanabe et al. 2010; Faham et al. 2008; Gabrielsen et al. 2012; Felts et al. 
2014; Henry et al. 2011; Zdravkovic et al. 2012; Zhao et al. 2011; C. Zhao et al. 2012; Caplan, 
Subbotina, and Noskov 2008; Koldsø et al. 2011). The S1 site is highly conserved in mammalian 
!!29 
transporters, and mutagenesis of many DAT residues near this site, including Phe-76, Asp-79, 
Val-152, Phe-155, Tyr-156, Asn-157, Phe-319, Val-327, and Ser-421, reduces dopamine 
transport (Kitayama et al. 1992; Lin et al. 1999; Lin, Wang, and Uhl 2000; Chen, Vaughan, and 
Reith 2001; Zhicheng Lin and Uhl 2002; Beuming et al. 2008; Henry et al. 2006; Lee et al. 
2000), supporting the participation of these amino acids in substrate recognition or translocation. 
In particular, Asp-79 in TM1 of DAT and the homologous Asp residues in NET and SERT 
coordinate the positive charge on monoamine substrates and play an essential role in transport 
(Pramod et al. 2013; Kristensen et al. 2011; Bröer and Gether 2012; Yamashita et al. 2005; 
Barker et al. 1999; Penmatsa, Wang, and Gouaux 2013). However, a second, highly 
controversial substrate site (S2) proposed to play a role in the initiation of transport has been 
identified in LeuT in the extracellular vestibule above the outer gate (Zhao et al. 2011; Piscitelli, 
Krishnamurthy, and Gouaux 2010; Quick et al. 2009; Wang, Elferich, and Gouaux 2012). The 
S2 site may also be conserved in mammalian NSS transporters, but its existence and role in NSS 
function remain a topic of debate. 
Intensive efforts to understand the basis for cocaine interaction with DAT, NET, and 
SERT have relied on site-directed mutagenesis (SDM), substituted cysteine accessibility method 
(SCAM) (Henry et al. 2003; Ferrer and Javitch 1998; Sen et al. 2005; Chen, Sachpatzidis, and 
Rudnick 1997), and quantitative structure activity relationship (QSAR) of ligand 
pharmacophores (Carroll et al. 1991; Carroll et al. 1994). Many studies support the formation of 
a salt bridge between the conserved Asp residue in the unwound region of TM1 and the 
positively charged tropane nitrogen of cocaine, suggesting that cocaine binds near S1 and 
competes with substrate for interaction at this crucial site (Kitayama et al. 1992; Beuming et al. 
2008; Henry et al. 2006; Henry et al. 2003; Chen, Sachpatzidis, and Rudnick 1997; Carroll et al. 
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1992). Numerous other residues, including Leu-104, Phe-105, Ala-109, Asn-157, Tyr-251, Tyr-
273, Thr-315, Ser-320, Thr-455, and Ser-459 found throughout core TM domains of DAT, have 
also been implicated in the binding of cocaine and its analogs (Beuming et al. 2008; Wu and Gu 
2003; Chen, Han, and Gu 2005; Itokawa et al. 2000; Bisgaard et al. 2011), but it has been 
difficult to unambiguously assign antagonist binding functionalities based on mutation-based 
strategies due to potential indirect effects on protein structure. Overlap of high affinity inhibitor 
binding with the S1 site is supported by biochemical studies (Henry et al. 2006; Henry et al. 
2003; Chen, Sachpatzidis, and Rudnick 1997; Andersen et al. 2009) and by recent structures of 
Drosophila (d) DAT and a LeuT/SERT hybrid co-crystallized with antidepressants (Penmatsa, 
Wang, and Gouaux 2013; Wang et al. 2013). However, some DA transport inhibitors lack the 
charged nitrogen necessary to form the salt bridge with Asp-79 (Ukairo et al. 2005; Madras et al. 
1996; Meltzer et al. 1997), suggesting that inhibitor binding can occur without this interaction 
and thus may not be limited to the S1 pocket (Plenge et al. 2012). This possibility is supported by 
crystal structures of LeuT complexed at relatively low affinity with several selective serotonin 
uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in regions that overlap with S2 
(Zhou et al. 2007; Zhou et al. 2009; Singh, Yamashita, and Gouaux 2007; Wang et al. 2013). 
However, as yet no crystal structures of NSS transporters complexed with cocaine have been 
obtained to distinguish between these possibilities, and many unknowns remain regarding the 
mechanistic relationship of S1 and S2 sites to each other and to the actions of cocaine and other 
categories of transport inhibitors. 
In this study, we investigated the site of cocaine binding on DAT by combining the 
strategies of comparative modeling, small molecule docking, molecular dynamics, peptide 
mapping, and SCAM protection to identify the attachment site for the irreversible cocaine analog 
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[125I]3β-(p-chlorophenyl)tropane-2β-carboxylic acid, 4′-azido-3′-iodophenylethyl ester ([125I]RTI 
82) (Fig. 11) (Carroll et al. 1992). RTI 82, cocaine, and the commonly used cocaine analog (−)-
2β-carbomethoxy-3β-(4-fluorophenyl)tropane (CFT) share a common pharmacophore consisting 
of the tropane ring and 3β-phenyl group that direct high affinity binding (Carroll et al. 1991; 
Carroll et al. 1994). All of these compounds bind noncovalently to DAT, but [125I]RTI 82 
contains a photoactivatable 4′-azido-3′-iodophenylethyl ester (AIP) moiety that forms a highly 
reactive singlet nitrene that reacts with C–H or N–H groups when the sample is irradiated with 
ultraviolet light, thus forming a covalent bond with the protein (Geurink et al. 2012; Kotzyba-
Hibert, Kapfer, and Goeldner 1995). Using irreversible labeling as a strategy for determining the 
site of ligand-protein interaction, we previously demonstrated that [125I]RTI 82 cross-links to 
human (h) DAT within a 40-residue region encompassing TM6 (Vaughan et al. 2007). Utilizing 
this information as a molecular constraint in flexible docking of RTI 82 to rat (r) DAT homology 
models based on “outward-occluded” and “open-to-out” LeuT crystal structures (Protein Data 
Bank codes 2A65 and 3F3A), we identify RTI 82 binding in the S1 pocket in an orientation that 
suggests TM6 residue Phe-319 as the likely site of AIP adduction. This prediction was verified 
by focused mapping of the [125I]RTI 82 attachment site using methionine substitution 
mutagenesis and cyanogen bromide (CNBr) digestion and by SCAM analyses that indicate 
protection of S1 but not S2 residues by cocaine and RTI 82. These positive function findings 
physically localize the tropane pharmacophore to the S1 site in transport-competent mammalian 
transporters and provide information crucial for refinement and experimental verification of 
results obtained by homology modeling. 
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Figure 11. Chemical structures of cocaine, CFT, and RTI 82. A, structure of cocaine 
highlighting the tropane ring 2β-methyl ester and 3β-phenyl ester (stars). B, structure of CFT 
showing phenyl fluoride moiety appended directly to the 3β position of the tropane 
pharmacophore. C, structure of [125I]RTI 82 showing substitution of 3β-phenyl chloride moiety 
and 2β-phenyliodoazido moiety on the tropane pharmacophore. The N3 group undergoes 
covalent adduction to the protein upon irradiation with UV light. 
  
Methodology 
Comparative DAT Homology Model Construction 
The three-dimensional coordinates from the outward-occluded and open-to-out crystal 
structures (Protein Data Bank IDs 2A65 and 3F3A, respectively) of the LeuT from A. aeolicus 
(Uniprot accession number O67854), were mapped onto rDAT sequence based on the 
comprehensive sequence alignment from Beuming et al. (Beuming et al. 2006) to construct the 
occluded and outward facing homology models of rDAT. The missing atomic densities in the 
loop regions of the transporter were rebuilt using the kinematic closure method (Mandell, 
Coutsias, and Kortemme 2009) in Rosetta3.1 (Leaver-Fay et al. 2011). The N and C termini, 
which are missing in LeuT, were truncated in the rDAT model to yield a structure consisting of 
amino acids 65–601, which includes TMs 1–12. Side chains for all residues in the protein were 
built using Rosetta's Metropolis Monte Carlo rotamer search algorithm (Kuhlman et al. 2003). 
The starting rDAT model was subjected to six iterative rounds of relaxation and minimization 
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using Rosetta3.1 to produce an ensemble of 100 rDAT models each for 2A65 and 3F3A. The top 
10 ranked models based on the Rosetta Etotal score for each template were verified manually and 
carried forward for docking. 
RosettaLigand Docking 
The three-dimensional structure for the RTI 82 ligand was built using “builder” of the 
Molecular Operating Environment (Chemical Computing Group, Inc. 2012) program and 
energy-minimized and was output as a mol file. The mol file was used as input for Rosetta3.1 to 
generate 1000 RTI 82 rotamers. The ligand parameter file, which assigns Rosetta atom types to 
the molecule for use in RosettaLigand 3.1 (RL), was generated using the Rosetta3.1 script 
“molfile_to_params.py”. Because of the multiple resonance states of the azide group and lack of 
an available parameterized force field for this chemical group, we utilized the atom type Nhis 
which was assigned to the azide nitrogens by Rosetta. Manually changing the atom types to 
Nhis-Nlys-Nlys, Nhis-NH2O-NH2O, Nlys-Nlys-Nlys, or Ntrp-Ntrp-Ntrp to test other bond 
hybridization and charge states resulted in markedly poorer docking energy scores. For the 
ensemble of 10 rDAT models built from the LeuT 2A65 structure, the collection of 1000 RTI 82 
conformers was randomly docked into the structures using RL (Meiler and Baker 2006). For 
more information regarding the RL docking protocol, see Combs et al. (Combs et al. 2013). 
Briefly, RTI 82 was placed at a coordinate in the rDAT model equivalent to the substrate-binding 
site in LeuT and allowed to randomly translate within a 10-Å sphere. Acceptable ligand 
translations underwent up to 1000 random rotations to energetically optimize the pose and 
minimize clashes. Residue side chains within 6 Å of RTI 82 were repacked using a Metropolis 
Monte Carlo simulated annealing algorithm and scored using the knowledge-based Rosetta 
energy function interface_delta, which is the difference between the total binding energy 
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E(transporter + ligand) and the sum of the energy of the individual components E(transporter) + E(ligand) 
separated by 500 Å. A total of 25,000 ligand dockings were conducted for the 10 models from 
2A65. The process was repeated for 3F3A-based models. 
The resulting rDAT-RTI 82 complexes were ranked based on the interface_delta scores, 
and the top 10% of each of the 10 rDAT structures was compiled and evaluated by ligand-based 
r.m.s.d. clustering (Combs et al. 2013). The top scoring 10% rDAT-RTI 82 complexes were 
evaluated by two methods as follows: 1) complexes found in the largest r.m.s.d.-based clusters 
were ranked by score, and 2) rDAT-RTI 82 complexes were filtered for RTI 82 poses with the 
azido moiety within 5 Å of residues of TM6 and the tropane nitrogen within 5 Å of residue Asp-
79. 
Induced Fit Docking 
The top Rosetta rDAT homology models of the 3F3A and 2A65 templates were modified 
to include two Na+ ions and one Cl− ion in their reported positions (Yamashita et al. 2005; 
Forrest et al. 2007) using Maestro (Schrödinger, LLC, Portland, OR). The protein was relaxed, 
optimized for hydroxyl and thiol groups, and minimized using default options in the protein 
preparation module of the Maestro software package (Maestro Schrödinger, LLC, Portland, OR). 
RTI 82 conformers were generated using the LIGPREP (Version 2.5) protocol. RTI 82 
conformers were docked into the rDAT homology models containing Na+ and Cl− ions utilizing 
induced fit docking (IFD) protocol (Sherman et al. 2006). As the Na+ and Cl−ions were relaxed 
during the IFD analysis, we verified that the ions remained coordinated by the same side chains 
before and after docking. The final ranking of the docked poses comes from the composite score, 
which is GlideScore + 0.05 × PrimeEnergy. 
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Molecular Dynamic Simulations 
Molecular dynamic simulations (GROMACS) were conducted on RTI 82 docked rDAT 
homology models with incorporated Na+ and Cl− ions. The top ranked RTI 82 docked rDAT 
poses were embedded in the center of a pre-equilibrated 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC) lipid bilayer (along the z axis, coinciding with the normal of the 
POPC bilayer) using Visual Molecular Dynamics package (Humphrey, Dalke, and Schulten 
1996). The dimensions of the simulation box were 20 × 20 × 14 Å containing one protein, one 
ligand, ~50,000 TIP3P water molecules, and ~225 POPC molecules. 186 Na+ and 188 Cl− 
counter-ions were added to obtain electroneutrality for the system reaching a salt concentration 
of 150 mM. All simulations were carried out with GROMACS version 4.5.4 (Hess et al. 2008) 
using CHARMM27 force field under periodic boundary conditions. SwissParam (Zoete et al. 
2011) was used to generate RTI 82 topology and parameter files, based on the Merck molecular 
force field, that are compatible with CHARMM and GROMACS. Isothermal-isobaric ensemble 
with velocity scaling (V-rescale) thermostat and Parrinello-Rahman barostat was used to perform 
simulations. For the CHARMM force field operating in GROMACS, electrostatics were 
calculated using particle mesh Ewald (Darden, York, and Pedersen 1993) with appropriate 
cutoffs as follows: rlist = 1.3; rcoulomb = 1.3; rvdw = 1.2; vdwtype = switch; and rvdw_switch = 
0.8. Fourier spacing of 0.12 nm and a particle-mesh Ewald electrostatic order of 4 was 
employed. V-rescale thermostat with a coupling constant of 0.1 ps was used to separately couple 
protein, lipid, and solvent, including water and ions. The pressure was coupled using the 
Parrinello-Rahman algorithm at 1 bar with a coupling constant of ρ = 1 ps, using a uniform 
compressibility of 4.5 × 10−5 bar−1. The coordinates were saved every 100 ps with an integration 
time step of 2 fs. The LINear Constraint SolVer (LINCS) algorithm was used to restrain all bond 
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lengths (Hess et al. 1997). The minimized, ion-bound rDAT-RTI 82 complexes in the POPC 
bilayer were further equilibrated for 4 ns in GROMACS at a temperature of 303 K, by fixing the 
position of the docked complex through application of position restraints of 1000 kJ·mol−1·nm−2 
on each heavy atom, whereas lipids and water were allowed to move normally. After an initial 
equilibration for 4 ns, the production runs were performed for 60 ns. The pressure was 
maintained at 1 atm using semi-isotropic pressure coupling to a Parrinello-Rahman barostat with 
a coupling constant of 5 ps. Conformations resulting from the production phase of each 
simulation were stored at intervals of 100 ps and analyzed. PyMOL (Delano 2013) was used to 
generate the molecular graphic diagrams. 
Cell Culture and Site-directed Mutagenesis 
For photoaffinity labeling experiments, WT and mutant cDNAs in pcDNA3.1/His vector 
were stably expressed in Lewis lung carcinoma-porcine kidney (LLC-PK1) cells. All mutants in 
the study were generated using the Stratagene QuikChange® kit and verified by sequencing 
(Northwoods DNA, Solway MN, Eurofins MWG Operon, Huntsville, AL). Mutants for SCAM 
analysis were generated in the E2C background (C90A and C305A) of pcDNA3-rDAT and 
expressed transiently in HeLa or HEK-GripTite cells (Invitrogen) using Lipofectamine® 2000 
(Invitrogen) or TransIT®-LT1 (Mirus). WT and mutant r/hDAT cells were maintained in a 
humidified chamber with 5% CO2 at 37 °C in α-minimum essential medium (AMEM: 5% fetal 
bovine serum, 2 mM L-glutamine, 200 µg/ml G418, and 100 µg/ml penicillin/streptomycin) for 
LLC-PK1 cells or Dulbecco's modified Eagle's medium (DMEM: 10% FBS, 100 units/ml 
penicillin G, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B) for HeLa and GripTite 
cells (600 µg/ml G418). Once plated, the S321M line was grown at 29 °C for better expression 
of mature DAT. 
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[3H]Dopamine Uptake and [3H]CFT Binding Assays 
WT and mutant His-hDAT LLC-PK1 cells were grown in 24-well plates to 80–90% 
confluency. For [3H]DA uptake, cells were rinsed twice with 500 µl of 37 °C Krebs-
Ringer/HEPES buffer (KRH: 25 mM HEPES, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 
1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4). Uptake was performed in a final 
volume of 500 µl of KRH with nonspecific uptake determined with 100 µM (−)-cocaine. Assays 
were initiated by addition of 10 nM [3H]DA plus 3 µM DA and allowed to proceed for 8 min at 
37 °C. For [3H]CFT binding, cells were rinsed twice with 500 µl of ice-cold KRH and incubated 
with 10 nM [3H]CFT in KRH for 2 h on ice in a final volume of 500 µl. Binding was performed 
in triplicate with nonspecific binding determined with 30 µM mazindol. Uptake and binding 
reactions were quenched by washing cells twice with ice-cold KRH followed by solubilization of 
cells with radioimmunoprecipitation assay buffer (RIPA: 1% Triton X-100, 0.1% SDS, 150 mM 
NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.5) containing protease inhibitors. Lysates were 
assessed for radioactivity by liquid scintillation counting and for protein content by the BCA 
method. DAT expression was assessed by immunoblotting with hDAT monoclonal antibody 369 
(mAb 369, Chemicon International) with band densities quantified using Bio-Rad Quality One 
software. All assays were performed in triplicate and repeated at least three times. Results were 
normalized for DAT levels and expressed relative to the WT protein set at 100%. Statistical 
significance was determined by ANOVA with post hoc Dunnett test with significance set at p < 
0.05. 
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RTI 82 Synthesis and Radioiodination 
RTI 82 and the amino precursor of [125I]RTI 82 were synthesized using modifications 
(Carroll et al. 1992) of the original procedure. Radioiodination was conducted as described 
previously (Lever et al. 1993). 
Photoaffinity Labeling and CNBr Peptide Mapping 
These procedures were performed as described previously (Vaughan et al. 2007; Parnas 
et al. 2008). WT and mutant cells were washed twice with ice-cold KRH and incubated with 5 
nM [125I]RTI 82 in KRH buffer for 2 h on ice in the presence or absence of 30 µM (−)-cocaine. 
Cells were irradiated with ultraviolet light (254 nm) for 5 min to covalently attach the ligand to 
the protein. The cells were washed twice with cold KRH to remove unbound ligand and were 
lysed with RIPA containing protease inhibitor for 30 min on ice with shaking. The lysates were 
centrifuged at 20,000 × g for 12 min at 4 °C, and supernatants were subjected to electrophoresis 
on 8% Tris-glycine polyacrylamide gels for gel purification or were immunoprecipitated with 
anti-His antibody and electrophoresed on 4–20% Tris-glycine polyacrylamide gels, followed by 
autoradiography. For CNBr analysis, photolabeled DAT bands were excised from the gel, 
electroeluted, dialyzed against purified H2O, lyophilized to dryness, and suspended in vehicle. 
Aliquots were counted in a scintillation counter, and equal amounts of radioactivity were 
subjected to peptide mapping. To assess fragment deglycosylation, samples were treated with 
vehicle or 150 units of neuraminidase (New England Biolabs) for 1 h at 37 °C followed by 
addition of 3000 units of PNGase F (New England Biolabs) for 15 h at 22 °C prior to treatment 
with CNBr. For CNBr proteolysis, samples were resuspended in 70 µl of 70% formic acid with 
or without addition of 1 M CNBr for 24 h at 22 °C in the dark. Reactions were quenched with 1 
ml of purified water, and samples were lyophilized to dryness, followed by four additional 
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rounds of resuspension with water and lyophilization. Samples were resuspended in 4SB buffer 
(50 mM Tris, 5 mM EDTA, 4% SDS, pH 7.4) and subjected to acetone precipitation followed by 
centrifugation at 20,000 × g for 15 min. Pellets were solubilized in sample loading buffer (0.625 
M Tris-HCl, 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.005% bromphenol blue) and 
analyzed by SDS-PAGE/autoradiography on 4–20% gels. For each experiment, 2–3 mutants 
were photoaffinity-labeled and analyzed with WT DAT exactly in parallel, and all results were 
replicated at least three times. CNBr peptide masses were calculated using PeptideCutter via 
ExPASy. 
RTI 82 Potency in Phe-319 Mutants 
HeLa cells were plated at a density of 50,000 cells/cm2 in 24-well culture plates, 
incubated for 24 h, and transfected with rDAT constructs using GeneCellin (Bulldog Bio) (1 µl 
per 200 ng of DNA). Following transfection (24 h), cells were washed with 37 °C KRH buffer 
and then incubated with 50 nM or 5 µM [3H]DA and increasing concentrations of 
nonradiolabeled RTI 82 without photoactivation. Transport was terminated after 15 min by 
washing with cold KRH. Cells were then dissolved in MicroScint 20 (PerkinElmer Life 
Sciences) scintillation fluid, and radioactivity was quantified by a TopCount scintillation 
counter. Specific uptake was determined by subtracting uptake observed in nontransfected cells. 
For binding analyses, transiently transfected cells were washed twice with ice-cold KRH buffer 
followed by addition of various concentrations of competitor and 10 nM [3H]CFT. Samples were 
incubated at 4 °C for 2 h, washed twice with KRH, and dissolved in MicroScint 20 scintillation 
fluid, and radioactivity was quantified as above. Nonspecific binding was determined with 30 
µM mazindol. All experiments were performed in triplicate and repeated in three or more 
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separate assays. IC50 data were analyzed using a one-way ANOVA and post hoc Dunnett test 
(Prism 4, GraphPad). 
SCAM Protection Analysis of S1- and S2-binding Sites 
HeLa or GripTite cells were plated and transfected as described above. For cocaine 
protection, HeLa cells were treated 24 h post-transfection with 5 µM (−)-cocaine or vehicle for 
10 min at 37 °C followed by addition of 5 mM MTSET for 10 min at room temperature in 
PBS/CM buffer (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, 0.1 mM 
CaCl2, 1.0 mM MgCl2, pH 7.4). Post-treatment, cells were washed with PBS/CM and incubated 
in KRH buffer at 37 °C for 30 min to allow for cocaine dissociation. Cells were then washed 
with KRH and assayed for transport activity by incubation with 50 nM [3H]DA. Uptake was 
terminated after 15 min by washing with cold KRH. Cells were dissolved in MicroScint Beta 
(PerkinElmer Life Sciences), and radioactivity was quantified as described above. All 
experiments were repeated in three or more separate assays. Cocaine inhibition of uptake was 
verified in samples that did not undergo washout. Data were analyzed using a two-way ANOVA 
followed by a post hoc Bonferroni test (Prism 4). For RTI 82 protection studies, GripTite cells 
(Invitrogen) were processed 48 h post-transfection by washing twice with PBS/CM and 
incubating with 10 or 50 µM RTI 82 or vehicle for 5 min followed by addition of 0.1 mM 
MTSEA-biotin (Biotium). Cells were then processed as described previously (Henry et al. 2003) 
to obtain cell lysates that were incubated with NeutrAvidin-agarose resin (ThermoFisher) to 
extract surface proteins labeled by MTSEA-biotin. Equal amounts of protein from total samples 
as determined by BCA assay (ThermoFisher) and equivalent volumes of surface protein pools 
were processed by SDS-PAGE and immunoblotting using anti-DAT monoclonal antibody (mAb 
16). Surface and total DAT levels were quantitated from the density of immunoblot bands using 
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ImageJ (National Institutes of Health). Surface values were normalized to total DAT levels and 
are expressed as percent of untreated samples. Data were analyzed using a paired t test (Prism 4). 
Results 
Computational Docking of RTI 82 
To facilitate elucidation of RTI 82 attachment to DAT, we generated LeuT-based 
comparative models of DAT followed by analysis of RTI 82 binding poses obtained from two 
independent computational docking methodologies, RL and IFD. For both methods, docking of 
RTI 82 was performed using rDAT homology models based on the LeuT outward-occluded 
(2A65) and open-to-out (3F3A) crystal structures. For RL, an ensemble of starting structures was 
used (10 for each conformation) (Kaufmann et al. 2009), and for IFD the lowest energy (top-
scoring) structure from Rosetta homology modeling was refined using Protein Preparation 
Wizard (Schrodinger Software Suite), resulting in one structure each from the 2A65- and 3F3A-
based templates. Best fit ligand-docked poses from these methods (see below) were then 
analyzed by molecular dynamics. 
RosettaLigand 
The rDAT-RTI 82 complexes obtained from RL docking, termed “decoys,” were ranked 
according to their interface_delta score that measures the interaction energy between the ligand 
and the protein (Combs et al. 2013). The top 10% (n = 2500 for each model) was evaluated by 
clustering of the ligand poses using CLUSTER with a 5 Å cutoff (Combs et al. 2013). The 
analysis resulted in five clusters of which clusters one and four contained the largest number of 
decoys (517 and 422, respectively) with the ligand occupying the central S1-binding site, and the 
remaining clusters contained between 11 and 178 decoys. In clusters one and four, the top 50 
scoring decoys were initially filtered using molecular distance constraints from biochemical data 
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to identify complexes where the RTI 82 azido group was within 5 Å of any atoms between 
residues 272–344 of rDAT, and the tropane nitrogen of RTI 82 was positioned within 5 Å of the 
Asp-79 side chain (Kitayama et al. 1992; Vaughan et al. 2007). 
In the 2A65-based outward-occluded models (Fig. 12A), the top 10 scoring decoys that 
satisfied the molecular constraints were chosen for further analysis. Notably, the top scoring 
models resulting from this selection method were identified as the highest scoring models prior 
to applying the distance filters, indicating that the computational docking methods were capable 
of identifying poses that were corroborated by biochemical cross-linking. Additionally, before 
the filtering step, all of the top-scoring decoys positioned the negatively charged carboxyl 
oxygen of Asp-79 within 3.5 Å of the positively charged tropane N, supporting salt bridge 
formation as a major contributor to energetically favorable binding. The top scoring 2A65-based 
decoys also displayed interaction between the RTI 82 3β-phenyl chloride group and TM3 residue 
Asn-157, an interaction that has previously been suggested as important for CFT and benztropine 
analog binding (Beuming et al. 2008; Bisgaard et al. 2011). In this “best pose,” which fulfilled 
multiple major biochemical constraints (Fig. 12A, green sticks), the AIP moiety was oriented 
toward the external vestibule with the arylazide positioned proximal to the phenyl side chain of 
Phe-319, suggesting this residue as the likely site of RTI 82 adduction. 
In the 3F3A-based outward-facing models, analysis of the decoys generated from 
docking of RTI 82 to rDAT revealed that the AIP moiety fell within 4 Å of TM6 in 310 of the 
top scoring docked complexes. The azido group was positioned proximal to Phe-319 and Phe-
325 in 208 and 224 of the complexes, respectively, with many of the poses placing the azido 
within 4 Å of both residues simultaneously. However, none of the 310 poses satisfied the second 
distance constraint between the tropane N and the Asp-79 side chain, and therefore, these decoys 
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were not further analyzed by MD. It is possible that the inability of Rosetta to account for Na+ 
and Cl− during the minimization of the ensemble of DAT structures may have had more of a 
negative impact on the more “open” 3F3A-based models than the “occluded” 2A65-based 
models and resulted in structures that were less able to approximate the native, ligand-bound 
conformation resulting in the inability to obtain a biochemically supported binding pose. 
However, given that Phe-325 was the most frequently identified candidate residue from these 
“outward-facing” models, its potential as a possible site of adduction was investigated in CNBr 
peptide mapping studies. 
 
 
Figure 12. Small molecule docking analysis. A, best RL rDAT/RTI 82-docked complex based 
on energy and constraint fulfillment. Image depicts transmembrane domains 1, 3, 6, and 8 from 
the LeuT-based rDAT homology model from the crystal structure of the outward-occluded 
template 2A65. RTI 82 is represented by green sticks, and side chains of select residues are 
represented as lines. Dashed yellow lines indicate ligand-residue interactions between azido 
nitrogen of RTI 82 and Phe-319 (1), tropane N of RTI 82 and carboxyl oxygen of Asp-79 (2), 
and phenyl chloride of RTI 82 and side chain N of Asn-157 (3). B, RTI 82 docking to rDAT 
open-to-out and outward-occluded models using IFD. Transmembrane domains 1, 3, 6, and 8 
from LeuT-based rDAT homology models based on outward-occluded and outward-facing 
templates 3F3A and 2A65 are represented as cyan and brown tubes, respectively. Na+ and 
Cl− ions are represented as purple and green spheres. 2A65 ions are designated with an asterisk. 
The best binding modes of RTI 82 identified in the IFD protocol are depicted as blue sticks for 
3F3A-based model and yellow sticks for 2A65-based model. Dashed yellow lines indicate ligand-
residue interactions between azido nitrogen of RTI 82 and Phe-319 (1), tropane N of RTI 82 and 
carboxyl oxygen of Asp-79 (2), and phenyl chloride of RTI 82 and side chain of Asn-157 (3). 
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Induced Fit Docking 
Docking analyses using IFD in the Schrödinger software suite (Fig. 12B) were conducted 
to allow for the integration of energetic contributions of Na+ and Cl− ions to ligand binding 
during the docking step (Yamashita et al. 2005; Barker et al. 1999; Forrest et al. 2007; Zomot et 
al. 2007; Wall, Innis, and Rudnick 1993). This alternative approach yielded 12 and 34 decoys 
from 2A65- and 3F3A-based models, respectively. Although the best scoring decoys consisted of 
RTI 82 poses in which the tropane N could be either protonated or unprotonated, only poses with 
protonated ligand were carried forward based on current data (Zhan et al. 2005) and analysis 
using FIXPKA in QUACPAK Version 1.5.0 (QUACPAC 2011), which predicts protonation of 
the group at pH 7.4. In both the 2A65- and 3F3A-based models, the top scoring poses positioned 
RTI 82 in the S1 pocket such that the AIP moiety was oriented toward Phe-319, with a π-π 
stacking interaction between the phenyl rings of the AIP group and the Phe-319 side chain (Fig. 
12B). For the 2A65-based model, the two top scoring poses differed in their proximity to Phe-
319 by only 0.011 Å, with the best energy scoring pose being selected (Fig. 12B, yellow sticks). 
For the 3F3A-based models, the AIP groups in the top two poses were proximal to the Phe-319 
side chain with distances of 3.5 and 3.9 Å and the docking scores of −11.45 and −12.12, 
respectively. As the docking scores were similar, the best 3F3A pose (Fig. 12B, blue sticks) was 
selected based on proximity of Phe-319 and the azido group of RTI 82. 
MD Simulation of RL and IFD Docked RTI 82 Poses 
To further refine the RTI 82 pose in the rDAT-RTI 82 complexes, the best-docked 
structures from RL and IFD analyses were embedded in a POPC lipid bilayer and refined by MD 
simulation for 60 ns in GROMACS (Hess et al. 2008). The r.m.s.d. analysis of the ligand atoms 
and Cα atoms of DAT during simulation revealed that RTI 82 was stable in the binding pocket 
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throughout the simulation (Fig. 13). In particular, we monitored the stability and time-dependent 
changes of two key protein-ligand interactions during simulation as follows: 1) the carboxylate 
oxygen of Asp-79 and the protonated tropane N, and 2) the amide nitrogen of Asn-157 and the 
3β-phenyl chloride. In all simulations, a stable (occupancies of 58% for RL-2A65, 52% for IFD-
2A65, and 98% for IFD-3F3A) salt bridge interaction distance (3.5 Å) was observed between the 
RTI 82 tropane N and the Asp-79 carboxyl oxygen (red and black lines in Fig. 13, A–C). In the 
RL-2A65 and IFD-3F3A simulations, this interaction is maintained through periodic reciprocal 
reorientation of the Oδ1 and Oδ2 atoms. In contrast, using a 4-Å cutoff, the predicted polar 
interaction between Asn-157 and the RTI 82 3β-phenyl chloride was observed to be stable (70% 
occupancy) only in the RL-docked pose (Fig. 13A, blue line), whereas negligible interaction (2–
4% occupancy) was found in the IFD-docked poses (Fig. 13, B and C, blue lines). 
 
 
Figure 13. Molecular dynamics simulations. Time-dependent changes in distances between 
RTI 82 and residues involved in anchoring and orienting the ligand in the binding pocket reveal 
stable complexes during simulation in RL-docked, 2A65-based model (A), IFD-docked, 2A65-
based model (B) and IFD-docked, 3F3A-based model (C). Shown are the distances during 
simulation between the side chain oxygen atom of Asp-79 and the protonated N of RTI 82 
(red and black traces for Oδ1 and Oδ2), which ranged from 2.5 to 4.5 Å (right inset, C) and the 
amide nitrogen of Asn-157 and phenyl chloride of RTI 82 (blue traces), which ranged from 3.0 
to 10.0 Å (left inset, C). Traces were smoothed using 5-point averaging in SciDavis 
(OpenSource). 
 
The best poses obtained by RL and IFD before and after MD simulation are illustrated in 
Fig. 14. All of the docking methodologies, irrespective of the input rDAT model, yielded RTI 82 
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poses with the AIP arm extended out of the S1 pocket and toward the external vestibule (Fig. 14, 
A–C). In RL (Fig. 14A), RTI 82 docked in the outward-occluded model exhibited a structure with 
the AIP group in a bent conformation (green sticks), and after MD simulation, the AIP moiety 
displayed an extended and more linear conformation (Fig. 14A, magenta sticks). This extended 
AIP configuration was also found in the IFD-generated pose from the occluded form, both prior 
to (yellow sticks) and after (black sticks) MD simulation (Fig. 14B). This extension may be 
stabilized by an interaction between the AIP azido moiety and outer gate residue Arg-85 (Fig. 
14, A andB). In contrast, in the IFD-generated open-to-out complex (Fig. 14C, blue sticks), the 
AIP group was slightly bent prior to simulation such that it formed a π-π stacking interaction 
with Phe-319 (blue arrowhead). During simulation of this docked complex, the AIP functional 
group (Fig. 14C, brown sticks) was repositioned between TM6 and TM10 near Ala-479, yet 
maintained π-π stacking with Phe-319 (brown arrow). 
Notably, the position of the RTI 82 tropane pharmacophore was relatively unchanged in 
all poses following simulation, indicating that this functionality is the major contributor to 
ligand-protein interaction. In fact, during simulation, we consistently observed a slight 
translation of the tropane ring deeper into the binding pocket (Fig. 14,A–C). This was 
accompanied by similar adjustments of interacting residues Phe-76, Asp-79, Phe-325, and Val-
327, which maintained their coordination with the ligand (Fig. 14, A–C). The interaction of the 
RTI 82 3β-phenyl chloride with Asn-157 was also maintained during MD simulation of the RL 
pose (Fig. 14A) but was lost in both IFD decoys (Fig. 14, B and C). The validity of our poses is 
further supported by recent crystal structures of the LeuT/SERT hybrid (Wang et al. 2013) and 
dDAT (Penmatsa, Wang, and Gouaux 2013) transporters that show binding of SSRI and TCA 
antidepressants to S1. The binding pose of nortriptyline at the dDAT S1 pocket (Penmatsa, 
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Wang, and Gouaux 2013) overlaps substantially with our RTI 82 pose as shown in Fig. 14D. 
These findings indicate that many classes of high affinity neurotransmitter transporter inhibitors 
may assume similar poses within the S1 pocket. 
 
 
Figure 14. Comparison of rDAT-RTI 82 complexes before and after molecular dynamic 
simulation. A, superimposition of RL-docked, 2A65-based rDAT-RTI 82 complex before 
(green) and after (magenta) simulation. B, IFD-docked, 2A65-based rDAT-RTI 82 complex 
before (yellow) and after (black) simulation are shown in comparison with the MD-simulated, 
RL-docked RTI 82 pose (magenta). C, IFD-docked, 3F3A-based RTI 82-rDAT complex before 
(blue) and after (brown) MD simulation. Arrows indicate potential π-π stacking interactions. The 
RL (magenta) and 2A65-based (black) post-MD poses are also shown. D, overlay of the RL-
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docked and 2A65-based (green) and IFD-docked and 3F3A-based (blue) rDAT-RTI 82 
complexes in comparison with nortriptyline binding from the dDAT crystal structure (orange 
spheres). In each panel, relevant residues are illustrated as lines, and Na+ and Cl− ions are 
represented by purple and green spheres, respectively. 
 
Analysis of 4′-Azido-3′-iodophenyl Moiety Interactions with Phe-319 
Our poses showing the proximity of the RTI 82 AIP group to the Phe-319 side chain 
suggested aromatic stacking as the basis for their interaction. To investigate this possibility, we 
generated a panel of conservative and nonconservative Phe-319 mutants (F319Y, F319W, 
F319M, F319C, and F319D) to analyze the potency of non-crosslinked RTI 82 to inhibit [3H]DA 
transport and [3H]CFT binding (Table 1). Using 50 nM DA to assess transport, the F319Y, 
F319W, and F319M mutants showed 8–43% of the WT DAT activity level, whereas uptake was 
undetectable in the F319C and F319D mutants (Table 1). The significant reduction in high 
affinity transport in F319M, F319C, and F319D DATs is consistent with the loss of aromatic 
interaction needed for Phe-319 to interact with its gating partner Tyr-156 (Kristensen et al. 2011; 
Yamashita et al. 2005; Singh, Yamashita, and Gouaux 2007). RTI 82 transport inhibition 
potencies did not differ between the WT protein or the Phe-319 mutants substituted with 
aromatic (Trp or Tyr) or nonaromatic hydrophobic (Met) residues, indicating that π-π 
interactions between the RTI 82 AIP group and the side chain of Phe-319 do not provide major 
contributions to RTI 82 binding. However, the potency of RTI 82 to inhibit [3H]CFT binding in 
F319C and F319D DATs was reduced by 4.3- and 7.1-fold (Table 1), indicating that inhibitor 
effects require hydrophobicity at Phe-319. We also found that when higher concentrations of DA 
(5 µM) were used for uptake, the F319C and F319D mutants remained nonfunctional, suggesting 
that the charge substitution at this position may impact substrate affinity. However, transport 
activity could be restored in the F319C mutant to 79% upon application of 3.5 mM DA, whereas 
the F319D mutant remained nonfunctional. 
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Table 1. Activity of Phe-319 mutants and inhibitory potency of RTI 82. Data are presented as 
mean ± S.E.; n ≥ 3. Data were analyzed by one-way ANOVA with Dunnett's post hoc test. 
 
 % Activity of rDAT Competitive Uptake
a 
RTI 82 IC50 (nM) 
Competitive Bindingc 
RTI 82 IC50 (nM) 
rDAT 100a,b 21 ± 6 20 ± 5 
F319Y 27 ± 5a 21 ± 7 ND 
F319W 43 ± 6a 27 ± 5 ND 
F319M 8 ± 6a 19 ± 6 ND 
F319C 0a, 79 ± 3d ND 85 ± 13** 
F319D 0a, 0b, 0d ND 142 ± 13*** 
a [3H]DA (50 nM) 
b [3H]DA (5 µM)   
c [3H]CFT (10 nM) 
d [3H]DA (3.5 mM)   
ND - Not Determined   
Data are presented as mean ± S.E.; n ≥ 3 
Data were analyzed by one-way ANOVA with Dunnett’s post-hoc test.  
** p<0.01, *** p<0.001 
 
CNBr Peptide Mapping of [125I]RTI 82-Labeled TM6 Mutants 
We then sought to validate the prediction from computational modeling that Phe-319 was 
the likely site of RTI 82 adduction. For this, we generated methionine (Met) substitutions of 
residues flanking Phe-320 in hDAT, which corresponds to Phe-319 in rDAT, for use in CNBr 
peptide mapping. hDAT is identical to rDAT in amino acid sequence across the region mutated 
for these studies (hDAT residues 318–330), and it was used because the two additional Met 
residues present in EL2 and EL3 of rDAT (Fig. 15) would significantly complicate the CNBr 
digestion analyses. In addition, to further strengthen the interpretation of the proteolysis patterns, 
we introduced all TM6 Met substitutions in an M272L background to eliminate Met-272 as a 
CNBr proteolysis site (Vaughan et al. 2007). In hDAT, Met-272 is the only Met between TM2 
and TM7. Thus, in the M272L background, the introduction of Met into TM6 would result in 
generation of CNBr fragments of ~50 kDa that would extend from TM2 (Met-106, Met-111, or 
Met-116) to the inserted Met or CNBr fragments of ~6 kDa that would extend from the inserted 
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Met to Met-371 in TM7 (Fig. 15). The masses of the labeled CNBr fragments produced thus 
indicate the relative positions of the inserted Mets and the site of [125I]RTI 82 adduction. For 
ease of discussion, we refer to the double mutants with TM6 Met substitutions in the M272L 
background solely by the TM6 mutation (e.g. V318M hDAT indicates M272L/V318M hDAT) 
and to the CNBr fragments by the flanking Mets, although the N terminus of each fragment is the 
residue following a proteolyzed Met. 
 
Figure 15. Schematic diagram of endogenous Met residues in DAT. The membrane topology 
of hDAT is shown with cylinders representing TM domains 1–12 and branched structures in EL2 
indicating glycosylation sites. Filled circles show positions of endogenous Mets present in both 
hDAT and rDAT (numbering specific for hDAT), and open circles represent Mets present only 
in rDAT. The star represents the predicted adduction site of RTI 82 at Phe-320. 
 
The mutants used for this study (V318M, C319M, F320M, S321M, L322M, V324M, and 
I330M) were stably expressed in LLC-PK1 cells and assessed for expression, [3H]DA uptake, 
and [3H]CFT binding (Fig. 16). The expression levels determined by immunoblotting ranged 
from ~50 to 100% of WT DAT (Fig. 16A), with all showing expression of full-length, mature 
protein. When normalized for transporter expression levels, the mutants showed [3H]DA uptake 
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Figure 16. Characterization of Met-substituted hDATs. A, LLC-PK1cells expressing the 
indicated DAT forms were lysed, and equal amounts of protein were Immuno blotted (IB) for 
DAT. B, LLC-PK1 cells stably expressing the indicated DAT forms were assayed for [3H]DA 
uptake (filled bars) or [3H]CFT binding (open bars). Values shown (means of ± S.E.) are 
normalized for total DAT protein and expressed relative to the WT level (100%). #, p < 
0.05 versus WT binding; ***, p < 0.001 versus WT uptake, by ANOVA with Dunnett's multiple 
comparison test. C, autoradiograph of the indicated hDAT forms photolabeled with [125I]RTI 82 
in the presence or absence of 30 µM (−)-cocaine. 
 
values that ranged from ~20 to 60% of the WT protein, except for F320M and S321M, which 
exhibited <10% of the WT activity (Fig. 16B). Loss of transport in these mutants is consistent 
with their functional roles, as Phe-320 is proposed to act as a substrate pocket gating residue, and 
Ser-321 coordinates Na+ at the Na1 site (Yamashita et al. 2005; Penmatsa, Wang, and Gouaux 
2013). [3H]CFT binding for the mutants was impacted less than transport, ranging from ~60 to 
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90% of WT levels when normalized for expression (Fig. 16B), and all forms showed [125I]RTI 82 
photoaffinity labeling that was fully blocked by cocaine (Fig. 16C), indicating that the mutations 
did not substantially disrupt the cocaine binding pocket. 
For peptide mapping studies, the photolabeled proteins were gel-purified and subjected to 
treatment with vehicle (formic acid) or CNBr, followed by SDS-PAGE/autoradiography. Within 
each experiment, equal amounts of radioactivity for WT and mutant forms were analyzed to 
allow for direct comparison of peptide fragment production. Fig. 17A shows a compilation of 
representative peptide maps produced from three or more independent replicates for each mutant, 
with schematic diagrams indicating the origin of the labeled fragments in the primary sequence 
and site of [125]RTI 82 adduction (star symbol). Full-length, unproteolyzed DAT migrates at ~90 
kDa (Fig. 17A, odd-numbered lanes) with no low molecular weight fragments observed. 
Aggregates seen at ≥180 kDa are most likely induced by the formic acid treatment, as they were 
not seen in samples subjected directly to electrophoresis. CNBr treatment of WT hDAT 
produced a labeled fragment of ~11 kDa (Fig. 17A, lane 2, arrow a), as we demonstrated 
previously (Vaughan et al. 2007), that corresponds to the region between Met-272 and Met-371 
(calculated mass 10.6 kDa, shaded region in schematic diagram a), as well as larger fragments 
that likely arise from missed cleavage of Met-272. CNBr treatment of [125I]RTI 82-labeled
V318M and C319M hDATs produced fragments of ~6 kDa (Fig. 17A, lanes 4 and 6, arrow b) 
that are consistent with peptides extending from the inserted Mets to Met-371 (calculated masses 
~5.6 kDa; shaded region in schematic diagram b), with higher molecular weight fragments in 
these samples also indicating missed cleavage of the inserted Mets. In contrast, mutants F320M, 
S321M, L322M, V324M, and I330M produced only the ~50-kDa fragments (Fig. 17A, arrow c) 
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Figure 17. CNBr mapping of [125I]RTI82-labeled TM6 DAT mutants. The indicated DAT 
forms were photolabeled with [125I]RTI 82 and gel-purified. A, equal amounts of radioactivity 
were treated with vehicle (formic acid, odd-numbered lanes) or CNBr (even-numbered lanes) 
and analyzed by SDS-PAGE/autoradiography. Unproteolyzed DAT is present in odd-numbered 
A 
B
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lanes at ∼90 kDa. CNBr proteolysis of the WT protein produces a fragment of ∼11 kDa (lane 2, 
arrow a) that corresponds to the shaded region in schematic diagram a. CNBr treatment of 
V318M and C319M hDATs produces fragments of ∼6 kDa (lanes 4 and 6, arrow b) that 
correspond to the shaded region in schematic diagram b. CNBr treatment of the remaining 
constructs produced fragments of ∼50 kDa (lanes 8, 10, 12, 14, and 16, arrow c) that correspond 
to the shaded region in schematic diagram c but no fragments of <8 kDa. Filled circles in 
schematic diagrams represent Mets present in the constructs and the star represents the site of 
ligand adduction at Phe-320. B, equal amounts of radioactivity were subjected to the indicated 
combinations of neuraminidase plus PNGase F treatment (N/P) and CNBr digestion. Arrow 
a, CNBr fragment obtained from untreated and deglycosylated WT DAT; arrow c, CNBr 
fragments obtained from V324M and I330M DATs prior to deglycosylation; arrow d, CNBr 
fragments obtained from V324M and I330M DAT after deglycosylation. 
 
that correspond to the shaded region in schematic diagram c (calculated peptide masses ~22.4–
23.3 kDa, with additional ~25 kDa of mass contributed from EL2 N-linked carbohydrate), with 
no production of fragments with masses of <8 kDa. Note that full-length DAT and the larger 
peptide fragments run with anomalously low electrophoretic mobility on these high percent gels 
and that more accurate mass estimates of the ~50-kDa CNBr fragment were obtained using lower 
concentration gels (Vaughan et al. 2007). 
To verify that the 50-kDa fragments in these mutants originated from the indicated 
region, we performed deglycosylation analysis of selected mutants with neuraminidase and 
PNGase F, which cleave terminal sialic acids and N-linked carbohydrates from canonical N-
glycosylation sites in EL2 (Vaughan and Kuhar 1996; Li et al. 2004). For full-length WT, 
V324M, and I330M DATs (Fig. 17B, lanes 1, 5, and 9) treatment with neuraminidase plus 
PNGase F led to reductions in molecular mass due to deglycosylation (lanes 3, 7, and 11, and 
data not shown). As expected, deglycosylation did not alter the mass of the ~11-kDa WT CNBr 
fragment (Fig. 17B, lanes 2 and 4, arrow a), but it did reduce the masses of the ~50-kDa 
fragments from V324M and I330M DATs (lanes 6 and 10; arrow c) by ~25 kDa (lanes 8 and 12, 
arrow d). These results are consistent with the presence of EL2 in the ~50-kDa peptide 
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fragments and further validate the indicated origins of the photolabeled fragments in the 
schematic diagrams. 
The cleavage patterns shown in Fig. 17, A and B, indicate that ligand adduction occurs C-
terminal to V318M and C319M and N-terminal to F320M, S321M, L322M, V324M, and I330M, 
and because CNBr proteolyzes peptide bonds on the C-terminal side of Mets, they demonstrate 
that the adduction of [125I]RTI 82 occurs at Phe-320. These results also rule out a significant 
level of [125I]RTI 82 adduction to other residues within this stretch of TM6, including Phe-326, 
an interaction that was suggested in a large portion of the decoys from RL docking to the 
outward-facing rDAT model. 
Although CNBr proteolysis of [125I]RTI 82-labeled F320M, S321M, L322M, V324M, 
and I330M did not produce the ~6-kDa fragments seen in V318M and C319M hDATs, some 
lightly labeled fragments of ~8–10 kDa were seen in some digests. These fragments likely 
originate from adduction of [125I]RTI 82 to a different region of the DAT primary sequence, as 
we have obtained preliminary evidence from antibody-based mapping that a small fraction of 
[125I]RTI 82 adduction occurs C-terminal to TM6. Multisite incorporation of DAT photoaffinity 
labels has been previously demonstrated (Vaughan et al. 2001) and likely occurs due to the 
proximity of the TM domains in the protein core in conjunction with small fluctuations in AIP 
moiety orientation during the photoactivation process. However, the significantly lower labeling 
intensity of this secondary site relative to that occurring in TM6 indicates that Phe-320 is the 
predominant site of adduction. 
Analysis of RTI 82 Protection of S2 Residues from Inactivation by Methanethiosulfonate 
(MTS) Reagents 
 
The convergence of our computational docking and peptide mapping results strongly 
indicated that binding of the RTI 82 tropane pharmacophore occurs within the S1-binding site 
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and positions the AIP group for adduction to Phe-319/320. However, Phe-319 is present at the 
interface between S1 and S2 (Fig. 18A), and thus RTI 82 tropane positioning in S2 could 
potentially also result in cross-linking of this site. To assess this possibility, we analyzed several 
residues present in S1 (yellow sticks), S2 (magenta sticks), or intermediate positions (green 
sticks) of the DAT permeation pathway (Fig. 18A) for cocaine- and RTI 82-induced protection 
from SCAM reagents. All mutants were made in an MTSET-insensitive rDAT E2C (C90A and 
C305A) background (Gaffaney et al. 2014). 
For transport protection experiments, we generated Cys mutations of residues Trp-84, Ile-
159, Asp-475, and Ala-479, which are part of S2 or line the S1-S2 transition region (Fig. 18A, 
magenta and green sticks). All mutants were active, possessing DA transport activities ranging 
from 15 to 78% of the E2C DAT level. As expected, MTSET treatment of E2C DAT did not 
reduce uptake, consistent with the remaining Cys residues in the protein being inaccessible to the 
reagent. For protection analysis, cells were co-incubated with cocaine prior to addition of 
MTSET. All DAT forms preincubated with cocaine showed recovery of transport activity after 
washing (wash control), demonstrating the reversibility of cocaine binding. MTSET treatment of 
W84C, I159C, D475C, and A479C DATs resulted in a 60–90% loss in transport activity (Fig. 
18B), indicating full or partial accessibility of these residues to modification. Co-incubation of 
the cells with (−)-cocaine during MTSET treatment did not protect the mutants from inactivation
indicating a lack of cocaine pharmacophore binding in S2. In addition, the sensitivity of I159C 
DAT to MTSET was enhanced compared with the non-cocaine-treated condition, suggesting that 
binding induced a conformational change that makes the I159C side chain more accessible to the 
reagent. We were unable, however, to assess RTI 82 protection of these residues by this method 
as RTI 82-pretreated cells recovered only a small amount of transport activity, even with 
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Figure 18. SCAM protection analysis of S1 and S2 binding pockets. A, representation of Cys-
engineered mutants in the S1 (yellow sticks) and S2 (magenta sticks) binding pockets as well as 
residues that reside in the interface between S1 and S2 (green sticks). The RosettaLigand pose 
for RTI 82 is shown (black sticks). B, HeLa cells transiently expressing the indicated DAT 
mutants were preincubated with vehicle or 5 µM (−)-cocaine for 10 min followed by addition of 
5 mM MTSET for 10 min. Cells were washed and incubated for 30 min at 37 °C to release 
bound cocaine and analyzed for recovered activity by [3H]DA transport assays. The samples 
labeled Control and Cocaine (white and black bars, respectively) were assayed following an 
initial wash and served as a control to verify cocaine inhibition of uptake. Results are normalized 
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to percent activity of control, and the values represent the mean ± S.E. from three independent 
experiments. MTS-treated samples with or without cocaine pretreatment were analyzed using 
two-way ANOVA with a post hoc Bonferroni test. ***, p< 0.001; n.s., not 
significant. C, immunoblots of the surface pool of DAT Cys mutants in the DAT E2C 
background purified with MTSEA-biotin in the absence (−) or presence of cocaine (+, 100 
µM; ++, 1 mM (top panel)) or RTI 82 (+, 10 µM; ++, 50 µM) (bottom panel). D, quantification 
of DAT bands in C and total DAT expression (data not shown) were determined using ImageJ 
(National Institutes of Health). Surface samples were normalized to total DAT and the surface 
cocaine- (black bars) or RTI 82 (red bars)-treated samples were expressed as percent of the 
respective untreated samples (white bars). The data represent three or more independent 
experiments. Paired t test analysis was used to determine significant differences between RTI 82-
treated and -untreated samples. *, p < 0.05; **, p < 0.01. 
 
extensive washing. This lower level of RTI 82 reversibility may be due to a slower release 
caused by hydrophobicity of the AIP or to other structural differences from (−)-cocaine related to 
its higher affinity. Furthermore, the impact of Cys substitution at S1 residues prevented 
accessibility testing by this method. 
For these reasons, we assessed the ability of RTI 82 and cocaine to protect S1 and S2 
residues by Cys-directed biotinylation. For these analyses, we generated additional S1 and S2 
Cys mutations at Asp-79, Ala-81, Asn-82, Arg-85, Val-152, Phe-319, Ser-421, and Ile-483. All 
mutants were expressed as full-length proteins and were active for [3H]CFT binding. MTSEA-
biotin protection assays were done using 10 µM RTI-82 or 100 µM cocaine, except for D79C 
and S421C DATs, which exhibited a marked loss in potency to inhibit binding and required 
higher inhibitor concentrations (50 µM RTI-82 or 1 mM cocaine) for protection analyses. 
Surface rDAT was readily labeled with MTSEA-biotin, and this labeling was unaffected 
by addition of RTI 82 or cocaine (Fig. 18C, Control). Biotinylation of rDAT E2C was 
undetectable (Fig. 18C, Control), confirming its use as a suitable background for analysis of 
inserted Cys residues. Recovery of biotinylated rDAT surface protein from the S1 mutants D79C 
and S421C was significantly reduced in the presence of either RTI-82 or cocaine, indicating the 
protection of these residues from the MTS reagent (Fig. 18, C and D). V152C and N82C showed 
!!59 
different patterns of reactivity, with V152C reactivity increased by cocaine but reduced by RTI-
82, and N82C reactivity being increased by both cocaine and RTI 82 (Fig. 18, C and D). Val-152 
is critical for high affinity antagonist binding and is thought to form important hydrophobic 
interactions with both substrates and inhibitors (Yamashita et al. 2005; Beuming et al. 2008; 
Henry et al. 2006), and thus the slight differences in cocaine and RTI 82 structure apparently 
induce different alterations of the Cys side chain that results in the differential accessibility. Asn-
82 is homologous to Asn-101 in human SERT, which is a structurally dynamic residue important 
in coupling to Na+ ions at the Na1 site (Felts et al. 2014; Henry et al. 2011), with our data 
supporting an increased accessibility of this site upon cocaine or RTI 82 binding. In contrast, 
neither RTI 82 nor cocaine altered the MTS accessibility of S2 residues W84C, R85C, I159C, 
and D475C (Fig. 18, C and D). Together, these findings strongly indicate that RTI-82 and 
cocaine bind to DAT in the S1 but not the S2 site. 
Residues Phe-319, Ile-483, and Ala-479 lie at the interface between S1 and S2 (Fig. 18A, 
green sticks). Co-incubation with cocaine protected all of these sites from MTS modification, 
whereas RTI 82 protected only A479C (Fig. 18, C and D). This outcome is not unexpected given 
that the AIP group of RTI 82 is oriented toward the outer vestibule and may prevent complete 
transition to the occluded structure, leaving the residues accessible to modification. Cocaine 
lacks the AIP group and may thus induce fuller transition to the occluded structure that provides 
more complete protection of these residues, which could account in part for the differential 
effects of RTI 82 and cocaine on increased or decreased MTS accessibility in S1 residues N82C 
and V152C. In addition, we found that cocaine protected A479C from MTS attack in the 
MTSEA-biotin pulldown study (Fig. 18C) but not in the washout studies (Fig. 18B). This 
discrepancy may be due to bulk size difference between MTSEA-biotin and MTSET. These 
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results suggest that the MTS accessibility of the intermediate residues may provide a readout for 
the S1 site on the transporter indicating whether a bound antagonist induces an occluded or more 
open conformation. 
Discussion 
The kinetic interactions of DAT with cocaine and its analogs are complex, resulting in 
high and low affinity binding states (Madras et al. 1989; Boja et al. 1998) and competitive and 
noncompetitive uptake inhibition (Missale et al. 1985; McElvain and Schenk 1992). We 
currently lack a complete mechanistic understanding of these properties, as some mutagenesis 
and comparative modeling studies support the interaction of cocaine at S1, where it could 
suppress transport by competing with substrate for key interactions (Beuming et al. 2008; 
Bisgaard et al. 2011), although other studies support binding near S2, where it could 
allosterically stabilize an inactive state of the transporter (Huang, Gu, and Zhan 2009; Hill et al. 
2011; Merchant and Madura 2012; Schmitt, Rothman, and Reith 2013). It has been proposed that 
these binding modes are not mutually exclusive and that cocaine may initially bind near the S2 
site before transitioning to S1 following conformational changes (Huang, Gu, and Zhan 2009; 
Hill et al. 2011). The current collection of LeuT and dDAT crystal structures supports multiple 
binding sites for substrates and inhibitors (Yamashita et al. 2005; Zhou et al. 2007; Zhou et al. 
2009; Singh, Yamashita, and Gouaux 2007; Singh et al. 2008; Penmatsa, Wang, and Gouaux 
2013; Quick et al. 2009; Wang et al. 2013; Plenge et al. 2012; Schmitt, Rothman, and Reith 
2013; Indarte, Madura, and Surratt 2008) and both allosteric and competitive inhibition 
mechanisms (Pramod et al. 2013; Kristensen et al. 2011; Zhou et al. 2009; Singh, Yamashita, and 
Gouaux 2007; Singh et al. 2008; Krishnamurthy and Gouaux 2012; Henry et al. 2006; Piscitelli, 
Krishnamurthy, and Gouaux 2010; Quick et al. 2009; Wang, Elferich, and Gouaux 2012; 
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Andersen et al. 2009; Plenge et al. 2012; Schmitt, Rothman, and Reith 2013; Plenge, Gether, and 
Rasmussen 2007; Singh 2008; Piscitelli and Gouaux 2012). To date, however, no high resolution 
crystal structures of cocaine-bound SLC6 transporters have been obtained (Pramod et al. 2013; 
Kristensen et al. 2011; Henry, Meiler, and Blakely 2007), and the exact cocaine binding site(s) 
on DAT and their relationships to the various kinetic states remain unresolved. 
As a positive function approach to these issues, our groups have developed irreversible 
binding tropane and benztropine analogs as probes for physical identification of ligand 
interaction sites (Vaughan et al. 2007; Parnas et al. 2008; Vaughan et al. 1999). Here, we provide 
the first identification of a specific photoaffinity analog contact point on DAT, and we used this 
information in conjunction with modeling and SCAM analysis to directly demonstrate binding of 
the tropane pharmacophore in the S1 substrate site. [125I]RTI 82 labeling of DAT occurs with 
appropriate pharmacology (Vaughan et al. 2007), and because our photolabeling analyses 
utilized 5 nM ligand, the [125I]RTI 82 adduction site identified in this study represents the high 
affinity, pharmacologically relevant antagonist-bound state of the transporter. It is likely that this 
site closely correlates with the (−)-cocaine-binding site, as the compounds share the N-methyl 
tropane pharmacophore that drives high affinity cocaine recognition (Runyon and Carroll 2008) 
and differ only in the substitution of the 3β-benzoyl ester with a phenyl chloride and addition of 
the 2β-ethyl aryliodoazido moiety. 
Several other lines of pharmacological and structural evidence support the validity of our 
findings and extend our understanding of the binding pocket. First, our top scoring models 
predict salt-bridge interaction between Asp-79 and the tropane nitrogen of RTI 82, consistent 
with the demonstrated requirement of this interaction in cocaine and CFT binding (Kitayama et 
al. 1992; Beuming et al. 2008; Carroll et al. 1994). During MD simulations of rDAT-RTI 82 
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complexes, we observed a slight downward translation of RTI 82 deeper into the S1 pocket, but 
importantly, the ligand maintained interaction with Asp-79, corroborating its importance in RTI 
82 binding. This is likely to represent an important molecular motif in all NSS proteins, as 
interaction of N-based antagonists with the TM1 Asp residue has also been demonstrated in the 
dDAT and the SERT/LeuT hybrid transporter co-crystallized with bound SSRI and TCA 
inhibitors (Penmatsa, Wang, and Gouaux 2013; Wang et al. 2013). A second important 
interaction was identified between the phenyl chloride of RTI 82 and Asn-157, which parallels 
the interaction of this residue with the phenyl fluoride of CFT (Beuming et al. 2008). It is unclear 
whether Asn-157 would interact with cocaine, which possesses a nonhalogenated benzoyl ester 
at the 3β position and suggests this interaction as likely to contribute to the higher binding 
affinity of CFT and RTI 82 (Runyon and Carroll 2008). In addition, residues homologous to Val-
152 and Ser-421, which we found as contact points for RTI 82 binding, have been implicated in 
high affinity antagonist binding in SERT (Henry et al. 2006; Andersen et al. 2009). Finally, in 
both RL and IFD, the RTI 82 poses we identified are virtually superimposable with respect to 
tropane pharmacophore orientation in the S1 pocket and extension of the arylazido arm out of the 
pocket toward the external vestibule. These findings are consistent with QSAR studies 
demonstrating that the tropane pharmacophore drives the major component of cocaine analog 
binding, and it provides a structural rationale for findings that bulky substituents can be 
accommodated at the 2β position of the tropane ring without significant impact on affinity 
(Runyon and Carroll 2008). 
The adduction site of RTI 82, Phe-319/320, functions as a gating residue on the outer 
margin of the S1 binding pocket and performs a crucial role in the transition between the 
“outward” and outward-occluded states by aromatic interaction with Tyr-156 (Penmatsa, Wang, 
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and Gouaux 2013). We obtained reasonable docked structures in both the open-to-out and 
outward-occluded models that identified Phe-319 as the RTI 82 adduction site; thus, it is possible 
that cocaine-like molecules suppress transport by inhibiting the transition from the outward state 
to the outward-occluded form or by stabilizing the outward-occluded state and preventing 
progression to the “inward-facing” structure. Here, our findings from RL docking could indicate 
that the outward-occluded structure better represents the native binding mode of RTI 82. 
However, other DAT inhibitors may stabilize distinct transporter conformations that could 
potentially confer different functional and behavioral outcomes (e.g. benztropines). 
Computational analysis by Beuming et al. (Beuming et al. 2008) predicted Phe-320 interaction 
with the tropane ring of CFT, and the homologous residue in the LeuT/SERT hybrid (Phe-253) 
has been shown to participate in binding of SSRIs and TCAs (Wang et al. 2013). Our findings, 
however, did not indicate interaction of the RTI 82 tropane with Phe-319. This is likely due to 
the AIP moiety restricting reorientation of this residue and preventing its movement toward the 
S1 pocket and closer to the tropane pharmacophore (Penmatsa, Wang, and Gouaux 2013). It is 
possible that by preventing closure of the aromatic lid, extensions to this arm of RTI 82 could 
stabilize outward-facing DAT conformations, which might result in different functional 
outcomes than the inhibitor-stabilized occluded form. 
The direct identification of photoaffinity ligand adduction sites confers major advantages 
for computational analyses of ligand poses by dramatically reducing the conformational space 
that must be sampled during docking analysis and by providing experimentally determined 
ligand-protein contact points that can be used as absolute requirements by which recovered 
binding poses can be filtered. This significantly enhances the confidence with which poses can 
be interpreted and further analyzed by computational and mutational strategies to clarify overall 
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transport and transport inhibition mechanisms. In addition, these procedures can be performed in 
functional mammalian transporters in which the WT form is directly compared with transport- 
and binding-competent mutant forms, which strongly increases the likelihood that 
physiologically relevant structures are being assessed. These multiple strengths support the 
utilization of this approach in further predictive docking analyses of these and other categories of 
DAT ligands. This is important because to date no SLC6 transporters have been co-crystallized 
with cocaine-like compounds or atypical DAT inhibitors and because the uncertain structural and 
functional relationships between mammalian transporters and the mutation-stabilized dDAT and 
LeuT/SERT hybrid homologs may obscure significant differences in the transport and inhibitor 
binding properties of the proteins (Penmatsa, Wang, and Gouaux 2013; Wang et al. 2013). 
The tremendous sociological and economical impacts of cocaine addiction make basic 
understanding of the mechanisms of cocaine binding and transport inhibition an important effort, 
especially with the promise afforded by the identification of the benztropine class of DAT 
antagonists, which bind to DAT and block DA uptake but do not produce the cocaine-like 
behavioral profiles and reduce cocaine self-administration in animal models (Tanda, Newman, 
and Katz 2009; Tanda et al. 2013). It has been suggested that the benztropines may bind distinct 
conformations of DAT and/or possess a slow rate of occupancy following administration, which 
may modulate the psychotropic effects of increased synaptic DA (Loland et al. 2008; Beuming et 
al. 2008; Tanda, Newman, and Katz 2009; Tanda et al. 2013). Recently, modafinil and its R-
enantiomer (armodafinil) have also been described as having distinctive interactions at DAT that 
might contribute to their nonaddictive and therapeutic profiles (Merchant and Madura 2012; 
Schmitt and Reith 2011; Loland et al. 2012). Thus, understanding cocaine binding in relation to 
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compounds like these atypical DAT inhibitors could provide critical insights for developing 
medication strategies toward treating cocaine addiction. 
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CHAPTER III 
IDENTIFYING THE ADDUCTION SITE OF THE PHOTOACTIVE AZIDE OF THE 
IRREVERSIBLE COCAINE ANALOG [125I]MFZ 2-24 FOR ELUCIDATING THE 
COCAINE BINDING SITE IN THE DOPAMINE TRANSPORTER  
 
Introduction 
The dopamine transporter (DAT) is a member of the Na+/Cl--dependent SLC6A family of 
solute carriers and functions to maintain dopamine homeostasis through reuptake of dopamine 
(DA) from the neuronal synapse. Altered DAT function through dysregulation or mutations can 
impact extracellular DA levels and has been linked to several neurological diseases and disorders 
including attention deficit hyperactivity disorder, addiction, depression, autism spectrum 
disorder, bipolar disorder, Parkinson disease, schizophrenia, Tourette syndrome, and hereditary 
DAT deficiency syndrome (Gainetdinov and Caron 2003; Gether et al. 2006; Torres and Amara 
2007; Hahn and Blakely 2007; Pramod et al. 2013; Kurian et al. 2011). DAT activity can be 
modulated endogenously by various post-translational modifications, including phosphorylation 
and palmitoylation (Vaughan and Foster 2013), and exogenously by drugs of abuse like cocaine 
and amphetamines, which block or reverse the transport of DA by DAT and lead to large 
increases in extracellular DA levels (Ritz et al. 1987; Bergman et al. 1989). Paradoxically, some 
DAT inhibitors including bupropion, methylphenidate, and benztropines bind and block DA 
reuptake but fail to induce the euphoric and addictive behavioral effects seen with cocaine 
(Volkow et al. 1996; Rothman et al. 2008; Stoops et al. 2012). Understanding the underlying 
molecular and physiological mechanisms that dictate whether or not a DAT blocker will induce 
psychotropic and addictive behaviors would greatly advance the development of 
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pharmacotherapeutics that could be used to treat drug abuse and addiction as well as attention 
and mood disorders. 
Major structural insights into DAT and the other monoamine transporters for serotonin 
and norepinephrine (SERT and NET) have resulted from the crystal structures of substrate and 
inhibitor bound complexes of both prokaryotic and eukaryotic SLC6 transporters (Yamashita et 
al. 2005; Singh, Yamashita, and Gouaux 2007; Singh et al. 2008; Krishnamurthy and Gouaux 
2012; Piscitelli and Gouaux 2012; Penmatsa, Wang, and Gouaux 2013; Wang, Penmatsa, and 
Gouaux 2015; Penmatsa, Wang, and Gouaux 2015; Coleman, Green, and Gouaux 2016). These 
proteins share a common structure of 12 transmembrane (TM) domains connected by 
intracellular and extracellular loops, with cytoplasmic N- and C-termini. The topology indicates 
an architecture of two 5 helix containing bundles arranged antiparallel to one another in the 
membrane (Shimada et al. 1991; Giros et al. 1992; Itokawa et al. 2000). Comparative modeling 
utilizing LeuT and dDAT templates assisted in understanding the mammalian monoamine 
transporters three-dimensional structural architecture as well (Huang and Zhan 2007; Koldsø et 
al. 2013). 
Examination of the substrate and inhibitor binding pockets in crystal structures of LeuT, 
dDAT, and hSERT demonstrated that antagonists and substrates could occupy a high affinity 
central substrate binding pocket (S1), generated by TM domains 1, 3, 6, and 8 (Yamashita et al. 
2005; Wang, Penmatsa, and Gouaux 2015), and, in the case of many SERT blocking 
antidepressants, a secondary, low affinity binding site (S2) located in the external vestibule 
(Singh, Yamashita, and Gouaux 2007; Coleman, Green, and Gouaux 2016). Antagonist 
occupancy of the S1 site would competitively inhibit transport whereas occupancy of the S2 site 
is thought to slow the dissociation of the S1 bound compound resulting in an allosteric 
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prolonging of the inhibitor effect through a noncompetitive mechanism (Chen et al. 2005; 
Neubauer, Hansen, and Wiborg 2006; Plenge et al. 2012). 
Findings from biochemical experiments and QSAR studies on cocaine binding as well as 
a dDAT/cocaine crystal complex suggest that cocaine could occupy the central, S1 substrate 
binding pocket in DAT (Carroll et al. 1992; Kitayama et al. 1992; Chen, Sachpatzidis, and 
Rudnick 1997; Henry et al. 2003; Henry et al. 2006; Beuming et al. 2008; Wang, Penmatsa, and 
Gouaux 2015). The data generated from site directed mutagenesis studies, where cocaine and 
cocaine analog binding sites were investigated, identified multiple residues in core TMs, 
including Leu-104, Phe-105, Ala-109, Asn-157, Tyr-251, Tyr-273, Thr-351 Ser-320, Thr-455, 
and Ser-459, that are involved in cocaine or cocaine analog binding, arguing against the S2 site 
as the cocaine binding site in DAT (Itokawa et al. 2000; Wu and Gu 2003; Chen, Han, and Gu 
2005; Beuming et al. 2008; Bisgaard et al. 2011). However, indirect effects resulting from these 
mutations cannot be ruled out (Uhl and Lin 2003).   
Here, we utilized the irreversible cocaine analog [125I]N-[4-(4′-azido-3′-iodophenyl)- 
butyl]-2-β-carbomethoxy-3β-(4-chlorophenyl) ([125I]MFZ 2-24) (Fig. 19) (Zou et al. 2001; Lever 
et al. 2005) in combination with comparative modeling, small molecule docking, molecular 
dynamics, peptide mapping, and SCAM protection analyses to identify the adduction site 
corresponding to high affinity binding of the photoactivatable ligand to DAT. MFZ 2-24, 
cocaine, and the cocaine analog (−)-2β-carbomethoxy-3β-(4-fluorophenyl)tropane (CFT) share a 
common pharmacophore consisting of the tropane ring and 3β-phenyl group that direct high 
affinity binding (Carroll et al. 1991; Carroll et al. 1994). All of these compounds bind 
noncovalently to DAT, but [125I]MFZ 2-24 contains a photoactivatable phenyl azido moiety that 
upon ultraviolet activation forms a highly reactive singlet nitrene that reacts with 
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Figure 19. Chemical structures of cocaine, CFT, and [125I]MFZ 2-24. (a) Structure of cocaine 
with tropane N and 3b-phenyl ester moieties indicated by stars. (b) Structure of CFT with phenyl 
fluoride moiety directly appended to the 3b position on the tropane pharmacophore (star). (c) 
Structure of [125I]MFZ 2-24 with AIP moiety appended directly to the tropane N. 
 
proximal C–H or N–H groups forming a covalent bond with the protein (Kotzyba-Hibert, 
Kapfer, and Goeldner 1995; Geurink et al. 2012). Using irreversible labeling as a strategy for 
determining the site of ligand-protein interaction, we previously demonstrated that [125I]MFZ 2-
24 cross-links to human (h) DAT between Asp-68 and Leu-80, a domain corresponding to the 
central and extracellularly directed regions of TM1 in DAT (Parnas et al. 2008). In this report, 
our computational approaches predicted MFZ 2-24 adduction at Leu-80 on TM1 in DAT and this 
finding was validated by mutagenesis and peptide mapping of the adduction site. Furthermore, 
our docking models predicted a S1 placement of the tropane core of MFZ 2-24, verified by 
SCAM analysis, a placement that overlaps with that of the tropane core of another cocaine 
analog, RTI 82 (Dahal et al. 2014). These findings show direct interaction of the core tropane 
pharmacophore of MFZ 2-24 with the central, S1 binding site, providing support for a 
competitive mechanism of action of cocaine for blocking DA transport. 
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Methodology 
Comparative DAT Homology Model Construction 
The outward-occluded and open-to-out rDAT homology models used in this study were 
generated previously (Dahal et al. 2014) using Rosetta3.1 (Leaver-Fay et al. 2011). An open-to-
out model of hDAT was constructed with Rosetta3.1 using the Drosophila dopamine transporter-
nortriptyline co-crystal (PDB ID 4M48) (Penmatsa, Wang, and Gouaux 2013). The top 10 
scoring models (Rosetta Etotal score) for each template were compared visually to the starting 
structure to verify overall structural integrity before moving forward with docking studies. 
Molecular Dynamics Analysis of DAT in Complex with MFZ 2-24 
The top scoring MFZ 2-24 poses, in complex with DAT, from RosettaLigand and 
Induced Fit Docking (IFD) were then subjected to molecular dynamic analysis for 150 ns using 
GROMACS (Dahal et al. 2014). 
Synthesis and Radiolabeling of MFZ 2-24 
Synthesis and radiolabeling of MFZ 2-24 was carried out as previously described (Zou et 
al. 2001; Lever et al. 2005).  
Chemicals and Materials 
[3H]CFT (76 Ci/mmol) was obtained from Perkin-Elmer (Waltham, MA, USA). [3H]DA 
(45 Ci/mmol), Protein A Sepharose, and Hyperfilm MP were from GE Healthcare Life Sciences 
(Piscataway, NJ). Site directed mutagenesis QuikChange® kit was from Stratagene (La Jolla, 
CA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Fisher 
Scientific (Pittsburgh, PA).  
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Cell Culture and Site-directed Mutagenesis 
Mutant constructs used for peptide mapping were stably expressed in Lewis Lung 
Carcinoma-Porcine Kidney (LLC-PK1) cells and were characterized previously (M111L/M116L, 
L80M/M111L/M116L) (Parnas et al. 2008) or were generated in the M111L/M116L rDAT 
cDNA background using the Stratagene QuikChange® kit and verified by sequencing 
(Northwoods DNA, MN). For ease of discussion, mutants V73M, A77M, D79, and L80M 
generated in the M111L/M116L background are referred by the TM1 mutation only. For stable 
expression of new constructs, LLC-PK1 cells were transfected using FuGENE transfection 
reagent and selected with 800 µg/mL of G418. Cells were maintained in a humidified chamber 
with 5% CO2 at 37°C in α-minimum essential medium (AMEM with 5% fetal bovine serum, 2 
mM L-glutamine, 200 µg/mL G418, and 100 µg/mL penicillin/streptomycin). Mutants for 
SCAM analysis were generated in the E2C background (C90A and C305A) of pcDNA3-rDAT 
using the Stratagene QuikChange® kit and verified by sequencing (Eurofins MWG Operon, 
Huntsville, AL). WT and mutant cDNAs were expressed transiently in HEK-GripTite cells 
(Invitrogen) using TransIT®-LT1 (Mirus) (1 µl per 200 ng of DNA). Cells were maintained in a 
humidified chamber with 5% CO2 at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM: 
10% FBS, 600 µg/ml G418). 
Photoaffinity Labeling and CNBr Peptide Mapping 
These procedures were performed as described previously (Dahal et al. 2014). Briefly, 
cells expressing WT or mutant DATs were washed twice with ice-cold Krebs-Ringers-Hepes 
(KRH) buffer (25 mM HEPES, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 
1.2 mM MgSO4, 5.6 mM glucose, pH 7.4) and incubated with 5 nM [125I]MFZ 2-24 in KRH for 
2 hr on ice in the presence or absence of 30 µM (-)-cocaine. Cells were irradiated with ultraviolet 
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light (254 nm) for 5 min to covalently attach the ligand to DAT, washed twice with cold KRH 
and lysed with radioimmunoprecipitation assay buffer (RIPA: 150 mM NaCl, 125 mM 
NaH2PO4, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, pH 7.4) containing protease inhibitor for 
30 min on ice with shaking. The lysates were centrifuged at 20,000 x g for 12 min at 4°C and 
supernatants were subjected to SDS-PAGE and autoradiography on 8% Tris-glycine 
polyacrylamide gels. Photolabeled DAT bands were excised from the gel, and protein was 
electroeluted and dialyzed against MilliQ H2O. Aliquots were counted in a scintillation counter 
and equal amounts of radioactivity from each sample were subjected to peptide mapping. For 
CNBr proteolysis, samples were lyophilized to dryness, and resuspended in 70 µL of 70% formic 
acid with or without addition of 1 M CNBr and incubated for 24 hr at 22°C in the dark. 
Reactions were quenched with 1 mL of MilliQ water and samples were lyophilized to dryness, 
followed by removal of CNBr with four additional rounds of resuspension with water and 
lyophilization. The final samples were suspended in immunoprecipitation buffer and divided into 
aliquots. Part of the sample (25-50%) was subjected directly to SDS-PAGE/autoradiography to 
visualize the total CNBr digestion pattern and the remainder was immunoprecipitated with 
monoclonal Ab 16 (mAb 16) prior to SDS-PAGE/autoradiography. For each experiment, 2-3 
mutants were photoaffinity labeled and analyzed with WT and L80M DAT exactly in parallel 
and all results were replicated at least 3 times. CNBr peptide masses were calculated using 
PeptideCutter via ExPASy. 
[3H]CFT Binding 
LLC-PK1 cells stably expressing WT and mutant rDATs were grown to ~80% confluency 
and washed with Hank’s balanced salt solution (HBSS). Cells were incubated with 10 nM 
[3H]CFT in KRH buffer for 2 hr at 4°C. Binding was performed in triplicate with nonspecific 
!!73 
binding determined in the presence of 10 µM mazindol. At the end of the incubation, cells were 
washed twice with KRH buffer, lysed with 1% TX-100, and samples assessed for radioactivity 
by liquid scintillation counting.  
[3H]DA Uptake 
WT or mutant rDAT-LLCPK1 cells were grown in 24-well plates to ~80% confluency in 
AMEM at 37°C. Cells were rinsed twice with 0.5 ml KRH buffer followed by addition of 0.5 ml 
warmed KRH (37°C). Uptake was performed in triplicate and initiated by addition of 10 nM 
[3H]DA plus 30 µM unlabeled DA, with nonspecific uptake determined in the presence of 100 
µM (–)-cocaine. Uptake was allowed to proceed for 8 min at 37°C and cells were rapidly washed 
three times with ice-cold KRH and solubilized in 1% Triton X-100. Radioactivity contained in 
lysates was assessed by liquid scintillation counting and protein content was assessed using BCA 
colorimetric reagent. 
SCAM Protection Analysis of S1- and S2-binding Sites 
GripTite cells were plated at a density of 150,000 cells/cm2 in 24-well culture plates, 
incubated for 24 hr, and transfected with rDAT constructs using TransIT®-LT1 (Mirus). 
Following transfection (48 hr), cells were processed as described previously (Henry et al. 2003; 
Dahal et al. 2014). Briefly, cells were incubated with 10 or 50 µM MFZ 2-24 or vehicle for 5 
min in PBS/CM (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, 0.1 mM 
CaCl2, 1.0 mM MgCl2, pH 7.4) followed by addition of 0.1 mM MTSEA-biotin for 10 min 
(Biotium). Cell lysates were obtained with RIPA solubilization buffer (10 mM Tris, pH 7.4, 150 
mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate) containing Halt™ Protease 
Inhibitor Single-Use Cocktail (ThermoFisher) and incubated with NeutrAvidin-agarose resin 
(ThermoFisher) to extract surface proteins labeled by MTSEA-Biotin. Following a BCA assay 
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(ThermoFisher) to determine protein concentration, equal amounts of protein from total samples 
and equivalent volumes of surface protein pools were processed by SDS-PAGE and 
immunoblotting using anti-DAT monoclonal antibody, mAb 16 (Foster, Pananusorn, and 
Vaughan 2002; Gaffaney and Vaughan 2004). DAT levels were quantitated from the density of 
immunoblot bands from at least three separate assays using ImageJ (National Institutes of 
Health). Surface values were normalized to total DAT levels and are expressed as a percent of 
untreated samples. Data were analyzed using a paired t test (Prism 4).   
Results 
Computational Docking of MFZ 2-24 to rDAT Homology Models 
To identify the site of MFZ 2-24 adduction to DAT and inform the biochemical 
crosslinking studies, in silico docking was performed on the open-to-out and outward-occluded 
rDAT comparative models (based on the LeuT crystal structures 2A65 and 3F3A) (Yamashita et 
al. 2005; Singh et al. 2008) using two independent methods, RosettaLigand (RL) and Induced Fit 
Docking (IFD). 
RosettaLigand Docking 
RL docking was performed and the top-scoring 5% (based on the interface_delta score, 
see methods) of the 25,000 RL-docked complexes (termed decoys) were filtered using three 
biochemically-defined molecular distance constraints. These constraints were defined as 5Å 
distance cutoffs between: (1) the MFZ 2-24 azido moiety and any atom in the residues Asp-79 
and Leu-80, (2) the tropane N of MFZ 2-24 and the side chain of Asp-79 (Dahal et al. 2014), and 
(3) the phenyl chloride of MFZ 2-24 and the side chain of Asn-157 (Beuming et al. 2008; Dahal 
et al. 2014). Using both filters (1) and (2) resulted in 89 and 5 decoys from the open-to-out and 
outward-occluded models, respectively. The addition of filter (3) reduced the number of decoys 
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fulfilling the constraints to 9 and 0 for the open-to-out and outward-occluded models, 
respectively. The top two scoring decoys had poses for MFZ 2-24 that only differed by 1.288 Å 
RMSD, however, evaluation of the distance between the N atom on the azido group that forms 
the reactive nitrene on MFZ 2-24 and the nearest C atom on the Leu-80 side chain indicated that 
the second best-scoring decoy (interface_delta score, -12.8) with intramolecular distance of 3.8Å 
(Fig. 20A) was more consistent with the molecular constraints than the top scoring decoy 
(interface_delta score, -15.4) which had an intramolecular distance of 5.8Å. Therefore, the 
second-best scoring pose was chosen and carried forward for molecular dynamic simulations. 
IFD Docking 
MFZ 2-24 was also docked into the open-to-out and outward-occluded models using IFD, 
which allows for the incorporation of the Na+ and Cl– ions along with their energetic and density 
contributions during the docking analysis (Wall, Innis, and Rudnick 1993; Barker et al. 1999; 
Yamashita et al. 2005; Forrest et al. 2007; Zomot et al. 2007; Dahal et al. 2014). IFD docking to 
the open-to-out and outward-occluded models yielded 12 and 2 structures, respectively. Of the 
12 open-to-out docked structures, only 1 complex fulfilled the nitrene/Leu-80 distance constraint 
(Fig. 21A). The nitrene/Leu-80 distance of the remaining 11 structures was >7.4Å, which 
eliminated them from further consideration. Analysis of the two outward-occluded IFD docked 
complexes revealed the distance between the nitrene group and the Leu-80 side chain was 5.3 
and 5.4Å, which is just outside of the molecular cutoff. However, to determine if refinement 
would result in a ligand pose that met the filter requirements, the best scoring complex was 
carried forward for MD analysis.  
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Figure 20. MFZ 2-24 and DAT RosettaLigand docking complexes and molecular dynamics 
simulation. (a) Best RL rDAT/MFZ 2-24-docked complex based on energy and constraint 
fulfillment. Image depicts the LeuT-based rDAT homology model from the crystal structure of 
the open-to-out template 2A65. (b) Molecular dynamics simulation of the RL rDAT/MFZ 2-24-
docked complex. (c) Superimposition of RL-docked MFZ 2-24 before (grey) and after (black) 
simulation. (d) Superimposition of RL-docked MFZ 2-24 pre-simulation (grey) and cocaine 
(yellow) from Drosophila DAT co-crystal. (e) Time-dependent changes in distances following 
molecular dynamics simulation between the protonated nitrogen of MFZ 2-24 and the side chain 
oxygen atom of Asp-79 (blue and black traces for ∂O1 and ∂O2) and the phenyl chloride of MFZ 
2-24 and the amide nitrogen of Asn-157 (red traces).     
  
MD Simulation of RL and IFD Docked MFZ 2-24 Poses  
To refine the selected RL and IFD poses the ligand-transporter complexes were placed in 
a POPC lipid bilayer and subjected to 120 ns of MD simulation using GROMACS (Hess et al. 
2008). Simulation of the RL f_1217 docked structure resulted in a pivoting movement of MFZ 2-
24 around the tropane N such that the phenyl Cl group moved down and away from Asn-157 to a 
distance of 8.5Å and the phenyl iodo azido arm moved slightly away from TM1 to a distance of 
4.1Å (Fig. 20B and 20C). The ∂O atoms of the Asp-79 side chain appear to alternate in 
coordinating the tropane N over the duration of the simulation (Fig. 20E), which was also 
observed in our previous analysis with the cocaine analog RTI 82 (Dahal et al. 2014). Similar to 
RL, MD analysis of the IFD pose resulted in moderate translation of MFZ 2-24 in the binding 
pocket. The Leu-80 and Asp-79 side chains also shifted such that they maintained a <5Å distance 
to the nitrene and tropane N, respectively (Fig. 21B and 21C). However, the intermolecular 
distance between Asn-157 and the phenyl Cl increases substantially; this constraint was used 
based on previous comparative modeling and mutagenesis work supporting interaction between 
the phenyl Fl of the cocaine analog CFT and Asn-157 (Beuming et al. 2008). Alignment of the 
pre- and post-MD RL and IFD-docked structures with the recent co-crystal of cocaine in the 
Drosophila DAT (Wang, Penmatsa, and Gouaux 2015) revealed that the MFZ 2-24 poses from 
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Figure 21. MFZ 2-24 and DAT Induced Fit Docking complexes and molecular dynamics 
simulation. (a) Best IFD rDAT/MFZ 2-24-docked complex based on energy and constraint 
fulfillment. Image depicts the LeuT-based rDAT homology model from the crystal structure of 
the open-to-out template 2A65. (b) Molecular dynamics simulation of the IFD rDAT/MFZ 2-24-
docked complex. (c) Superimposition of IFD-docked MFZ 2-24 before (grey) and after (black) 
simulation. (d) Superimposition of IFD-docked MFZ 2-24 pre-simulation (grey) and cocaine 
(yellow) from Drosophila DAT co-crystal. (e) Time-dependent changes in distances following 
molecular dynamics simulation between the protonated nitrogen of MFZ 2-24 and the side chain 
oxygen atom of Asp-79 (blue and black traces for ∂O1 and ∂O2) and the phenyl chloride of MFZ 
2-24 and the amide nitrogen of Asn-157 (red traces).     
 
the pre-MD structures are closer to cocaine in the co-crystal structure than structures following 
refinement by MD simulations (Fig. 20D and 21D). 
Peptide Mapping of Photoaffinity Labeled Site 
We previously demonstrated that [125I]MFZ 2-24 cross-links to DAT in TM1 between 
Ile-67 and Leu-80 (Parnas et al. 2008). Here we use Met substitution mutagenesis, CNBr 
proteolysis, and epitope specific immunoprecipitation to further narrow the adduction site. In this 
approach, Mets are substituted one at a time for endogenous residues between positions 67 and 
80 to generate novel CNBr cleavage sites for peptide mapping. The photolabeled proteins are 
digested and the fragments subjected to immunoprecipitation with mAb 16 directed against N-
terminal residues 42-59. There are no endogenous Mets in DAT between positions 11 and 106, 
thus if [125I]MFZ 2-24 adducts to a residue N-terminal to the inserted Met, the labeled fragment 
will contain the epitope for mAb 16 and will immunoprecipitate, whereas if adduction occurs C-
terminal to the inserted Met, CNBr digestion will separate the ligand from the antibody epitope 
and the photolabeled fragment will not immunoprecipitate. 
Because molecular modeling suggested adduction of [125I]MFZ 2-24 at Asp-79 or Leu-
80, we focused our efforts on residues close to these sites, inserting Met in place of Val-73, Ala-
77, and Asp-79. Mutants were stably expressed in LLC-PK1 cells and analyzed for expression, 
[3H]DA uptake, [3H]CFT binding, and [125I]MFZ 2-24 labeling. V73M and A77M DATs were 
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expressed as full-length protein and showed robust cocaine-sensitive transport and CFT binding 
activity. D79M DAT expressed poorly and, as expected, showed negligible transport, but the 
full-length protein displayed a small amount of [125I]MFZ 2-24 labeling and was analyzed due to 
molecular modeling findings that indicated Asp-79 as a possible adduction site. 
For peptide mapping studies, the photolabeled proteins were gel purified and subjected to 
treatment with vehicle (formic acid) or CNBr. For all experiments, WT and L80M DATs were 
labeled, digested, immunoprecipitated, and electrophoresed in parallel with the new constructs to 
provide positive controls for generation and immunoprecipitation of labeled fragments. Digested 
samples were divided into aliquots that were directly subjected to SDS-PAGE/autoradiography 
to visualize the total spectrum of CNBr fragments or were immunoprecipitated with mAb 16 
prior to SDS-PAGE/autoradiography. Within each experiment, samples from WT and mutant 
forms were adjusted to contain equal amounts of radioactivity to allow for direct comparison of 
fragment production and immunoprecipitation signals.  
Figure 22 shows the results of these analyses from [125I]MFZ 2-24-labeled WT and 
mutant DATs with the accompanying schematic diagrams indicating the origin of the labeled 
fragments in the primary sequence. Panel A shows the spectrum of total CNBr fragments 
generated from [125I]MFZ 2-24 labeled WT and mutant DATs with left and right panels showing 
independent analyses of the indicated mutants. In non CNBr-treated samples, full length DAT 
migrates at ~90 kDa (odd numbered lanes) with no low molecular weight fragments observed. 
Aggregates seen at ≥180 kDa are most likely induced by the formic acid treatment, as they were 
not seen in samples subjected directly to electrophoresis. CNBr treatment of WT rDAT produced 
a labeled fragment of ~12 kDa (lane 2; arrow a) that corresponds to the region between Met-1/11 
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Figure 22. CNBr mapping of [125I]MFZ 2-24-labeled DAT mutants. The indicated DAT 
forms were photolabeled with [125I]MFZ 2-24, gel purified, and equal amounts of radioactivity 
were treated with vehicle (odd numbered lanes) or CNBr (even numbered lanes). Aliquots of 
each sample were analyzed directly by SDS/PAGE-autoradiography to visualize the total pattern 
of CNBr fragments (a), or were immunoprecipitated with mAb 16 prior to SDS/PAGE-
autoradiography (b).  Left and right panels show independent experiments, and molecular mass 
markers shown on left gels are indicated by tic marks on right gels.  Arrow a indicates migration 
of ~12 kDa CNBr fragment that extends from the Met-1/11 to Met-106/111/116 and arrows b 
and c indicate ~3-8 kDa fragments produced by cleavage of exogenous TM1 Mets. Schematic 
diagrams show the cytosolic N-terminus, TMs 1 and 2, positions of endogenous and exogenous 
Met residues (filled circles), epitope for mAb 16 (bold line), adduction site of [125I]MFZ 2-24 
(star), and origin of photolabeled CNBr fragments in primary sequence (grey shading). 
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and Met-106/111/116 (shaded region in diagram a). The presence of doublets in some 
experiments is likely due to different proteolysis combinations, as the calculated mass of 
fragments extending from Met-1 to Met-116 is 12.7 kDa and the calculated mass of fragments 
extending from Met-11 to Met-106 is 10.5 kDa. CNBr treatment of [125I]MFZ 2-24 labeled 
L80M DAT produced a fragment of ~8 kDa, which is consistent with peptides extending from 
Met-1 or Met-11 to L80M (shaded region in schematic diagram b) with calculated masses of 7.5 
and 8.7 kDa, as demonstrated previously (Parnas et al. 2008). All of the new mutants showed 
similar levels of CNBr fragments in this low molecular mass region indicating that the ligand 
became adducted to the protein in a similar manner and arguing against the possibility that the 
mutation induced adduction of [125I]MFZ 2-24 in a different region of the primary sequence that 
would generate a different fragment pattern. For V73M, A77M, and D79M DATs, a labeled 
fragment similar to that generated from L80M DAT would be produced if the ligand becomes 
adducted N-terminal to the new CNBr site whereas a labeled fragment ~3 kDa extending from 
the new Met to Met106 (shown in diagram c) would be produced if the ligand adducts C-
terminal to the new CNBr site.  These possible fragments would not be distinguishable by SDS-
PAGE and both forms are indicated in Panel A with arrows b and c. Importantly, the intensity of 
fragment production for mutant DATs was comparable to that of the WT and L80M proteins 
allowing for direct comparison of immunoprecipitation signals. 
Panel B shows the mAb 16 immunoprecipitation profiles of the total digests shown in the 
upper panels. As we previously demonstrated (Parnas et al. 2008), mAb 16 immunoprecipitated 
the 12 kDa fragment from the WT DAT (lanes 2 and 10, arrow a) and the 8 kDa fragment from 
L80M DAT (lanes 4 and 12, arrow b) indicating that ligand incorporation occurs at or N-terminal 
to Leu-80 (diagrams a and b). In striking contrast, even though labeled fragments were present at 
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equal intensities in the total digests from V73M, A77M, or D79M DATs, these samples showed 
negligible immunoprecipitation by mAb 16 (lanes 6, 8, and 14). This strongly indicates that 
cleavage of TM1 at Mets 73, 77, and 79 separated epitope 16 from the [125I]MFZ 2-24 adduction 
site and thus that adduction occurred C-terminal to those Mets (diagram c). Therefore, because 
CNBr cleaves the peptide bond on the C-terminal side of Met residues, these data provide strong 
experimental evidence that [125I]MFZ 2-24 adduction occurs at Leu-80. 
Analysis of MFZ 2-24 Protection of S1- and S2-binding Pockets from Cys-directed 
Biotinylation 
 
Our computational docking and peptide mapping results strongly indicate that binding of 
the MFZ 2-24 tropane pharmacophore occurs within the S1-binding site and positions the azido 
group for adduction to Leu-80. In order to confirm binding of MFZ 2-24 to S1, we analyzed 
several residues present in the S1- or S2-binding sites in addition to several that line the 
transition between S1 and S2 (intermediate residues) in the DAT permeation pathway. Mutants 
were constructed in a methanethiosulfonate (MTS)-insensitive rDAT E2C (C90A and C305A) 
background and assessed for MFZ 2-24-induced protection from the SCAM reagent MTSEA-
biotin. 
Previously (Dahal et al. 2014), we identified that surface rDAT was readily labeled with 
MTSEA-biotin whereas labeling of rDAT E2C is undetectable (Fig. 23, Control), confirming it 
as a cysteine-reduced, MTS-inactive background suitable for analysis of inserted Cys residues. 
Utilizing rDAT E2C as a template, we generated Cys mutations of the S1 residues Asp-79, Ala-
81, Asn-82, Val-152, and Ser-421, the S2 residues Trp-84, Arg-85, Ile-159, and Asp-475, and the 
intermediate residues Phe-319, Ala-479, and Ile-483. MTSEA-biotin protection assays were 
done using 10 µM MFZ 2-24, except for the mutants D79C and S421C where marked losses in 
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potency to inhibit binding were observed, which required a higher concentration (50 µM) for 
protection analyses. 
 
 
Figure 23. SCAM protection analysis of S1 and S2 binding pockets. (a) Immunoblots of the 
surface pool of DAT Cys mutants in the rDAT E2C background purified with MTSEA-biotin in 
the absence (-) or presence of MFZ 2-24 (+, 10 µM; ++, 50 µM). (b) Quantification of DAT 
bands in A and total DAT expression (data not shown) were determined using ImageJ (National 
Institutes of Health). Surface samples were normalized to total DAT then expressed as a percent 
of MFZ 2-24-treated samples (black bars) to the respective untreated samples (white bars). These 
data represent three or more independent experiments. Significant differences between treated 
and untreated samples were determined with a paired t test *, p < 0.05; **, p < 0.01. 
 
Treatment with MFZ 2-24 did not affect recovery of biotinylated rDAT surface protein 
(Fig. 23, Control) indicating a lack of protection of residues Cys-90 and/or Cys-305, both of 
which are located on the extracellular ends of TMs 1 and 6, respectively. Recovery from the S1 
mutants D79C and S421C was significantly reduced in the presence of MFZ 2-24 (Fig. 23, S1), 
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demonstrating protection of these residues from the MTS reagent. Mutant A81C showed no 
change in recovery whereas MFZ 2-24 increased N82C and V152C recovery in a manner similar 
to cocaine, unlike RTI 82 (Dahal et al. 2014). This difference in cocaine analog protection likely 
arises from the position of the phenyl azido moiety, as the RTI 82 extension is oriented toward 
the external vestibule whereas MFZ 2-24 is bent inwards. In the S2 mutants, MFZ 2-24 did not 
alter recovery from W84C, R85C, I159C, and D475C (Fig. 23, S2) indicating a lack of 
protection of these residues from MTS attack. In combination, these data reveal binding of MFZ 
2-24 to DAT in the S1, but not S2, site. 
The intermediate residues Phe-319, Ala-479, and Ile-483 that lie at the interface between 
the S1- and S2-binding sites may provide insight into the conformation of DAT that is adopted 
upon antagonist binding. MFZ 2-24, like RTI 82 (Dahal et al. 2014), only protected mutant 
A479C from MTS modification (Fig. 23, Intermediate) whereas cocaine protected all 
intermediate sites. Though the azido groups of RTI 82 and MFZ 2-24 adduct to distinct sites in 
DAT, each analog has the addition of a phenyl azido moiety that, through its added bulk, may 
prevent DAT from transitioning to an occluded conformation. Cocaine, however, lacks the 
phenyl azido group and may induce a more complete transition to the occluded structure 
therefore providing protection of these residues. 
Discussion   
Cocaine interactions with DAT are complex and have been proposed to result in high and 
low affinity binding states (Madras et al. 1989; Boja et al. 1998) that alter uptake through 
competitive and noncompetitive mechanisms (Missale et al. 1985; McElvain and Schenk 1992). 
Cocaine may interact at the primary substrate binding site, S1, thereby competiting for DA 
binding (Beuming et al. 2008; Bisgaard et al. 2011; Dahal et al. 2014), or at the S2 site located in 
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the vestibule on the extracellular side of the outer gate (Huang, Gu, and Zhan 2009; Merchant 
and Madura 2012; Schmitt, Rothman, and Reith 2013). Binding of cocaine to either of these sites 
would likely lock the transporter into an inactive conformation, which would block substrate 
uptake. To address this discrepancy, our groups have developed a series of irreversible binding 
cocaine analogs to directly identify the site of incorporation. Here, we demonstrate covalent 
attachment of the cocaine photoaffinity analog MFZ 2-24 to the TM1 residue Leu-80 and, in 
conjunction with modeling and SCAM analysis, determined that the binding of the tropane 
pharmacophore occurs in the S1 substrate binding site.     
 Similar to our previous findings regarding the cocaine photoaffinity analog RTI 82 
(Dahal et al. 2014), our top scoring RL and IFD models maintain a salt-bridge interaction 
between the positively charged tropane nitrogen of MFZ 2-24 and the negatively charged side-
chain of residue Asp-79. These models also support an interaction between the phenyl chloride 
of MFZ 2-24 and Asn-157, an interaction that parallels previous findings with the phenyl 
chloride of RTI 82 (Dahal et al. 2014) and the phenyl fluoride of CFT (Beuming et al. 2008). 
Cocaine possesses a nonhalogenated benzoyl ester that does not interact with Asn-157 (Wang, 
Penmatsa, and Gouaux 2015), suggesting that interaction of a compound with Asn-157 may be 
dependent on the presence of a halogen. Though this interaction was originally thought to 
contribute to the higher affinity binding of CFT, RTI 82, and MFZ 2-24 (Runyon and Carroll 
2008), recent crystal structures of the cocaine analogs β-CFT and RTI-55 in complex with DAT 
suggest that Asn-157 does not directly participate in binding and that the halogen substituted 
phenyl groups do not markedly affect the architecture of the binding pocket (Wang, Penmatsa, 
and Gouaux 2015). This recent finding may explain why, after MD simulation, the phenyl Cl 
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group of MFZ 2-24 in our RL and IFD docked structures moves away from Asn-157 to distances 
greater than 5Å. 
 The adduction site of MFZ 2-24, Leu-80, coordinates substrate binding by forming a 
hydrophobic-aromatic interaction with Tyr-156, as mutation of Leu-80 destabilizes Tyr-156 
resulting in unmeasurable DA uptake though cocaine and CFT binding are unaffected (Beuming 
et al. 2008; Parnas et al. 2008). Mutation of the homologous site in SERT also resulted in 
decreased substrate transport, suggestive of a conserved role for this position in substrate 
transport (Henry et al. 2003). The S1 location of this residue, one helical turn above the TM1 
residue proposed to interact with the tropane nitrogen of MFZ 2-24 (Asp-79), indicates that MFZ 
2-24 inhibits DA uptake through a competitive mechanism either by binding to S1 in an 
occluded or outward-facing conformation. Our models reveal that an outward-facing 
conformation is more likely as our docking methods were unable to identify an MFZ 2-24/DAT 
complex based on an occluded homology model. Furthermore, our SCAM data supports binding 
of MFZ 2-24 in a manner similar to RTI 82 unlike cocaine. Whereas cocaine was able to protect 
intermediate residues from MTS inactivation, MFZ 2-24 and RTI 82 were unable to. This is 
likely a result of cocaine binding to an occluded conformation while the added bulk of the phenyl 
azido moieties of MFZ 2-24 and RTI 82 prevents closure of the extracellular gate and, therefore, 
formation of an outward-facing conformation. 
The physiological effects and economical burden imparted by cocaine abuse are several 
factors that highlight the importance of understanding the mechanism of cocaine binding and 
transport inhibition. The advent of the benztropine class of DAT antagonists, compounds that do 
not produce cocaine-like behavioral profiles (Agoston et al. 1997; Katz et al. 2004), suggests that 
a cocaine-abuse pharmacotherapeutic is possible. GBR12909 for example was a promising 
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pharmacotherapeutic as it decreased self-administration of cocaine following pretreatment 
(Baumann et al. 1994; Glowa et al. 1995; Tella 1995), but due to prolonged QTc intervals in 
patients participating in Phase II clinical trials (Vocci, Acri, and Elkashef 2005) and the ability to 
block multiple ion channels (Lacerda et al. 2010), it will likely benefit treatment of abnormal 
heart rhythms instead (Obejero-Paz et al. 2015; Piccini et al. 2016). Thus, understanding cocaine 
binding in relation to typical and atypical DAT inhibitors will provide needed insights for 
developing cocaine-abuse pharmacotherapeutics. 
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CHAPTER IV 
ANTAGONISM OF THE DOPAMINE TRANSPORTER BY THE IRREVERSIBLE 
BENZTROPINE ANALOG [125I]GA II 34 OCCURS AT THE CENTRAL SUBSTRATE-
BINDING SITE 
 
Introduction 
The dopamine transporter (DAT), a member of the SLC6 family of neurotransmitter 
transporters, or neurotransmitter sodium symporters (NSS), is responsible for the reuptake of 
dopamine (DA) from the synapse following vesicular release, effectively regulating 
dopaminergic neurotransmission. Disruptions in this mechanism of homeostatic regulation have 
been implicated in a variety of fundamental brain processes, including movement, emotion, 
behavior, and memory (Pramod et al. 2013; Kristensen et al. 2011). Furthermore, when targeted 
by the psychostimulant drugs cocaine, amphetamine, and methylphenidate, the function of DAT 
is inhibited through blockade of transport (Cheng et al. 2015; Gether et al. 2006; Sulzer et al. 
2005; Rothman and Baumann 2003), which results in elevated levels of extracellular DA and 
amplification of dopaminergic signaling. Although drugs of abuse are reinforcing, several classes 
of DAT uptake blockers have been developed that are both potent and selective yet lack the 
behavioral effects seen, for example, with cocaine (Rothman et al. 2007; Reith et al. 2015; 
Schmitt et al. 2008; Schmitt and Reith 2011). This suggests that development of improved 
pharmacotherapies for drug abuse and DA disorders is possible, though the molecular basis by 
which structurally distinct classes of inhibitors interact with the transporter and induce 
differential physiological outcomes is yet unclear. 
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The SLC6 family of transporters share a common topology of 12 transmembrane (TM) 
spanning domains connected by intracellular (IL) and extracellular (EL) loops with cytoplasmic 
N- and C-termini (Pramod et al. 2013; Kristensen et al. 2011; Bröer and Gether 2012). Similar to 
the biogenic amine, cocaine-sensitive serotonin (SERT) and norepinephrine (NET) transporters, 
with sequence identities of ~49- and ~67% respectively (Giros et al. 1992; Ramamoorthy et al. 
1993; Pacholczyk, Blakely, and Amara 1991; Reith 2002), DAT functions through the use of a 
Na+- and Cl--dependent electrochemical gradient, which drives translocation of substrate against 
its concentration gradient (Rudnick et al. 2013). Considerable insight into the structural 
mechanisms underlying substrate translocation emerged from crystal structures of the leucine 
transporter (LeuT) from Aquifex aeolicus, a prokaryotic homolog of the SLC6 transporters, as 
well as from more recent structures of Drosophila melanogaster (d) DAT and human SERT 
(hSERT) (Yamashita et al. 2005; Wang, Penmatsa, and Gouaux 2015; Coleman, Green, and 
Gouaux 2016). Based on a predicted alternating access mechanism (Jardetzky 1966), crystal 
structures have provided snapshots of the transporter in conformations corresponding to the three 
principal states of the transport cycle: outward-facing, occluded, and inward-facing 
(Krishnamurthy and Gouaux 2012; Yamashita et al. 2005). An outward-facing conformation 
opens to an aqueously accessible primary/central binding site (S1) composed of residues from 
TMs 1, 3, 6, and 8 that, after binding of substrate, two Na+ ions (Na1 and Na2), and one Cl- ion, 
initiates a conformational cascade beginning with the closure of an extracellular gate, which 
occludes S1, followed by opening of an intracellular gate and release of solutes into the 
cytoplasm (Zhao et al. 2011; Cheng and Bahar 2015; Tavoulari et al. 2015; Felts et al. 2014; 
Henry et al. 2011; Forrest et al. 2008). Alternatively, structures of LeuT, dDAT, and hSERT 
crystallized in complex with inhibitors have identified how the transport mechanism is halted in 
!!91 
the outward-facing or occluded conformation where antagonists are either bound to the S1 site 
(Penmatsa, Wang, and Gouaux 2015; Wang, Penmatsa, and Gouaux 2015; Penmatsa, Wang, and 
Gouaux 2013; Singh et al. 2008; Coleman, Green, and Gouaux 2016) or a highly controversial 
S2 site (Zhou et al. 2009; Quick et al. 2009; Singh, Yamashita, and Gouaux 2007; Zhou et al. 
2007; Coleman, Green, and Gouaux 2016), an extracellularly accessible site in the outer 
vestibule located above the outer gate, of which the existence and functional role still remain a 
topic of debate (Piscitelli, Krishnamurthy, and Gouaux 2010; Shi et al. 2008).  
As DAT is the primary target of cocaine, efforts to understand how the drug interacts 
with the transporter have identified the formation of a salt bridge between the negatively charged 
TM1 residue Asp79, a S1 residue responsible for coordinating the positive DA charge (Pramod 
et al. 2013; Kristensen et al. 2011; Bröer and Gether 2012), and the positively charged tropane 
nitrogen of cocaine, suggestive of a cocaine binding site in S1 and, consequently, a competitive 
mechanism of inhibition (Carroll et al. 1992; Kitayama et al. 1992; Beuming et al. 2008). To 
date, multiple DA uptake inhibitors have been developed in an attempt to identify a cocaine-
abuse therapeutic (Rothman 1990; Newman and Kulkarni 2002; Desai et al. 2005). One such 
compound is benztropine, a DAT antagonist equipotent to cocaine, and its analogs that do not 
demonstrate cocaine-like behavioral profiles (Newman, Allen, and Izenwasser 1994; Newman et 
al. 1995; Agoston, Wu, et al. 1997; Katz, Newman, and Izenwasser 1997; Katz et al. 2004; 
Hiranita et al. 2009), a result originally suggestive of a binding site separate from cocaine 
(Vaughan et al. 1999; Reith et al. 2001; Chen, Zhen, and Reith 2004; Ukairo et al. 2005; 
Rothman et al. 2007). However, subsequent computational docking studies and mutational 
analyses observed that cocaine and benztropines bind to the primary, S1 binding site (Beuming 
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et al. 2008; Bisgaard et al. 2011), though the interaction with DAT that accounts for the distinct 
behavioral effects is yet unknown.  
To determine the molecular interactions of benztropine with DAT, we developed the 
irreversible benztropine analog [125I]N-[n-butyl-4-(4′-azido-3′-iodophenylethyl-ester)]-4′,4′′- 
difluoro-3α-(diphenylmethoxy)tropane ([125I]GA II 34) (Fig. 24) (Agoston, Vaughan, et al. 
1997). GA II 34, benztropine, cocaine, and the cocaine analogs RTI 82 and MFZ 2-24 share the 
!
 
Figure 24. Chemical structures of cocaine, benztropine, [125I]GA II 34, [125I]MFZ 2-24, and 
[125I]RTI 82. Structures of cocaine (a), benztropine (b), [125I]GA II 34 (c), [125I]MFZ 2-24 (d), 
and [125I]RTI 82 (d) with the shared tropane nitrogen pharmacophore.   
 
common tropane nitrogen pharmacophore, but [125I]GA II 34 contains a photoactivatable 4′-
azido-3′-iodophenylethyl ester (AIP) moiety that forms a highly reactive singlet nitrene upon 
irradiation with ultraviolet light, thus forming a covalent bond with either a C-H or N-H group in 
the protein (Kotzyba-Hibert, Kapfer, and Goeldner 1995; Geurink et al. 2012). Using irreversible 
labeling as a strategy for determining the site of ligand-protein interaction, we previously 
demonstrated [125I]GA II 34 cross-links to rat DAT (rDAT) within TMs 1-2 (Vaughan et al. 
1999). Here, we utilized methionine substitution mutagenesis and cyanogen bromide (CNBr) 
digestion to narrow the site of [125I]GA II 34 attachment to either residue Asp-79 or Leu-80 as 
well as substituted cysteine accessibility method (SCAM) analyses that indicated that GA II 34, 
like cocaine and several cocaine analogs (Dahal et al. 2014; Pramod et al. in preparation), 
protected residues in S1, but not S2, indicative of a competitive mechanism of inhibition. These 
!!FIGURE!1!
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findings localize [125I]GA II 34 to a binding site overlapping that of cocaine, but whereas cocaine 
bound DAT forms a more occluded structure (Dahal et al. 2014), protection of one S2 residue as 
well as several S1 residues by [125I]GA II 34 suggests that the extracellular gate is unable to 
close and a more outward-open conformation is adopted, a finding that will need to be 
investigated further to explain the altered behavioral profiles.   
Methodology 
Cell Culture and Site-directed Mutagenesis 
For photoaffinity labeling experiments, wild-type (WT) and mutant cDNAs in pcDNA3-
rDAT vector were generated as previously described (Parnas et al. 2008; Dahal et al. 2014) using 
the Stratagene QuikChange® kit and verified by sequencing (Northwoods DNA, Solway, MN; 
Eurofins MWG Operon, Huntsville, AL). For stable expression of WT and mutants V78M, 
L80M, and M111L/M116L/M272L, Lewis Lung Carcinoma-Porcine Kidney (LLC-PK1) cells 
were transfected with 2 µg cDNA using FuGENE transfection reagent and selected with 800 
µg/mL of G418. Mutants for SCAM analysis, D79C, W84C, R85C, V152C, I159C, F319C, 
S421C, D475C, and A479C, were generated in the E2C background (C90A and C305A) of 
pcDNA3-rDAT and expressed transiently in HEK-GripTite cells (Invitrogen) using TransIT®-
LT1 (Mirus) (1 µl per 200 ng of DNA). Cells were maintained in a humidified chamber with 5% 
CO2 at 37°C in α-minimum essential medium (AMEM with 5% fetal bovine serum, 2 mM L-
glutamine, 200 µg/mL G418, and 100 µg/mL penicillin/streptomycin) for LLC-PK1 cells, or 
Dulbecco’s modified Eagle’s medium (DMEM: 10% FBS, 600 µg/ml G418) for HEK-GripTite 
cells. 
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GA II 34 Synthesis and Radioiodination  
GA II 34 and the amino precursor of [123I]GA II 34 were synthesized using modifications 
of the original procedure (Agoston, Wu, et al. 1997; Vaughan et al. 1999). Radioiodination was 
conducted as previously described (Agoston, Vaughan, et al. 1997). 
Photoaffinity Labeling and In Situ Proteolysis of Native DAT 
These procedures were performed as described previously (Parnas et al. 2008; Vaughan 
et al. 2007). Rat striatal membranes were homogenized in ice-cold sucrose phosphate (SP) buffer 
(0.32 M sucrose and 0.1 M Na2HPO4, pH 7.4). The homogenate was centrifuged at 3,000 x g for 
3 min. Supernatant was transferred to a fresh tube and centrifuged at 12,000 x g for 12 min. The 
final membrane pellet was resuspended at a concentration of 20 mg/ml (original wet weight) in 
Krebs Ringers HEPES (KRH) buffer (25mM HEPES, 125 mM NaCl, 4.8 mM KCL, 1.2 mM 
KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4) followed by addition of 10 
nM [125I]GA II 34. Samples were incubated on ice for 1.5-2 hr, irradiated with UV light (254 
nm) for 5 min to covalently attach the ligand to DAT, and washed 3x with 50 mM Tris-HCl to 
remove unbound ligand. After resuspension to a final concentration of 40 mg/mL original wet 
weight, 45 µl of photolabeled lysates were treated with 5 µl of trypsin prepared in 50 mM Tris-
HCl (10 µg/ml), pH 8.0, and incubated at 30ºC for twenty minutes. Digestion was halted with 
soybean trypsin inhibitor and centrifugation at 20,000 x g for 20 min. Membranes were 
solubilized with radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 0.1% SDS, pH 7.5) containing protease inhibitors (Complete Mini). Lysates 
were centrifuged at 20,000 x g for 12 min at 4°C, immunoprecipitated with polyclonal antibody 
16 (Ab16) or polyclonal antibody 19 (Ab19), and electrophoresed on 4-20% polyacrylamide gels 
followed by autoradiography.  
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Photoaffinity Labeling of Expressed DAT 
As previously described (Dahal et al. 2014), WT and mutant cells were plated on 6 well 
plates and, when 90-95% confluent, washed with KRH and incubated with 15 nM ligand on ice 
for 1.5-2 hr. Irreversible ligand incorporation was achieved with 254 nm UV light for 5 min and 
unbound ligand removed by washing twice with cold KRH. Samples were lysed with RIPA, the 
lysates centrifuged, and the supernatant subjected to SDS-PAGE and autoradiography on 8% 
Tris-glycine polyacrylamide gels. Photolabeled DAT bands were excised and the protein 
extracted by electroelution (Vaughan 1995). Electroeluted samples were dialyzed against 
deionized water in 10 kDa cut-off Slide-A-Lyzer dialysis cassettes (Pierce) and lyophilized. 
Aliquots were counted in a scintillation counter and equal amounts of radioactivity were 
subjected to peptide mapping.   
CNBr Peptide Mapping 
Gel purified samples were divided equally based on their radioactivity, lyophilized to 
dryness, and subjected to CNBr digestion. Samples were resuspended in 70 µL of 70% formic 
acid with or without addition of 1 M CNBr for 24 hr at 22°C in the dark. Reactions were 
quenched with MilliQ water and the samples lyophilized to dryness. To remove excess CNBr, 
samples were washed and lyophilized 3x followed by resuspension in immunoprecipitation 
buffer (50 mM Tris-HCl, 0.1% Triton X-100, pH 8.0). Sample was either directly subjected to 
SDS-PAGE/autoradiography to visualize the total CNBr digestion pattern or first 
immunoprecipitated with Ab16. For each experiment, mutants were photoaffinity labeled and 
analyzed with WT or L80M DAT exactly in parallel and all results were replicated twice. CNBr 
peptide masses were calculated using PeptideCutter via ExPASy. 
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SCAM Protection Analysis of S1- and S2-binding Sites 
GripTite cells were plated at a density of 150,000 cells/cm2 in 24-well culture plates, 
incubated for 24 hr, and transfected with rDAT constructs using TransIT®-LT1 (Mirus). 
Following transfection (48 hr), cells were processed as described previously (Dahal et al. 2014; 
Henry et al. 2003). Briefly, cells were incubated with 10 or 50 µM GA II 34 or vehicle for 5 min 
in PBS/CM (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, 0.1 mM CaCl2, 
1.0 mM MgCl2, pH 7.4) followed by addition of 0.1 mM MTSEA-biotin for 10 min (Biotium). 
Cell lysates were obtained with RIPA solubilization buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 
1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate) containing HaltTM 
Protease Inhibitor Single-Use Cocktail (ThermoFisher) and incubated with NeutrAvidin-agarose 
resin (ThermoFisher) to extract surface proteins labeled by MTSEA-Biotin. Following a BCA 
assay (ThermoFisher) to determine protein concentration, equal amounts of protein from total 
samples and equivalent volumes of surface protein pools were processed by SDS-PAGE and 
immunoblotting using anti-DAT monoclonal antibody, mAb 16 (Foster, Pananusorn, and 
Vaughan 2002; Gaffaney and Vaughan 2004). DAT levels were quantitated from the density of 
immunoblot bands from three separate assays using Image Studio (LI-COR). Surface values 
were normalized to total DAT levels and are expressed as a percent of untreated samples. Data 
were analyzed using a paired t test (Prism 5).      
Results 
Proteolytic Peptide Mapping of [125I]GA II 34 
Labeling and characterization of DAT with the benztropine photoaffinity analog [125I]GA 
II 34 was originally demonstrated in rat striatal membranes (Vaughan et al. 1999). To further 
characterize and reestablish interaction of [125I]GA II 34 with the dopamine transporter, LLC-
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PK1 cells expressing human DAT (hDAT) were incubated with 15 nM [125I]GA II 34 in the 
presence or absence of mazindol (Fig. 25). Immunoprecipitation of a ~100 kDa fragment by N-
terminal antibody 16 (Ab16), absent with the addition of mazindol, demonstrates specificity of 
[125I]GA II 34 for hDAT.  
!
Figure 25. Photoaffinity labeling of hDAT with [125I]GA II 34. 
hDAT LLC-PK1 cells photolabeled with 15 nM [125I]GA II 34 in the 
absence or presence of 10 µM mazindol followed by 
immunoprecipitation with Ab16. !
 
 
To reexamine the incorporation of [125I]GA II 34 with rDAT, 20 mg/ml of a rat striatal 
membrane suspension was incubated with a 10 nM final concentration of [125I]GA II 34. The 
subsequent lysate was treated with 10 µg/ml of trypsin, a protease known to digest peptides at 
arginine (Arg) and lysine (Lys) residues. The digested samples were immunoprecipitated with 
Ab16 or C-terminal antibody 19 (Ab19) to generate proteolytic peptide maps. Examination of the 
peptide maps indicates immunoprecipitation of the ~100 kDa fragment by both Ab16 and Ab19 
revealing [125I]GA II 34 labeling of rDAT as previously demonstrated (Fig. 26) (Vaughan et al. 
1999). Immunoprecipitation of the proteolyzed sample with Ab16 produced a fragment of ~45 
kDa previously determined to correspond to digestion at Arg-218 with incorporation of the AIP 
moiety somewhere within the N-terminus, TMs 1-3, or the glycosylated region of EL2 (Vaughan 
and Kuhar 1996; Parnas et al. 2008). Incubation of the irreversible cocaine analog [125I]RTI 82 
labeled DAT with antibody 5, directed against the C-terminal region of EL 2 (Vaughan, Uhl, and 
Kuhar 1993), has been shown to immunoprecipitate fragments of ~32 and ~10 kDa (Vaughan et 
al. 2007). Positive peptide maps with Ab19 have yet to be published, but immunoprecipitation of 
~32 and ~10 kDa fragments by Ab19 here does not indicate incorporation of the ligand to TMs 
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4-12 as these fragments are present in the undigested lane as well as the Ab16 lane indicating 
nonspecific immunoprecipitation.  
!
 
Figure 26. Photoaffinity labeling, in situ proteolysis, and immunoprecipitation of [125I]GA 
II 34 labeled rDAT. (a) Rat striatal membranes photolabeled with 10 nM [125I]GA II 34 were 
digested with 10 µg/ml trypsin followed by immunoprecipitation with Ab16 or Ab19 and SDS 
PAGE/autoradiography. (b) Schematic diagram of rDAT. TM domains are depicted as cylinders 
with the black circle representing Arg-218, the potential site of trypsin digestion. The presence of 
a 45 kDa fragment after immunoprecipitation with Ab16 indicates adduction of [125I]GA II 34 
within the shaded TMs.!
 
CNBr Mapping of [125I]GA II 34 Attachment 
Although trypsin digestion is extremely useful as a foundation from which to narrow the 
site of AIP attachment, the abundance of Lys and Arg residues available for digestion makes it 
difficult to identify the single residue at which adduction occurs. In contrast, the number of 
methionine (Met) residues in hDAT is limited to 13 (15 Mets in rDAT) allowing chemical 
digestion by cyanogen bromide (CNBr) to produce larger fragments while possibly retaining 
epitopes for immunoprecipitation. To implement CNBr digestion, we photolabeled WT hDAT 
expressed in HEK cells with [125I]GA II 34 as well as a mutant transporter 
M111L/M116L/M272L, hereby referred to as M272L, which was previously used to localize 
a b 
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incorporation of RTI 82 (Dahal et al. 2014). The M111L/M116L background is used in all 
mutant DAT constructs to rule out incorporation between residues Met-106, Met-111, and Met-
116. CNBr digestion of both [125I]GA II 34 labeled WT and M272L produced a ~10 kDa 
fragment (Figure 27) indicative of AIP adduction to a residue in DAT N-terminal to Met-106. 
Formation of a ~65 to 75 kDa fragment in M272L suggests a possible second incorporation site 
of [125I]GA II 34 elsewhere in DAT, however it is more likely that this fragment is a result of 
incomplete digestion of [125I]GA II 34 labeled M272L (Gaffaney and Vaughan 2004). 
Subsequently, as the majority of the radioactive signal is apparent at ~10 kDa, we focused on 
residues N-terminal to Met-106 to localize the site of AIP covalent attachment. 
!!
Figure 27. Localizing [125I]GA II 34 covalent attachment N-terminal to Met-106. HEK cells 
expressing WT hDAT or M111L/M116L/M272L hDAT were photolabeled with [125I]GA II 34 
and gel purified. Samples were treated with formic acid only (vehicle) or CNBr followed by 
analysis with SDS-PAGE/autoradiography. TM domains are depicted as cylinders. Black circles 
represent Met residues. CNBr digestion of WT hDAT produced a ~10 kDa (a) fragment 
indicating adduction N-terminal to Met-106. This fragment occurred after CNBr digestion of 
M272L as well, along with a ~65-75 kDa (b) fragment likely resulting from incomplete digestion 
of [125I]GA II 34 labeled M272L.   
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Localizing [125I]GA II 34 Adduction to TM1 in DAT 
Based on the structural similarity of [125I]GA II 34 to the irreversible cocaine analog 
[125I]MFZ 2-24 (Fig. 24), which was recently shown to adduct to Leu-80 (Pramod et al. in 
preparation), we predicted that incorporation of the AIP moiety of [125I]GA II 34 to DAT would 
occur near or at Leu-80 as well. Therefore, mutants M111L/M116L, L80M, and V78M were 
labeled with [125I]GA II 34 and subjected to CNBr digestion (Fig. 28). Digestion of the 
!!
Figure 28. CNBr mapping of [125I]GA II 34 labeled DAT to TM1. CNBr digestion of 
[125I]GA II 34 labeled M111L/M116L (M106), L80M, and V78M (A) immunoprecipitated with 
Ab16 (B). Digestion of M111L/M116L produced a ~10 kDa (a) fragment cooresponding to 
incorporation of [125I]GA II 34 to a residue N-terminal to Met-106 while digestion of mutant 
L80M resulted in ~8 and ~10 kDa fragments, of which the ~8 kDa (b) fragment is consistent 
with digestion N-terminal to Leu-80. Loss of the ~8 kDa fragment with V78M digestion 
indicates incorporation of [125I]GA II 34 C-terminal to Val-78, but at or N-terminal to Leu-80 
(c).   !
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M111L/M116L control resulted in a ~10 kDa fragment that immunoprecipitated with Ab16, 
demonstrating incorporation of [125I]GA II 34 to a residue N-terminal to Met-106 as the 
calculated mass of a fragment extending from Met-11 to Met-106 is 10.5 kDa. [125I]GA II 34 
labeled L80M produced two fragments of ~8 and ~10 kDa after digestion, both of which 
immunoprecipitated with Ab16 suggesting incomplete digestion at Met-106. The ~8 kDa 
fragment is consistent with peptides extending from Met-1 or Met-11 to L80M, with calculated 
masses of 7.5 and 8.7 kDa, respectively, as we previously described (Parnas et al. 2008). With 
digestion of V78M however, the ~8 kDa fragment is absent strongly indicating that cleavage of 
TM1 at Met-78 separated epitope 16 from the [125I]GA II 34 adduction site. Thus, binding of the 
AIP moiety of [125I]GA II 34 occurs at or N-terminal to Leu-80, but C-terminal to Val-78, 
narrowing the site of AIP covalent attachment to either Asp-79 or Leu-80. 
Analysis of GA II 34 Protection of S1- and S2-binding Pockets from Cys-directed 
Biotinylation 
 
Our peptide mapping results suggest that binding of the GA II 34 tropane pharmacophore 
occurs within the S1-binding site and positions the AIP group for adduction to Asp-79 or Leu-80. 
To confirm binding of GA II 34 to S1, we analyzed several residues present in the S1- or S2-
binding sites in addition to several that line the transition between S1 and S2 (intermediate 
residues) in the DAT permeation pathway (Fig. 29). Mutants were constructed in a 
methanethiosulfonate (MTS)-insensitive rDAT E2C (C90A and C305A) background and 
assessed for GA II 34-induced protection from the SCAM reagent MTSEA-biotin. 
Previously (Dahal et al. 2014), we identified that surface rDAT was readily labeled with 
MTSEA-biotin whereas labeling of rDAT E2C is undetectable (Fig. 29, Control), confirming it 
as a cysteine-reduced, MTS-inactive background suitable for analysis of inserted Cys residues. 
Utilizing rDAT E2C as a template, we generated Cys mutations of the S1 residues Asp-79, Ala-
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81, Asn-82, Val-152, and Ser-421, the S2 residues Trp-84, Arg-85, Ile-159, and Asp-475, and the 
intermediate residues Phe-319, Ala-479, and Ile-483. MTSEA-biotin protection assays were 
done using 10 µM GA II 34, except for the mutants D79C and S421C where marked losses in 
potency to inhibit binding were observed, which required a higher concentration (50 µM) for 
protection analyses. 
Treatment with GA II 34 did not affect recovery of biotinylated rDAT surface protein 
(Fig. 29, Control) indicating a lack of protection of residues Cys-90 and/or Cys-305, both of 
which are located on the extracellular ends of TMs. Recovery from the S1 mutants D79C and 
S421C was significantly reduced in the presence of GA II 34, demonstrating protection of these 
residues from the MTS reagent (Fig. 29, S1). Mutants A81C and N82C however showed no 
change in recovery whereas V152C recovery was increased by GA II 34. Notably, Asn-82 
accessibility was increased upon cocaine analog binding (Dahal et al. 2014), unlike the 
benztropine analog in which the added bulk of a diphenyl results in the differential accessibility. 
The intermediate residues Phe-319, Ala-479, and Ile-483 that lie at the interface between 
the S1 and S2 binding sites may provide insight into the conformation of DAT that is adopted 
upon antagonist binding. GA II 34, like the cocaine analogs RTI 82 and MFZ 2-24 (Dahal et al. 
2014; Pramod et al. in preparation), only protected mutant A479C from MTS modification 
whereas cocaine protected all intermediate sites (Fig. 29, Intermediate). Though the cocaine and 
benztropine analogs differ structurally and each azido group adducts to distinct sites in DAT, 
each analog has the addition of an AIP moiety that, through its added bulk, may prevent DAT 
from transitioning to an occluded conformation. Cocaine, however, lacks the AIP group and may 
induce a more complete transition to the occluded structure therefore providing protection of 
these residues.   
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In the S2 mutants, GA II 34 did not alter recovery from R85C, I159C, and D475C 
indicating a lack of protection of these residues from MTS attack (Fig. 29, S2). Conversely, 
recovery of surface protein was significantly less in the mutant W84C after GA II 34 treatment, 
which, based on our computational data (not shown), is not unexpected as the AIP moiety is in 
close proximity to Trp-84. In combination, these data reveal binding of GA II 34 to DAT in the 
S1, but not S2, site.  
 
Figure 29. SCAM protection analysis of S1 and S2 binding pockets. (a) Immunoblots of the 
surface pool of DAT Cys mutants in the rDAT E2C background purified with MTSEA-biotin in 
the absence (-) or presence of GA II 34 (+, 10 µM; ++, 50 µM). (b Quantification of DAT bands 
in A and total DAT expression (data not shown) were determined using Image Studio (LI-COR). 
Surface samples were normalized to total DAT then expressed as a percent of GA II 34-treated 
samples (black bars) to the respective untreated samples (white bars). These data represent three 
independent experiments. Significant differences between treated and untreated samples were 
determined with a paired t test *, p < 0.05; **, p < 0.01.!
 
 
a 
b 
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Discussion 
As DAT is the biological target responsible for the abuse liability of cocaine (Kuhar, 
Ritz, and Boja 1991), several high affinity DAT selective ligands have been developed and tested 
for the purpose of treating cocaine addiction. Despite substantial effort, there are currently no 
FDA-approved cocaine-abuse pharmacotherapies (Kim and Lawrence 2014) as the major 
obstacle with developing DAT antagonists is that they often have pharmacologies similar to 
cocaine. However, with the advent of the benztropine class of DAT antagonists came the 
development of compounds that do not demonstrate cocaine-like behavioral profiles (Agoston, 
Wu, et al. 1997; Katz et al. 2004). These findings suggest that the altered chemical structure of 
benztropine compared to cocaine results in distinct interactions with DAT that may account for 
the different pharmacological and behavioral profiles.  
To address whether benztropine binds to DAT in a manner that is different from that of 
cocaine, our groups have developed irreversible binding tropane and benztropine analogs to 
probe specific sites of ligand interaction (Vaughan et al. 1999; Vaughan et al. 2007; Parnas et al. 
2008; Dahal et al. 2014; Pramod et al. in preparation). Previously, we provided evidence that 
adduction of [125I]GA II 34 occurred at a site located within TMs 1-2 (Vaughan et al. 1999) and 
in the present study we narrowed the site of AIP incorporation to residues Asp-79 or Leu-80 as 
well as directly demonstrated binding of the benztropine pharmacophore in the central, S1 
binding site. As [125I]GA II 34 binds near or at Asp-79, a residue vital for the transport of DA 
(Penmatsa, Wang, and Gouaux 2015) and one that retains 85% homology in the cocaine-
sensitive monoamine transporters (Amara and Kuhar 1993), it is likely that a salt-bridge forms 
between Asp-79 and the tropane nitrogen of GA II 34, an interaction that is duplicated by 
cocaine and its analogs (Beuming et al. 2008; Dahal et al. 2014; Pramod et al. in preparation). 
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Furthermore, the near overlap of computationally docked [125I]GA II 34 and [125I]MFZ 2-24 in a 
homology model of hDAT (Pramod et al. in preparation, data not shown) supports binding of 
GA II 34 to a site overlapping that of cocaine.  
 Prior to the development of the photoaffinity ligand [125I]GA II 34, its precursor GA 103, 
which is not iodinated nor does it have an azido group, was evaluated extensively. This 
compound demonstrated high affinity and selectivity for DAT, but did not significantly increase 
locomotor activity in mice (Agoston, Wu, et al. 1997). Furthermore, in rats trained to 
discriminate cocaine from saline, there was no GA 103 dose-related increase on the cocaine-
appropriate response key. Based on these data as well as the ability of [125I]GA II 34 to bind to 
DAT with an affinity equipotent to cocaine (160 nM (Vaughan et al. 1999) compared to 187 nM 
(Katz et al. 2001)), it was originally suggested that [125I]GA II 34 exerts its non cocaine-like 
effects by binding to a site in DAT distinct from cocaine (Vaughan et al. 1999). As our data 
suggests otherwise, by supporting a shared binding site, the next step in explaining the varied 
behavioral profiles of benztropines and cocaine, which are likely not a result of the 
antihistaminic and antimuscarinic properties of benztropines (Newman and Katz 2008), is to 
identify distinct S1 residues (or S2 residues, as [125I]GA II 34 protected Trp-84 from MTS 
modification) in DAT that preferentially interact with [125I]GA II 34. In contrast to previous 
SCAM analysis (Loland et al. 2008), our findings suggest that cocaine stabilizes an occluded 
DAT structure (Dahal et al. 2014) while cocaine analogs and [125I]GA II 34 prevent closure of 
the extracellular gate thereby causing DAT to adopt a more extracellularly-facing conformation, 
results that may explain the altered behavioral profiles. Thus, though the binding sites overlap, 
understanding the distinct interactions of [125I]GA II 34 with DAT in comparison to cocaine will 
help direct development of cocaine-abuse pharmacotherapies.   
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CHAPTER V 
MEMBRANE POTENTIAL SHAPES REGULATION OF DOPAMINE TRANSPORTER 
TRAFFICKING AT THE PLASMA MEMBRANE 
 
Introduction 
Central nervous system dopaminergic (DAergic) neurotransmission is essential in 
multiple neurological functions, including cognition, extrapyramidal motor control, the reward 
pathway and attention (Schultz 2007; Nieoullon 2002; Koob and Volkow 2010; Jaber et al. 
1996). In addition to the timing of vesicular release of dopamine (DA) and the expression 
profiles of G-protein-coupled DA receptors (Mundorf et al. 2000; Beaulieu and Gainetdinov 
2011), one major regulator of DA signaling magnitude and timing is the DA transporter (DAT), 
which rapidly transports extracellular DA into the intracellular space for vesicular re-packaging 
or effluxes DA through reversal of DAT-mediated transport (Jaber et al. 1997; Sitte et al. 1998). 
Commonly abused psychotropic drugs, amphetamine (AMPH), methamphetamine and cocaine 
achieve their effects either by inducing DA efflux through DAT and/or blocking DA uptake 
(Kahlig et al. 2005; Khoshbouei et al. 2003; Amara and Sonders 1998). 
The physiological function of DAT to remove DA is coupled to the translocation of one 
Cl− and two Na+ ions (Sitte et al. 1998; DeFelice and Galli 1998; Sonders et al. 1997), and can 
even function in the absence of substrate, conducting an uncoupled, cocaine-sensitive, 
depolarizing current under physiological conditions (Sonders et al. 1997; Ingram, Prasad, and 
Amara 2002), which is increased in hyperpolarized states (Khoshbouei et al. 2003). In addition 
to direct modulation of transport function, DAT density at the cell membrane, and 
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therefore its functional capacity, is also dynamic. Regulated trafficking mechanisms control 
surface-membrane DAT levels under physiological conditions (Schmitt and Reith 2010; 
Mortensen and Amara 2003) and in response to DAT substrates (Schmitt and Reith 2010; 
Mortensen and Amara 2003), thus having an impact on DA homeostasis. Cell signaling 
molecules involved in the regulation of DAT trafficking range from protein kinase C (PKC) 
(Pristupa et al. 1998; Sorkina et al. 2005), mitogen-activated protein kinase (Morón et al. 2003) 
to Akt (Wei et al. 2007) among others (Schmitt and Reith 2010; Mortensen and Amara 2003) 
and determine the presence of DAT in regulated or constitutive pools segregated to specific 
membrane microdomains (Cremona et al. 2011; Adkins et al. 2007; Sakrikar et al. 2012). Many 
DAT substrates also influence DAT trafficking (Schmitt and Reith 2010; Kahlig and Galli 2003; 
Zahniser and Sorkin 2004), including DA and AMPH, which decrease DAT surface density (Chi 
and Reith 2003; Zahniser and Sorkin 2009; Saunders et al. 2000), and cocaine, which increases 
DAT surface expression (Daws et al. 2002). 
Interestingly, AMPH's effects are twofold, as it causes DAT internalization (Chi and 
Reith 2003; Zahniser and Sorkin 2009; Saunders et al. 2000) and a DAT-dependent membrane 
depolarization (Sonders et al. 1997; Ingram, Prasad, and Amara 2002), which suggests an 
influence on DAT trafficking via a voltage-dependent mechanism in addition to DAT 
phosphorylation. Indeed, previous studies using striatal synaptosomes have revealed a reduction 
in DA uptake in depolarized (elevated KCl) conditions (Woodward et al. 1986; Holz and Coyle 
1974), while in vitro preparations have suggested elevated DAT function at hyperpolarized states 
(Sonders et al. 1997). However, it is not known whether these changes in functional capacity 
arise from changes in ionic driving forces, essential for DA transport, changes in DAT protein 
presence at the membrane or both. While changes in the cell membrane voltage state are only 
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typically considered in terms of neurotransmitter release, action potential generation and timing 
or in the activity of voltage-sensitive transmembrane proteins, it is possible that changes in 
membrane potential (MP) alone may rapidly and reversibly affect DAT trafficking to and from 
the cell surface. Here we use confocal and total internal reflection fluorescence microscopy 
(TIRFM), biochemistry, electrophysiology and optogenetics to demonstrate the degree to which 
surface-membrane DAT levels are shaped by and sensitive to MP changes. 
Methodology 
Cell Culture 
Cell lines. HEK cells overexpressing FLAG-tagged or YFP-tagged human DAT (hDAT), 
HEK FLAG-DAT (Hastrup, Karlin, and Javitch 2001; Hastrup, Sen, and Javitch 2003) or YFP-
DAT HEK (Kahlig, Javitch, and Galli 2004), respectively, were a generous gift from Dr. 
Jonathan Javitch (Columbia University) prepared from HEK293 EM4 as previously described 
(Goodwin et al. 2009; Eshleman et al. 1994). The addition of the YFP tag and FLAG epitope to 
hDAT is a widely used construct and has not been shown to alter basic functional properties of 
the transporter or other transporter-mediated activity (Kahlig and Galli 2003; Hastrup, Karlin, 
and Javitch 2001; Hastrup, Sen, and Javitch 2003; Goodwin et al. 2009; Saha et al. 2014). HEK 
cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 5% L-
glutamine, penicillin (50.µl.ml−1) and streptomycin (50.µl.ml−1) at 37.°C and 5% CO2. Cells were 
typically passaged and/or used for electrophysiology or imaging experiments after reaching 60–
80% of full confluency (every 2–3 days). To induce expression of constructs not stably 
expressed in HEK cell lines, HEK293 EM4 cells were transfected using a standard calcium 
phosphate protocol. Transfected cells were used in experiments 12–36.h after transfection. 
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Midbrain primary neuron culture. All animals used were housed in the University of 
Florida's McKnight Brain Institute animal care facility, an Association for Assessment and 
Accreditation of Laboratory Animal Care International-accredited facility. The University of 
Florida's Institutional Animal Care and Use Committee approved of all procedures undertaken. 
Primary cultures of the ventral midbrain containing DAergic neurons were prepared as 
previously described (Kahlig et al. 2005; Saha et al. 2014; Fog et al. 2006) and are described 
here in brief. The ventral midbrain, including DA neuron-rich regions, was acutely dissociated 
and isolated under sterile conditions from 0- to 2-day-old C57Bl/6J mice of both sexes and 
incubated at 34–36.°C under continuous oxygenation for 30.min in a dissociation medium, 
containing (in mM): 116 NaCl, 5.4 KCl, 26 NaHCO3, 25 glucose, 2 NaH2PO4, 1 MgSO4, 1.3 
cysteine, 0.5 EDTA, 0.5 kynurenic acid and containing 20 units.ml−1 papain. Subsequently, tissue 
was triturated with fire-polished Pasteur pipettes in glial medium, containing (in %): 50 MEM, 
38.5 FBS, 7.7 penicillin/streptomycin, 2.9 D-glucose (45%) and 0.9 glutamine (200.mM). 
Dissociated cells were pelleted at 450g for 10.min and were re-suspended in glial medium. Cells 
were plated on 12-mm round coverslips placed in 35 × 10.mm style tissue culture Petri dishes or 
glass-bottom 35 × 10.mm (MatTek, Ashland, MA) coated with 100.µg.ml−1 poly-D-lysine and 
5.µg.ml−1 laminin. One hour after plating, the medium was changed to neuronal medium, 
containing (in %): 2 MEM, 75 Ham's-F12 medium, 19 heat-inactivated horse serum, 2 FBS, 1.56 
D-glucose (45%), 0.04 insulin (0.025.g.ml−1) and 0.4 apotransferrin (50.mg.ml−1). Neuronal 
cultures were transfected with TAGRFP-T-DAT, CFP-DAT and/or Arch-YFP constructs via 
nucleofection (Mouse Nucleofector Kit, programme O-005, Lonza Group Ltd, Basel, 
Switzerland) immediately before plating or via calcium phosphate 3–5 days after plating using 
standard protocols. All cultures were used at 7–9 days in vitro (DIV) and 4–9 days post 
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transfection. No difference between transfection methodologies was observed regarding protein 
expression level and/or function. 
Plasmid Constructs 
The plasmid coding for the cyan fluorescent protein-tagged DAT was described 
previously (Sorkina et al. 2003; Miranda et al. 2005) and was provided as a generous gift from 
Dr. Alexander Sorkin (University of Pittsburgh). The RFP-tagged hDAT (TagRFP-T-DAT) 
(Gabriel et al. 2013), generated as previously described, was a gift from Dr. Haley Melikian 
(University of Massachusetts), and the construct for fatty-acid receptor GPR40-eYFP driven by 
the cytomegalovirus promoter was a gift from Dr. Sergei Zolotukhin and Seth Currlin 
(University of Florida). DsRed-Rab11 WT (Choudhury et al. 2002), a recycling endosome 
marker, was a gift from Richard Pagano (Mayo Clinic and Foundation, Addgene plasmid 
#12679). TagRFP-T-EEA1 (Navaroli et al. 2012), an early endosome marker, was provided by 
Silvia Corvera (University of Massachusetts Medical School, Addgene plasmid #42635). The 
GFP-C1-CAMKIIα-K42R (Shen and Meyer 1999) was a gift from Tobias Meyer (Stanford 
University, Addgene plasmid #21221), and the pTfR-PAmCherry1 (Subach et al. 2009) plasmid 
was a gift from Vladislav Verkhusha (Albert Einstein College of Medicine, Addgene plasmid 
#31948). To confer optical control of MP hyperpolarization, neuronal cultures were transfected 
with AAV-CaMKα-eArch 3.0-EYFP plasmid, a generous gift from Dr. Karl Deisseroth 
(Stanford University). Arch was chosen for its ability to induce large magnitude H+-current-
hyperpolarizing shifts (10–50.mV) in the neuronal MP, which were relatively stable over seconds 
to minutes with minimal decay when continuously activated (Mattis et al. 2012; Zhang et al. 
2011). 
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Electrophysiology 
HEK cells and cultured neurons were visualized with a × 60 objective on an inverted 
Nikon Ti Eclipse microscope (Nikon, Melville, NY). All currents and MPs were recorded via an 
Axoclamp 200A amplifier using the whole-cell configuration after forming a high-resistance seal 
in the cell-attached configuration (>1.MΩ). All signals were digitized with a Digidata 1440A at 
10.kHz, and a 5-kHz low-pass Bessel filter was applied during acquisition. An additional 2-kHz 
Gaussian filter was applied to all traces for presentation only. The standard external solution for 
electrophysiology experiments using HEK cells was the same used in all microscopy and 
biochemistry experiments and contained (in mM) the following: 130 NaCl, 10 HEPES, 34 
Dextrose, 1.5 CaCl2, 0.5 MgSO4 and 1.3 KH2PO4, with a pH of 7.35 and osmolarity of 275–
290.mOsm. Pipettes for whole-cell recordings were pulled from borosilicate glass on a P-2000 
laser-based puller (Sutter Instruments, Novato, CA). Pipettes used for recording the MP (3–
6.MΩ) were filled with an internal solution containing (in mM) the following: 130.K-gluconate, 
10 KCl, 10 HEPES, 1 EGTA, 2 MgCl2 adjusted to pH 7.35 and osmolarity of 262.mOsm. For 
recording of DAT-mediated whole-cell currents, pipettes were filled with (in mM) the following: 
120 CsCl, 30 dextrose, 10 HEPES, 1.1 EGTA, 2 MgCl2 and 0.1 CaCl2 adjusted to pH 7.35 and 
osmolarity of 264.mOsm. Recordings were performed at 37.°C. For determining DAT-mediated 
current and IV changes at different holding potentials, a stable IV (−100 to +40 in 20.mV steps) 
was generated after 5.min of continuously holding the cell at the given potential (−60, −40 or 
+20.mV), and then the DAT blocker GBR12935 (20.µM) was added to the bath and subsequent 
IVs were measured every 30–60.s. To determine the DAT-mediated current amplitude, the IV in 
the presence of GBR12935 (Fig. 39c; protocol #2; grey traces) was subtracted from the 
preGBR12935 IV following the prolonged clamp of the MP (Fig. 39c; protocol #1; red=+20.mV, 
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black=−40.mV, blue=−60.mV) to yield the DAT-mediated (GBR12935-sensitive) current at each 
voltage step of the IV (the curve displayed in Fig. 39d) corresponding with manipulation of the 
MP state in previous TIRFM experiments (Fig. 38). For statistical comparisons between groups 
(Fig. 39e,f), the DAT-mediated current (pre-GBR12935–post-GBR12935 amplitude) at the 
−100.mV step, where DAT-mediated current is largest, was used. 
For recording and imaging of DAergic neurons in primary culture, the external solution 
contained (in mM) the following: 146 NaCl, 5 HEPES, 5 KCl, 30 Dextrose, 2.5 CaCl2 and 1.2 
MgCl2, with pH 7.35 and had an osmolarity of 290–300.mOsm. Patch pipettes (4–6.MΩ) were 
filled with an internal solution containing the following (in mM): 135 K-gluconate, 5 KCl, 2 
MgCl2, 10 HEPES, 0.1 EGTA, 2 Mg-ATP and 0.2 Na-GTP, pH adjusted to 7.35 and osmolarity 
of 270.mOsm. Recordings of the neuronal MP were corrected offline for a calculated liquid 
junction potential of 16.1.mV. All recordings occurred at 37.°C. 
Microscopy 
All microscopy analyses were performed at 37.°C, and cells were washed twice with 
external solution as described above before all experiments. For all imaging experiments, 
cells/neurons were set on 35-mm glass-bottom dishes (MatTek, Ashland, MA) with glass 
thickness of 0.13–0.16.mm (TIRFM) or 0.085–0.13.mm (confocal). Wide-field fluorescence 
images were acquired identically to TIRFM images; however, a Lambda LS Xenon Arc Lamp 
provided the light source that bypassed the additional TIRFM mirror set and was passed through 
appropriate excitation (Ex)/emission (Em) filters and dichroic mirror. Microscopy data were 
analyzed in the Nikon's NIS Elements software. 
TIRFM. TIRFM imaging of HEK cells and neurons plated on poly-d-lysine-coated 
dishes was performed at 37.°C using Nikon Eclipse TE-2000-U inverted microscope, with a × 60 
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1.49 numerical aperture (NA) objective and equipped with a multiline solid-state laser system 
(470, 514 and 561.nm) and appropriate filter combination for YFP (Ex: 514.nm/Em: 535.nm), 
TagRFP (Ex: 561.nm/Em: 584.nm) and CFP (Ex: 445.nm/Em: 475.nm), similar to as previously 
described (Saha et al. 2014). TIRFM was achieved via the ‘through-the-objective' laser guidance 
method with the laser incident angle set to 76°, which is greater than the critical angle of 62° and 
generated an evanescent field depth between 66 and 72.nm depending on the wavelength of light 
used. Temperature control was maintained with a stage and an objective heater (20/20 
Technology Inc.). Image exposure time was coupled with laser excitation duration at 200–
300.ms, and laser intensity was maintained at 40–60% of maximum intensity, but neither 
changed throughout the course of a given experiment. Images were detected digitally using an 
attached CoolSNAP HQ2 CCD camera and stored on a computer hard drive at 5–10-s intervals. 
For imaging of HEK cells, baseline images were acquired during perfusion of standard external 
solution before changing the solution to 100-mM KCl-based external solution (osmotically 
balanced) or 10.µM AMPH, prepared as described above, or throughout the entirety of being 
held in the whole-cell configuration. For simultaneous patch-clamp and TIRFM, membrane-
holding potentials of +20, −40 and −60.mV were determined in preliminary experiments to 
approximate endogenous resting potential of these cells (−40.mV), to mimic the effects of 100-m 
KCl depolarization (+20.mV) and to oppose depolarizing effects of +20.mV with a similar 
magnitude of change (−60.mV). 
For quantification of cell-surface fluorescence intensity of isolated HEK cells and 
primary culture neurons, regions of interest were created, including the TIRFM footprint of each 
HEK cell in its entirety or the neuron's soma. For all image sequences, a background ROI similar 
to the size of a cell was placed in a region devoid of cells/fluorescence and was subtracted from 
!!114 
the entire image and recalculated for each frame. The mean intensity (in arbitrary fluorescent 
units) over time was monitored and plotted/analyzed as a fraction of the baseline intensity (the 
mean raw intensity of all frames within 30–60s before initiation of indicated manipulation) and 
used for analysis. Bleaching was controlled for in two ways. The first was the inclusion of a 
vehicle group and/or non-patched adjacent cells for each assay appropriately. However, because 
of relatively large observed cell-to-cell variability in the change in baseline fluorescence over 
time ranging from −3.0 to +2.1% per min (average 0.4±0.3% per min), a correction factor or rate 
was determined for each cell and was used to account for this change in each cell. Since the 
bleaching rate with the current TIRFM imaging parameters was linear, a linear fit was generated 
for 120.s before a solution change and was used to determine that the rate of bleaching was 
extrapolated over the entire 12–15 min experiment. This projected rate of change in fluorescence 
intensity due to bleaching was then accounted for during each experiment. 
Confocal microscopy and JHC 1-064 labeling of DAT. Imaging of YFP-DAT (Ex: 
514.nm, Em: 540/30.nm), mCherry, dsRed and JHC 1-064 (all Ex: 561.nm, Em: 585/65.nm) was 
performed using the Nikon A1R confocal system mounted on a Nikon Eclipse Ti-E inverted 
microscope (Nikon) using a × 60 1.49 NA Plan-Apo objective (Nikon). For YFP-DAT and 
endosome co-localization experiments, YFP-DAT HEK cells grown on glass-bottom dishes and 
transfected with TagRFP-T-EEA1 or DsRed-Rab11 were treated with either 100.mM KCl for 
5.min, 10.µM AMPH for 1.h or with standard external solution vehicle throughout all the 
experiments at 37.°C. After the treatment, the dishes were placed on ice and washed with the ice-
cold standard external solution, then washed two more times with ice-cold PBS solution and then 
fixed in 3.7% paraformaldehyde. Cells were then washed and imaged using identical imaging 
parameters (for example, laser power, gain, and so on) immediately in PBS. For co-localization 
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analysis, a region of interest (ROI) was drawn over the intracellular space of each cell in the raw 
image and the Pearson correlation coefficient for the two channels was calculated on a cell-by-
cell basis in NIS Elements (Nikon). For clarity and image display only, a single-count 3 × 3 pixel 
matrix smooth was applied, and intensity of all pixels was enhanced by 40%. 
The fluorescent cocaine analogue, JHC 1-064, which has a high affinity for DAT, was 
used as previously described to selectively label membrane-resident DAT (Cha et al. 2005; 
Eriksen et al. 2009; Eriksen et al. 2010; Rickhag et al. 2013). When YFP-DAT HEK cells had 
reached 60–80% confluency after 2–3 days or midbrain primary culture neurons had reached 
DIV 5, they were washed twice with the appropriate standard external solution and incubated 
with 10–20.nM JHC 1-064 for a minimum of 30.min at 4.°C. After at least 30.min, the JHC 1-
064-containing solution was removed and replaced with fresh 4.°C external solution. 
Immediately, the dish was placed on the stage, and cells were selected and a baseline image was 
acquired. Following acquisition, the cold solution was removed and replaced with either vehicle 
or KCl-based external solution at 37.°C, and images were acquired every 5.min. Imaging 
parameters (for example, laser power, gain, pinhole, and so on) were identical for images of 
HEK cells and were within the imaging series of each neuron. For analysis of JHC 1-064/DAT 
complexes in HEK cells, an area devoid of cells was selected and used as a background ROI, and 
the mean pixel intensity of this region was subtracted from intensity of all pixels. For 
determination of the mean intracellular intensity, an ROI was drawn within the boundaries of 
each cell and the mean intensity (normalizing for changes in cell size) was again normalized to 
the intensity of the entire image to account for bleaching and was plotted as a fraction of the 
initial internal fluorescence in the original control 4.°C image (Kahlig et al. 2006). For manual 
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counts of intracellular JHC 1-064 puncta and clarity for display (Fig. 36 and 42), all images were 
processed identically. 
Depolarization-induced Ca2+ influx. Neuronal intracellular free calcium [Ca2+], was 
measured using cell-permeant, ratiometric calcium dye Fura-2 AM (Life Technologies). Primary 
culture of midbrain neurons were washed twice with 37.°C external solution supplemented with 
1% bovine serum albumin (fatty acid free). Neurons were then incubated in external solution 
containing 5 µM Fura-2 AM in dark at 37.°C for 40 min. Cultures were then washed twice with 
supplemented external solution and incubated at 37.°C for another 20 min in either external 
solution (control) or external solution containing KN93 (10 µM) or KN92 (10 µM). KN93 or 
KN92 were also present in the bathing solution throughout subsequent imaging. The neurons 
were then incubated for another 10 min under continuous perfusion of standard external before 
switching the bath perfusion to 100 mM KCl-based external, all at 37.°C on an inverted Nikon 
TE2000-E microscope, before starting the imaging using a CoolSNAPHQ2 camera and 40x, 1.3 
oil immersion Plan Fluor objective lens. The Fura-2 dye was excited using excitation 
wavelengths of 340 nm (for Ca bound Fura-2) and 380 nm (for free Fura-2) and emission 
detected at single wavelength of 510 nm with images collected at 1Hz. Both image acquisition 
and analysis were done using Nikon Elements Advanced Research imaging software (Nikon 
Instruments) and data were quantified in a ratiometric manner and normalized to basal values. 
Biotinylation Assay 
For biotinylation assays, YFP-DAT HEK cells or parental HEK293 cells were plated on 
24-well poly-D-lysine-coated plates at a density of 2 × 105 cells per well and transfected with 
either GFP-C1-CaMKIIα-K42R or pTfR-PAmCherry1, as previously described (Dahal et al. 
2014). Forty-eight to ninety-six hours after plating, cells were pre-treated (30.min) with external 
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solution (vehicle) or 80.µM Dynasore, followed by 30 min treatment with vehicle, 
vehicle+10.µM KN92 or vehicle+10.µM KN93. Cells were then washed and treated for 5.min 
with either vehicle, 10.µM AMPH, 2.5.µM PMA, iso-osmotic 50.mM KCl, iso-osmotic 100.mM 
KCl, 100.mM KCl+KN92 or 100.mM KCl+KN93. Cell-surface proteins were then biotinylated 
and analyzed via western blot analysis as described previously (Felts et al. 2014). Total protein 
concentrations for each sample were determined using the Pierce BCA protein assay kit (Thermo 
Scientific), and the resulting values were used to load equal amounts of protein for each sample 
when conducting SDS–PAGE. Blots of total and surface protein were probed with an N-
terminal-targeted anti-DAT monoclonal antibody (1:1,000; mAb 16 (Foster et al. 2003); a gift 
from Dr. Roxanne Vaughan of the University of North Dakota) or an anti-transferrin receptor 
antibody (1:1,000; C2F2, BD Biosciences), and the density of the immunoblot bands was 
quantitated using ImageJ (NIH) or Image Studio (LI-COR). Prism5 (GraphPad) was used for 
statistical analysis following normalization of surface values to vehicle and determination of the 
vehicle variance by normalizing to AMPH. 
Drug/Solution Application and Optical Stimulation 
In electrophysiology, microscopy and biochemistry experiments, increased KCl 
concentrations (100.mM) were achieved by replacing NaCl in the standard external solution or 
ACSF with KCl in an equa-molar manner, conserving osmolarity. For TIRFM imaging of HEK 
cells, vehicle (standard external solution), the KCl-based external solution or 10.µM AMPH was 
applied via bath perfusion using a laminar flow insert for 35-mm Petri dishes at a rate of 
2.ml.min−1. For neuronal recordings and TIRF microscopy, vehicle or KCl-based external 
solution was applied via pressure (2.psi) injection from a pipette identical to recording pipettes 
positioned 20.µm from the cell body. HEK293 or YFP-DAT HEK cells were exposed to either 
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80.µM Dynasore (Gabriel et al. 2013) (Thermo Fisher Scientific), 10.µM KN92, 10.µM KN93 or 
10.µM BIM (all from EMD Millipore) for 25–30.min before and throughout treatment with 
vehicle or 100.mM KCl to maintain the respective inhibition of dynamin, CaMK and PKC 
throughout each imaging or biotinylation experiment as indicated. 
For steady-state photo-activation of eArch3.0 in cultured neurons, 590-nm light was 
generated from a light-emitting diode (LED) source (Thorlabs) and coupled to an optical fibre 
and placed at a 45° angle, with the tip 150–200.µm from the cell body. The output at the fibre tip 
(200.µm diameter) was regulated via a potentiometer on the externally-triggered LED driver and 
was calibrated so that the light power density at the tip was 15.mW.mm−2. Changes in MP in 
response to eArch 3.0 activation were determined by taking the average MP over 50.ms before 
light onset and the last 50.ms of a 1-s light pulse. 
Data Analysis 
All data were analyzed with Microsoft Excel, IBM SPSS, Prism5 or Igor Pro. Statistical 
analyses used for comparison are identified in the legend, and all values are the mean±s.e.m., 
unless otherwise stated. 
Results 
MP Depolarization Reduces Membrane DAT Levels 
AMPH-mediated activation of DAT induces a depolarizing DAT-mediated Na+ current 
and simultaneously causes internalization of cell-surface-membrane DAT (Ingram, Prasad, and 
Amara 2002; Saunders et al. 2000). To determine whether AMPH-induced DAT internalization 
was the result of a psychostimulant-specific action or may be, in part, due to activation of 
voltage-sensitive mechanisms, we performed live cell TIRFM of yellow fluorescent protein-
tagged DAT (YPF-DAT) in Human Embryonic Kidney (HEK) cells when perfused with only
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Figure 30. Depolarization causes CaMK-dependent reduction of membrane YFP-DAT 
levels in HEK cells. (a) Representative live cell sequential TIRF microscopy images of YFP-
DAT HEK cells 60.s before and throughout 5 min perfusion with vehicle (standard external 
solution, top row), 10.µM amphetamine (middle row; N=5, n=14) or depolarizing 100.mM KCl-
based external solution (bottom row) followed by a 5 min washout period. Scale bar, 20.µm. (b) 
Enlarged insets corresponding to boxes in left-most column before and 150.s after vehicle (top 
pair), 100.mM KCl (middle pair) and 10.µM amphetamine (bottom pair). Scale bar, 5.µm. (c) 
TIRF microscopy images of YFP-DAT HEK cells 60.s before and throughout 5 min perfusion, 
with 100.mM KCl pre-incubated with 10.µM KN92 (top), 10.µM KN93 (middle) or expressing a 
kinase-inactive CaMKII-K42R. Scale bar, 20.µm. (d) Mean±s.e.m. normalized fold change in 
number of YFP-DAT puncta per cell when perfused with vehicle (open circles; N=5, n=17), 100 
KCl only (closed circles; N=6, n=14), 100.mM KCl when pre-incubated and perfused with 
10.µM KN92 (closed triangles; N=5, n=12) or 10.µM KN93 (open triangles; N=6, n=23) and 
RFP-DAT puncta expressed alone (closed squares; N=9, n=9) or co-expressing a kinase-inactive 
GFP-CaMKII-K42R (open squares; N=10, n=12) during 100.mM KCl perfusion. (e) 
Mean±s.e.m. steady-state membrane potential of YFP-DAT HEK cells perfused with vehicle, 
10.µM amphetamine or 100.mM KCl (n=5–7 cells per group). Using independent samples t-test 
*P<0.05 for comparison of 100.mM KCl effects with respective controls. 
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extracellular solution (vehicle), 10.µM AMPH or 100.mM KCl (Fig. 30), which depolarized cells 
by 13.5 and 35.7.mV, respectively (Fig. 30e). The distribution of YFP (yellow fluorescent 
protein)-DAT at the cell membrane (TIRFM footprint) was unchanged throughout perfusion of 
vehicle, whereas 10.µM AMPH noticeably altered the YFP signal in the TIRFM footprint within 
the first 60.s, causing a reduction in surface-membrane high-intensity regions and puncta that did 
not recover in washout (Fig. 30a,b and 31a), in line with previous reports at longer
 
 
Figure 31. Amphetamine causes redistribution in membrane DAT and the GPCR, GPR40, 
is insensitive to depolarization-induced changes in membrane expression. (a) Timecourse 
plot of mean±s.e.m. normalized (to pre-KCl time point) number of membrane surface-resident 
YFP-DAT punctae before and during vehicle (open circles; N=5, n=17), 10 µM amphetamine 
(diamonds; N=5, n=14) or 100 mM KCl (closed circles; N=6, n=14) bath application showing the 
amphetamine-induced loss of membrane DAT stabilizes after 2 min and is not as dramatic and 
depolarization-induced membrane DAT loss. *P<0.05 compared to control with independent 
samples t-test. (b) Distribution of the membrane G-protein coupled receptor, GPR40-eYFP, is 
unaffected by membrane depolarization. Live cell sequential TIRF microscopy images of 
GPR40-eYFP-transfected HEK cells 60 sec before and throughout 5 min perfusion with 
depolarizing 100 mM KCl-based external solution (N=7, n=7). Scale bar is 20 µm. (c) 
Timecourse plot of mean±s.e.m. normalized (to pre-KCl time point) number of membrane 
surface-resident GPR40-eYFP punctae before and during 100 mM KCl bath application indicates 
the relative insensitivity of the trafficking of this naturally-occurring membrane protein to 
depolarization (N=7, n=7). 
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AMPH treatment durations (Sorkina et al. 2009). Similarly, depolarizing 100-mM KCl-based 
external solution significantly altered the YFP-DAT distribution in TIRFM footprint; however, 
the effects occurred rapidly, obvious within 30.s, and typically all YFP puncta and high-intensity 
regions were absent from the surface membrane after 3.min (Fig. 30a,b,d). In contrast to AMPH, 
treatment with KCl resulted in the return of YFP signal profile and the reappearance of YFP 
puncta immediately on washout (Fig. 30a). To determine the relative specificity of this effect of 
depolarization for DAT, we identically depolarized HEK cells transfected with an eYFP-tagged 
version of an unrelated naturally occurring membrane protein, GPR40 (La Sala et al. 2013), 
which had a membrane distribution similar to DAT, but its trafficking appeared insensitive to 
depolarization (Fig. 31b,c). 
 
 
Figure 32. Depolarization-dependent redistribution of YFP-DAT is not PKC-dependent. 
Representative TIRF microscopy images of HEK YFP-DAT cells 60 sec before and throughout 5 
min perfusion with 100 mM KCl pre-incubated with 10 µM bisindolylmaleimide I (BIM; N=4, 
n=8). Scale bar is 10 µm. 
 
Since the depolarization induced by KCl will likely increase free [Ca2+] and trigger the 
activation of Ca2+-dependent signaling molecules, we chose to determine the role of CaMKII and 
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PKC in initiating this depolarization-induced redistribution. The depolarization-induced loss of 
YFP-DAT signal did not appear affected by the PKC inhibitor, bisindolylmaleimide I (10.µM; 
Fig. 32). However, the KCl depolarization-induced loss of YFP-DAT surface puncta was 
significantly reduced in the presence of the CaMK inhibitor KN93 (10.µM) relative to the same 
treatment in the presence of the inactive homologue, KN92 (10.µM; Fig. 30c,d), which produced 
results similar to KCl treatment alone (Fig. 30a–d). However, because of the KN93-induced 
attenuation of the depolarization-triggered Ca2+ influx (Fig. 33), we chose to biochemically
 
 
Figure 33. CaMKII inhibitor, KN93, attenuates but does not abolish depolarization 
induced Ca2+ influx. (a) Representative Fura-2 ratiometric (340 nm/380 nm) image of midbrain 
primary culture neurons before (top) and during the peak Ca2+ signal (bottom) evoked with bath 
application of 100 mM KCl in control conditions. Image color scale of raw ratio values for 
emission intensity excited by 340 nm/380 nm light. (b) Mean±s.e.m. normalized change in 
FURA2 fluorescence (ΔF/F0) ratiometric signal in response to 100 mM KCl-based external 
solution (black; control) and when the CaMKII inhibitor, KN93 (10 µM; light gray), or its 
inactive homolog, KN92 (10 µM; dark gray), are pre-incubated with the neuronal cultures and 
included in the bathing solution. The black bar indicates the administration of 100 mM KCl-
based external solution. Values are mean±s.e.m. (N=4-5, n=23-26). 
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inhibit CaMKIIα specifically and assess membrane DAT using TIRFM by co-expressing a 
kinase-inactive version of CaMKIIα, a green fluorescent protein (GFP)-tagged K42R mutant and 
RFP (red fluorescent protein)-DAT. In response to KCl-induced depolarization, RFP-DAT alone 
behaved similarly to YFP-DAT; however, when GFP-CaMKIIα-K42R was co-expressed, KCl 
treatment was unable to alter the membrane distribution of RFP-DAT (Fig. 30c,d). These 
changes in membrane DAT in response to depolarization (100.mM KCl application) and 
repolarization (washout) suggest that the MP state is capable of bidirectionally shaping the cell-
surface distribution of DAT through activation of CaMKIIα. 
Membrane DAT Reduction is CaMKIIα and Dynamin Dependent 
To determine the degree to which real-time changes in the YFP-DAT TIRFM footprint 
were indicative of changes in DAT protein density at the cell membrane, a cell-surface 
biotinylation assay was used to quantify differences in membrane DAT protein levels. In YFP-
DAT HEK cells, compared with vehicle treatment (100%, n=17), surface DAT (Fig. 34) was 
significantly reduced following a similar 5 min treatment as above with both 50.mM (62±6%, 
n=14) and 100.mM (70±5%, n=17) KCl-based external solution as well as the positive control 
treatments with AMPH (10.µM; 59±7%, n=13) and the PKC agonist phorbol myristate acetate 
(PMA, 2.5.µM; 53±5%, n=13). The CaMKIIα dependency of this effect observed in TIRFM 
studies was also supported by biotinylation experiments (Fig. 34), wherein 100.mM KCl had 
little effect on membrane DAT protein when YFP-DAT HEK cells were transfected with the 
kinase-inactive, dominant-negative GFP-CaMKIIα-K42R (105±11%, n=6) or in the presence of 
the CaMK inhibitor KN93 (10.µM; 98±9%, n=9), whereas the inactive homologue KN92 did not 
significantly block the KCl-dependent reduction in surface DAT (10.µM; 63±6%, n=12). To 
determine whether the reduction in membrane DAT distribution observed using TIRFM and
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Figure 34. Depolarization-induced reduction in surface-membrane-biotinylated DAT is due 
to CaMKII-dependent endocytosis. (a) Representative western blots show the surface DAT 
present under each indicated condition. (b) Mean±s.e.m. DAT band density from YFP-DAT 
HEK cells (control, black bars) or YFP-DAT HEK cells transfected with GFP-C1-CAMKIIα-
K42R (grey bars) or YFP-DAT HEK pre-treated (30.min) with external solution (vehicle) or 
80.µM Dynasore (white bars), followed by 30 min treatment with vehicle, vehicle+10.µM KN92 
or vehicle+10.µM KN93. Cells normalized to vehicle treatment from at least five independent 
experiments indicate that AMPH, PMA and depolarization-induced reduction in surface DAT are 
endocytosis-dependent (Dynasore-sensitive), and both PMA- and depolarization-induced 
internalization are CaMKIIα-dependent. Depolarization-induced internalization is sensitive to 
both pharmacological and molecular inhibition of CaMKII activity. A two-way analysis of 
variance (ANOVA) with Bonferroni post hoc test was performed to identify significant 
differences from control (*P≤0.05; **P≤0.01; ***P≤0.001), a one-way ANOVA with a 
Dunnett's post hoc test to determine changes from vehicle treatment (###P≤0.001) and an 
unpaired t-test to compare KN92 and KN93 treatments (††P≤0.01). See text for number of 
experiments. 
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confirmed using biotinylation was a trafficking event, we evaluated the capacity for 
depolarization to induce a loss in surface DAT in the presence of Dynasore, a dynamin inhibitor 
(Gabriel et al. 2013). Indeed, inhibition of dynamin by Dynasore blocked depolarization- 
(115±6%, n=6), AMPH- (101±11%, n=6) and PMA-dependent (108±8%, n=6) internalization of 
DAT in HEK cells, whereas expression of CaMKIIα-K42R only blocked depolarization- and 
PMA-dependent (117±13%, n=6) but not AMPH-dependent (66±9%, n=6) internalization (Fig. 
34). Importantly, treatment with 100.mM KCl did not alter surface levels of the native or 
overexpressed, membrane-resident transferrin receptor in comparison with vehicle control, 
providing further support for the specificity of depolarization-induced downregulation of 
membrane DAT (Fig. 35). Taken together, these data suggest that CaMKIIα- and dynamin-
dependent pathways are involved in depolarization-dependent DAT trafficking at the cell 
membrane. 
 
Figure 35. Membrane levels of the endogenous 
transferrin receptor (TfR) are unchanged upon 
membrane depolarization. (a) Representative Western 
blots show the surface and total TfR present when HEK-293 
cells (left, EndoTfR) or HEK-293 cells transfected with a 
positive control pTfR-PAmCherry1 plasmid (right, 
mCherryTfR) were treated for 5 min with either standard 
external solution (veh) or 100 mM KCl-based external 
solution. (b) Mean±s.e.m. surface TfR band density from 
HEK-293 cells when normalized to vehicle treatment (n=3) 
indicate that surface levels of endogenous TfR or mCherry-
tagged TfR are unchanged upon membrane depolarization 
(n=3). Arrows indicate endogenous and mCherry TfR as 
labeled. !
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MP Depolarization Internalizes JHC 1-064/DAT Complexes 
Next, we used JHC 1-064 (Cha et al. 2005), a fluorescent cocaine analogue, to label cell 
membrane-resident DAT in HEK FLAG-DAT cells in conjunction with live cell confocal 
microscopy to investigate whether KCl-induced membrane depolarization would drive the 
internalization of cell-surface JHC 1-064/DAT complexes, an approach used previously to study 
DAT trafficking to defined endosome compartments in vitro (Fig. 36a) (Eriksen et al. 2009). In 
 
 
Figure 36. Membrane depolarization with KCl increases internalization of JHC 1-064/DAT 
complexes in HEK cells. (a) JHC 1-064 binds to surface DAT in HEK cells. Confocal image of 
YFP signal in YFP-DAT HEK cells (top), with no initial detectable fluorescence emitted 
between 553 and 617.nm when excited with 561.nm (bottom left, T=0.min) until after 20 min 
exposure to 10 nM JHC 1-064 (bottom right) corresponding with YFP fluorescence. (b) 
Representative confocal images of JHC 1-064/DAT labeling (white) at ~4.°C and 5.min 
following solution change at 37.°C. Note the increase at 5.min in the number of white 
intracellular puncta in the KCl condition. (c,d) Mean±s.e.m. number of individual JHC 1-
064/DAT puncta per cell (c) and normalized (to 4.°C) fluorescence intensity (d) in the 
intracellular space corresponding to vehicle (N=3, n=69, black bars) or 100.mM KCl-containing 
solution treatment (N=3, n=85, red bars). Independent samples t-tests were used to compare 
vehicle with KCl effects. Scale bars, 10.µm. ***P<0.0001 using independent samples t-test. 
 
all cases, the presence of JHC 1-064/DAT complex puncta in the intracellular space was limited 
or nonexistent at 4.°C (Fig. 36b). However, when changing bath temperature from 4 to 37.°C 
with either vehicle or depolarizing (iso-osmotic) 100-mM KCl-based external solution (Fig. 36b–
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d), the number of fluorescent punctate JHC 1-064/DAT complexes (Fig. 36c) and average 
intracellular fluorescence intensity (Fig. 36d) were significantly greater in depolarizing KCl-
based external solution (3.2±0.3 puncta per cell; normalized fold change in intracellular JHC 1-
064 intensity: 0.26±0.05) compared with vehicle (1.7±0.2 puncta per cell; normalized fold 
change in intracellular JHC 1-064 intensity: −0.10±0.05). 
MP Depolarization Redistributes DAT into Early Endosomes 
To determine the identity of the intracellular destination of depolarization-dependent 
internalized DAT, fluorescent versions of the endosome markers (which were not apparent at the 
cell membrane in TIRFM), EEA1 (TagRFP-T-EEA1) that marks early endosomes or the 
recycling endosome marker Rab11 (DsRed-Rab11), were expressed in HEK YFP-DAT cells and 
then treated with standard external solution (vehicle), iso-osmotic 100 mM KCl-based external 
solution for 5.min or 10.µM AMPH for 5.min as a temporal comparison. Another time point of 
60.min AMPH (10µM) treatment was used as a positive control as it has been shown previously 
to cause DAT internalization to specific endosomes (Sorkina et al. 2005; Hong and Amara 2013; 
Eriksen et al. 2010; Rao, Simmons, and Sorkin 2011), and would thus allow for comparability to 
previous work. Average Pearson correlation coefficients per cell for intracellular YFP-DAT and 
TagRFP-T-EEA1 or DsRed-Rab11 in vehicle (EEA1: 0.17±0.01; Rab11: 0.19±0.01) were 
significantly less than in cells treated with AMPH at 5.min for EEA1 (0.32±0.03; Fig. 37a,b) and 
Rab11 (0.47±0.06; Fig. 37c,d), while 60 min AMPH treatment increased YFP-DAT association 
with EEA1 (0.24±0.01; Fig. 37a,b), but not Rab11 (0.22±0.15; Fig. 37c,d). Similarly, 
depolarizing conditions significantly enhanced the co-localization of intracellular YFP-DAT 
with EEA1 (0.30±0.02; Fig. 37a,b) over vehicle and 60 min AMPH treatments, although 
comparable to the 5 min AMPH treatment. The treatment had no effect on the degree of 
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Figure 37. Depolarization-dependent internalized DAT preferentially localizes to early but 
not recycling endosomes. (a,c) Representative single-plane confocal images of (left) YFP-DAT, 
(middle) TagRFP-T-EEA1 (a) or DsRed-Rab11 (c) and merge of the two (right) expressed in 
HEK cells treated with vehicle (top; EEA1: N=5, n=106; Rab11: N=6, n=77), 10.µM 
amphetamine for 1.h (middle; EEA1: N=3, n=50; Rab11: N=3, n=61) or 5.min 
(EEA1: N=2, n=27; Rab11: N=2, n=13) or 100.mM KCl for 5.min (bottom; EEA1: N=3, n=84; 
Rab11: N=3, n=4). (b,d) Mean±s.e.m. Pearson correlation coefficient per cell of intracellular 
YFP-DAT signal with EEA1 (b) or Rab11 (d) for vehicle, 5.min and 1.h amphetamine and 
100.mM KCl-treated cells. Value inset in merged images is the mean Pearson correlation 
coefficient for cells in given image. Scale bar, 10.µm and applies to all images. *P<0.05 
compared with vehicle, #P<0.05 for indicated comparison using ANOVA with Bonferroni post 
hoc test. 
 
association of intracellular YFP-DAT with Rab11 (0.16±0.07; Fig. 37c,d) compared with 
vehicle. While biotinylation and confocal imaging inherently lack the temporal resolution of 
TIRFM, the collective results indicate that MP depolarization rapidly reduces cell-surface-
membrane DAT and internalizes the transporter to intracellular early endosome compartments, 
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suggesting that membrane DAT levels and DAT trafficking may be partially dependent on the 
MP state and therefore could change rapidly with MP fluctuation on local changes in the activity 
of receptors, ion transporters and channels. 
Change in MP State Alters Cell Surface Membrane DAT Levels 
To further examine whether the membrane distribution of DAT is altered in response to 
MP changes (depolarization and hyperpolarization), we employed simultaneous single-cell 
TIRFM and whole-cell patch clamp electrophysiology (Fig. 38a). This technique allowed for 
time-resolved, bidirectional and precise control of the MP and provided internal controls in 
adjacent non-clamped cells. Acquisition of TIRFM image sequences (5-s intervals) throughout 
the course of 5 min duration voltage steps indicated that the surface YFP-DAT signal is stable 
during whole-cell voltage clamp at −40.mV (typical MP for YFP-DAT HEK cells; Fig. 38b–e), 
but MP changes from baseline to hyperpolarized (−60.mV; Fig. 38b,f–h) or depolarized 
(+20.mV; Fig. 38b,i–k) potentials could rapidly (between frames, 5.s duration) increase or 
reduce, respectively, YFP-DAT puncta in the TIRFM footprint (Fig. 38b). In some cases, the 5-s 
interframe interval during depolarization was sufficient to eliminate all DAT puncta from the cell 
surface, and hyperpolarization to −60.mV caused complete recovery of the fluorescent signal 
profile within 5–10.s (Fig. 38b). The effect of the hyperpolarizing voltage step on the TIRFM 
footprint intensity of patch-clamped cells rapidly increased, typically plateauing within 5.min, 
and began to reverse (decrease in intensity) following return of the membrane voltage to −40.mV 
(Fig. 38f). Continuous clamping of the MP at −40.mV did not significantly alter the YFP-DAT 
TIRFM footprint intensity at 3.min relative to adjacent cells (n=4 clamped, four adjacent cells; 
P>0.05; Fig. 38c–e). However, when comparing intensity changes between clamped and adjacent 
cells 3.min into the voltage step, stepping the MP to −60.mV significantly increased the YFP-
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Figure 38. Membrane potential state alters cell membrane YFP-DAT levels. (a) 
Simultaneous whole-cell patch-clamp recording with the patch pipette visible in dissolved 
inorganic carbon (top) of YFP-DAT HEK cell and TIRF imaging of YFP-DAT (white) of the 
same cell (bottom). (b) TIRF image sequence with 5 s interframe interval of YFP-DAT HEK cell 
footprint with the membrane potential clamped at indicated holding potentials. Hyperpolarized 
potentials (−40 to −60.mV transition) increase cell-surface YFP-DAT signal, while depolarized 
potentials (−40 to +20.mV transition) reduces cell-surface YFP-DAT within 5.s and recovers 
within 5–10.s on hyperpolarization (+20 to −60.mV transition). (c,f,i) The mean normalized 
intensity of the surface-membrane YFP-DAT over time for all clamped cells (solid line) held at 
−40.mV (c), −60.mV (f) and +20.mV (i) for 5.min. Error bars are omitted for clarity, and the 
mean intensity for matched corresponding adjacent non-patched cells (color-matched dashed 
line) and the mean of all non-patched adjacent cells (grey line) are included for comparison. 
(d,g,j) Normalized fluorescence intensity values for patched-clamped (solid line) and paired 
adjacent cells (dotted line) before (0.min) and 3.min after membrane potential change (n=4–5 
cells per group). (e,h,k) Representative images of YFP-DAT HEK TIRFM footprints of patched 
cells before (0.min), 3 and 5.min after the membrane potential change and 1.min after returning 
the membrane potential to −40.mV. (l) Average normalized YFP intensities at 5.min after the 
potential change to hyperpolarized (−60.mV, blue) or depolarized (+20.mV, red) membrane 
potentials are significantly different relative to continuous clamping near the endogenous 
(−40.mV, black) membrane potential. #P<0.05, **P<0.001 using independent samples t-test. All 
values are mean±s.e.m. Scale bars, 10.µm. 
 
DAT TIRFM footprint intensity (n=5 clamped, five adjacent cells; P<0.01; Fig. 38f–h), while 
stepping to +20.mV produced the opposite effect (n=5 clamped, five adjacent cells; P<0.01; Fig. 
38i–k). Further comparison of voltage effects between only cells clamped at −40, −60 or +20.mV 
also indicates a significant difference in normalized YFP-DAT TIRFM footprint intensity for the 
−60.mV (n=5 cells; P<0.05) and +20.mV (n=5 cells; P<0.001) condition when compared with 
the −40.mV (n=4 cells) condition 5.min following the voltage change (Fig. 38l). 
Change in MP State Alters DAT-Mediated Current 
Since the mere presence of DAT at the cell surface (YFP fluorescence signal) is not 
necessarily indicative of relative DAT function, we sought to determine whether MP change-
induced variations in the surface DAT density (Fig. 38) correlated with the uncoupled DAT-
mediated current. To investigate this, as in previous TIRFM experiments, the MP was clamped 
for 5.min at +20, −40 or −60.mV but was followed by acquisition of a baseline IV curve (Fig. 
39a). The subsequent GBR12935-sensitive current was then taken as the DAT-mediated current 
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Figure 39. Membrane potential state significantly alters DAT-mediated current. (a) 
Schematic of the whole-cell voltage protocol for examining membrane potential state-dependent 
changes in DAT-mediated current recorded from HEK cells expressing YFP-DAT (see 
Methods). (b) Representative image of an YFP-DAT HEK cell following the complete recording 
paradigm for the +20 mV condition. Scale bar, 10.µm. (c) Representative current responses of 
the −100 mV voltage step before (colored trace) and after 20 µM GBR12935 (grey trace) for the 
given prolonged holding potential condition. (d) Group average IV plots for each voltage-state 
condition. (e) Bar graphs depict the mean current amplitude at −100.mV step from full IV plot 
for each condition and were used for statistical comparison between groups (n=5–8 cells per 
group). (f) Average DAT-mediated current amplitude plotted against the relative mean fraction 
of original intensity of the YFP-DAT TIRFM footprint (from Fig. 5) for cells patched at control, 
hyperpolarized and depolarized potentials indicates a positive correlation between increasing 
DAT-mediated current density and peri-membrane YFP intensity with TIRF 
microscopy. #P<0.05 using independent samples t-test. All values are mean±s.e.m. 
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for each cell for a given condition. Cells clamped at −40.mV (near their endogenous resting MP) 
had a DAT-mediated current amplitude of −15.3±2.16.pA (n=8; Fig. 39c–f, black). However, 
when cells were depolarized to +20.mV for 5.min (Fig. 39c–f, red), the DAT-mediated current 
(−8.8±1.6.pA, n=7) was significantly reduced by 42.3% (P<0.05), and cells hyperpolarized to 
−60.mV for 5.min (Fig. 39c–f, blue) displayed a 47.7% larger (P<0.05) DAT-mediated current 
(−22.6±2.0.pA, n=5) compared with cells held at −40.mV. For comparison of MP state-
dependent changes in YFP-DAT membrane density (Fig. 38) and DAT functional capacity, the 
average fold change in YFP-DAT TIRFM footprint intensity and DAT-mediated current 
amplitude for each MP-holding potential state are plotted against each other (Fig. 39f), indicating 
a positive correlation between the two measures. While the cell-surface-membrane DAT levels 
(TIRFM) are influenced by the MP state, these data imply that functional DAT may be 
particularly influenced by MP state changes as they are more profoundly affected. 
Neuronal MP Changes Alter Surface-Membrane DAT Levels 
To determine whether MP influences surface-membrane DAT density in functional 
neurons, real-time imaging of membrane DAT (TIRFM fluorescence footprint) was coupled with 
two characterized non-invasive methods (Fig. 40) of transient reliable membrane depolarization 
and hyperpolarization: 100-mM KCl focal application (Fig. 41a) and archaerhodopsin (Arch) 
activation (Fig. 41b), respectively. Cultured primary neurons were transfected with TagRFP-T-
DAT (RFP-DAT) or CFP-DAT with or without co-transfection with Arch-YFP (Arch-YFP; Fig. 
40) and were subjected to whole-cell recordings (K-gluconate-based internal solution) or 
imaging in the presence of tetrodotoxin (TTX) and receptor blocker cocktail (see Methods), 
unless otherwise indicated. Pressure application of KCl-based external solution induced a 
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Figure 40. Fluorescently-tagged protein expression and imaging scheme for TIRF imaging 
of neurons and example effect of resulting prolonged Arch activation. (a) DIC and 
fluorescent images of midbrain primary culture neurons expressing TagRFP-T-DAT with 
picospritzer pipette positioned 20 µm from soma (top), CFP-DAT (middle) or CFP-DAT and 
Arch-YFP (bottom) imaged in wide-field fluorescence. (b-c) Schematic of simultaneous TIRF 
imaging of TagRFP-T-DAT and transient KCl-induced (applied via picospritzer pipette) 
membrane depolarization (b) or TIRF imaging of CFP-DAT and transient Arch-activation-
induced membrane hyperpolarization via stimulation with adjacent optical fiber placed near the 
soma (c, upper). (c) Lower: For imaging, the timing of Arch photostimulation was continuous 
except during the 200-300 ms TIRF illumination and exposure period during which time the 590 
nm LED light source was inactive. (d) Representative recording of membrane potential from 
primary culture neuron expressing Arch-YFP in response to pulses of 590 nm light stimulation 
via adjacent optical fiber corresponding to temporal parameters of stimulation/pauses during 
simultaneous TIRF imaging. Scale bar is 5 sec and 5 mV. 
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Figure 41. Neuronal membrane potential rapidly alters membrane-surface DAT level. (a,b) 
Cultured neuron membrane potential response to (a) vehicle or 100.mM KCl and (b) 590.nm 
stimulation in neurons with/without YFP-Arch 0.5.mM TTX omitted in bottom trace. Scale bar, 
10.s (a) and 500.ms (b) and 10.mV for (a,b). (c) Membrane potential before, during and after 
vehicle (black; n=3) or 100.mM KCl (red; n=4) and (d) 590 nm light stimulation of neurons with 
(blue; n=13)/without (grey; n=3) Arch-YFP expression. (e) Resting potential change. (f) TIRFM 
image of primary culture neuron expressing RFP-DAT. (g) The mean normalized intensity of the 
surface RFP-DAT during vehicle (black; n=4) or 100.mM KCl (red; n=3) application. (h) The 
mean normalized intensity of the surface CFP-DAT when a 590 nm light pulse was delivered to 
cells with (blue; n=5)/without (grey; n=4) Arch-YFP expression. (i) Normalized somatic 
membrane RFP- or CFP-DAT fluorescence change for each condition. #P<0.05, *P<0.01 with 
independent samples t-test. 
 
reversible 36.9±8.3-mV membrane depolarization in RFP-DAT-expressing neurons (Fig. 41a,c–
e), and photo-activation (590.nm) of Arch caused a reversible −23.3±3.2-mV membrane 
hyperpolarization (Fig. 41a,c–e). In the absence of TTX, Arch activation suppressed action 
potential firing and induced a rebound burst when the light was turned off (Fig. 41b) and was 
relatively stable over long pulse durations (Fig. 40) used for subsequent imaging experiments 
(Mattis et al. 2012). The MP of neurons lacking Arch-YFP expression was unaffected by 590 nm 
light stimulation. 
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On characterizing the reliability of these tools, we performed simultaneous TIRFM of 
primary culture neurons (Fig. 41f) during each manipulation (Fig. 40b and Fig. 41g,h). TIRFM 
of neurons expressing RFP-DAT while focally applying 100 mM KCl-based external solution 
(Fig. 40b) for a short duration (45.s) caused a rapid and dramatic reduction (−21.1±8.5%) in the 
RFP-DAT TIRFM footprint intensity, while vehicle application had no effect (Fig. 41g). 
Similarly, bath application of 100 mM KCl-based external solution also enhanced the 
internalization of endogenous DAT in primary neurons labeled with JHC 1-064, causing a 
dramatic increase in JHC 1-064 complexes in the intracellular space (Fig. 42). In contrast, 
 
 
Figure 42. Depolarization enhances internalization of JHC 1-064/DAT complexes in 
midbrain primary cultured neurons. a) JHC 1-064 (10 nM for 30 min) labels membrane DAT 
in a subset of mouse midbrain primary culture neurons. Scale bar is 10 µM. b) Single plane 
confocal image of primary neuron cell bodies labeled with JHC 1-064 imaged 5 min after 
replacing bath solution with 37.°C standard (vehicle; top) or KCl-based external solution 
(bottom). Note JHC 1-064 punctae present only in the intracellular space of the neuron exposed 
to depolarizing KCl-based external solution. Scale bar is 20 µM. c) Average number of JHC 1-
064 punctae in the intracellular space of neurons at 4.°C and after being at 37.°C in standard 
(n=5) and KCl-based (n=3) external solution. Within a given condition, the same cells are 
represented in the 4.°C and 37.°C states. #P<0.05 using independent samples t-test. Values are 
mean±s.e.m. 
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simultaneous MP hyperpolarization via activation of Arch by 590 nm light staggered with 
TIRFM imaging of CFP-DAT (Fig. 41h) indicated that hyperpolarization caused a reversible 
increase (+9.0±3.5%) in CFP-DAT intensity in the TIRFM footprint overtime, which stabilized 
after 120.s (Fig. 41h). No significant change (−3.8±3.3%) in CFP-DAT TIRFM footprint 
intensity was observed in neurons lacking Arch-YFP expression (Fig. 41h). These KCl-induced 
decreases and Arch activation-induced increases in neuronal cell-surface DAT TIRFM signal, 
which parallel MP state-dependent changes in the surface density of DAT protein (Figs 30, 34, 
36-38) and DAT function (Fig. 39) in YFP-DAT HEK cells, were significantly different from 
their respective controls (depolarization: P<0.05, hyperpolarization: P<0.05; Fig. 41i). 
Discussion 
 The presence of DAT at the cell membrane is crucial in the regulation of DAergic 
signaling, timing and magnitude throughout the brain, and thus any alteration in the functional 
capacity of the transporter may significantly have an impact on neurological functions in which 
DA is involved. Previous studies have demonstrated that KCl-induced depolarization reduces 
DA uptake (Woodward et al. 1986; Holz and Coyle 1974), and that membrane hyperpolarization 
increases DAT-mediated inward current and DA uptake (Sonders et al. 1997), albeit with an 
unknown mechanism. Here we asked whether changes in MP alone may rapidly and reversibly 
regulate DAT trafficking. One aspect regulating transporter function is that the trafficking of 
mature DAT to and from the cell membrane is a highly regulated process, which is affected in 
various disease states and by the activity of DAT-targeting psychostimulants. Using live cell 
TIRFM and biotinylation on identically treated HEK cells expressing YFP-DAT, we determined 
that membrane depolarization alone could induce a CaMKIIα- and dynamin-dependent (Figs 30 
and 34) rapid reversible (increase in hyperpolarization recovery) reduction in membrane DAT 
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(Fig. 30). This depolarization-induced effect on DAT distribution in the TIRFM footprint was 
distinctly different when compared with the effects of AMPH, which did not recover as quickly. 
Another difference between AMPH- and depolarization-induced DAT internalization is the 
insensitivity of AMPH-induced internalization to the loss of CaMKIIα activity through the 
coexpression of a dominant-negative, kinase-inactive CaMKIIα (Fig. 34), which, along with the 
sensitivity of both versions to KN93, may suggest that different isoforms of the kinase may have 
distinctly different roles in regard to regulating DAT function. Notably, similar fast changes in 
membrane DAT levels have been reported using this approach with acute AMPH exposure 
(Furman, Chen, and Guptaroy 2009). However, the direction of the AMPH effect on human 
DAT using the multifaceted approach reported here contrasts with this previous finding and 
could be due to intrinsic differences between rat and human DAT, AMPH concentrations and/or 
cell types. 
To determine the degree of DAT internalization, with the DAT-specific fluorescent 
cocaine analogue, JHC 1-064 (Eriksen et al. 2009), we followed the distribution of JHC 1-064 
fluorescence (JHC 1-064/DAT complexes; Fig. 36) when cells were left at rest or depolarized. 
These data suggested that indeed membrane-resident DAT was being more rapidly brought into 
the intracellular space when depolarized as compared with constitutive internalization (Fig. 
36c,d). While biotinylation and confocal imaging inherently lack the temporal resolution of 
TIRFM, together, results indicate that in contrast to the effects of AMPH on DAT, depolarization 
resulted in DAT being segregated specifically into early endosome compartments (EEA1), but 
not recycling endosomes (Rab11; Fig. 37). This divergence in the destination of internalized 
DAT in cells treated with AMPH versus those simply depolarized again suggests the 
involvement of differing mechanisms, which may leave initially internalized DAT residing in 
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early endosomes free to transition into rapid recycling endosomes, distinct from recycling 
endosomes (Grant and Donaldson 2009), putatively underlying the faster recovery to the 
membrane surface during hyperpolarization. 
Although few studies have examined DAT activity immediately after depolarization or 
following the return to the resting hyperpolarized state, our data provide a potential mechanism 
for the decreased DA uptake in striatal synaptosomes during the fast phase of depolarization-
induced DA release (Holz and Coyle 1974). Therefore, to determine any bidirectionality of the 
KCl effect on DAT trafficking, we used whole-cell voltage-clamp techniques to clamp the MP of 
YFP-DAT HEK cells while performing TIRFM simultaneously (Fig. 38). Once cells were 
clamped near their endogenous resting potential (−40.mV), the YFP-DAT TIRFM footprint was 
relatively similar over time (Fig. 38c–e). However, when stepping the membrane-holding 
potential from −40.mV to a hyperpolarized potential, an increase in YFP-DAT intensity and 
puncta number in the TIRFM footprint began immediately (Fig. 38b) and plateaued after 3.min 
(Fig. 38f–h). In contrast, when cells were depolarized the opposite effect occurred with a loss of 
YFP-DAT signal, which paralleled the effects seen in the presence of depolarizing KCl (Fig. 
38i–k). In fact, the ~10% change in YFP-DAT intensity directly corresponded to reductions in 
DAT-mediated (GBR12935-sensitive) current when cells were clamped at depolarized or 
hyperpolarized potentials (Fig. 39). On the basis of these data and the known electrogenic nature 
of DAT-mediated DA uptake and efflux, we hypothesize that at depolarized conditions, where 
efflux is more likely to occur (Khoshbouei et al. 2003), the cell may actively attenuate this efflux 
by downregulating DAT at the membrane. In contrast, membrane hyperpolarization, known to 
facilitate DA uptake (Sonders et al. 1997), may be doing so through interactions with ionic 
driving forces and increases in membrane DAT. 
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With two tools that induced reversible and reliable depolarization (focal KCl application) 
or hyperpolarization (Arch activation) of magnitudes, similar to those used in previous 
experiments (Fig. 41a–e), we used TIRFM to monitor fluorescent-tagged DAT expressed in 
midbrain primary cultures during MP manipulation. The effect of these manipulations on 
membrane DAT levels were larger than in HEK cells using methods that induced similar voltage 
differences, implying that these effects are indeed applicable to neuronal populations and results 
obtained using HEK cells are relevant to shaping conclusions about MP-dependent trafficking of 
DAT in the nervous system. Together, these data indicate that, while the magnitude of change in 
membrane DAT levels due to MP changes varies depending on the assay, all changes observed 
are in a physiologically relevant range and the direction of the effect (increase or decrease) is in 
agreement across all examinations. 
This effect of the MP on DAT trafficking sheds light on an additional mechanism by 
which the activation of hyperpolarizing D2Rs may be altering DA transport. The activation of 
D2Rs has long been understood to enhance DAT function (Meiergerd, Patterson, and Schenk 
1993), and previous studies have suggested that a D2R activation initiates a signaling cascade to 
upregulate cell-surface DAT (Morón et al. 2003). Although others have examined how changes 
in the neuronal MP similarly to those initiated by D2R activation may alter DAT function and 
found no impact on [3H]-DA uptake (Prasad and Amara 2001), those experiments were 
performed at room temperature, which likely attenuates trafficking rates as opposed to the 
studies here conducted at near-physiological temperatures (37.°C). Thus, this methodological 
difference may explain the discrepancies between that [3H]-DA uptake study (Prasad and Amara 
2001) relative to the data presented here. Nevertheless, collectively this study and previous 
studies support the involvement of multifaceted regulatory mechanisms for DAT trafficking that 
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are substrate-, kinase- and activity-dependent. The existence of multiple regulatory mechanisms 
supports the notion that the DAT proteins at the membrane are responsive to diverse regulatory 
mechanisms. The overriding mechanism for activation of a given trafficking pathway will be 
determined by the nature of the stimulation and the availability of specific regulatory 
constituents. 
DA signaling is crucial in many neurological functions, as aberrations in DA 
neurotransmission contribute to multiple neuropsychiatric disorders, including addiction (Koob 
and Volkow 2010; Kalivas 2007), Parkinson's disease and movement disorders (Vernier et al. 
2004; Kurian et al. 2011; Hansen et al. 2014), schizophrenia (Lodge and Grace 2011; Cordeiro et 
al. 2010) and attention-deficit hyperactivity disorder (ADHD) (Nieoullon 2002), all of which 
have been linked to how extracellular DA may be mishandled by altered DAT expression and 
function (Sakrikar et al. 2012; Cordeiro et al. 2010; Madras, Miller, and Fischman 2002). As a 
result, disease-related deviations from physiological states and variations in neuronal MPs may 
be altering the functional capacity of DAT by affecting its trafficking to and from the membrane. 
This dynamic balance of electrophysiological and biochemical processes to regulate subtle but 
essential aspects of neurotransmission opens a range of possibilities for exploring related 
aberrations in disease states and in pharmacotherapy targeting this interaction. Broadly, the 
regulation of protein (DAT) trafficking by the MP may provide additional means by which 
plasticity (for example, activity-dependent changes) in DAergic and possibly non-DAergic 
systems is maintained and controlled. 
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CHAPTER VI 
INHIBITION OF SEROTONIN TRANSPORT IS ALTERED BY METABOLITES OF 
SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS AND 
REPRESENTS A CAUTION TO ACUTE OR CHRONIC TREATMENT PARADIGMS 
 
Introduction 
The serotonin transporter (SERT) is a member of the solute carrier 6 (SLC6) family of 
neurotransmitter transporters. SERT is expressed in the brain and periphery (Baganz and Blakely 
2013; Berger, Gray, and Roth 2009), where it is the primary mechanism for termination of 
serotonergic signaling following vesicular release of serotonin (5-hydroxytryptamine, 5-HT). 
Altered activity of SERT has been implicated in multiple neurobehavioral disorders, including 
major depression, autism spectrum disorder, anxiety, post-traumatic stress disorder and 
obsessive-compulsive disorder (Daws and Gould 2011; Lucki 1998). Antidepressants (ADs) 
such as tricyclic antidepressants (TCA), selective serotonin reputable inhibitors (SSRI), and 
serotonin-norepinephrine reuptake inhibitors (SNRI) effectively block 5-HT and/or 
norepinephrine (NE) reuptake thereby increasing synaptic levels of those neurotransmitters. Of 
these drugs, SSRIs and SNRIs are prescribed most often due to their superior safety profile. 
Although treatment with SSRIs and SNRIs effectively block 5-HT and/or NE reuptake almost 
immediately upon administration, chronic blockade is required for clinical efficacy (Schloss and 
Henn 2004; Andersen, Kristensen, et al. 2009). The mechanisms underlying the delay in clinical 
efficacy of AD treatment and the distinct roles of both NET and SERT as primary targets in 
depression are areas that remain poorly understood (Wong and Licinio 2001; Nemeroff and 
Owens 2002). 
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Structurally, SERT and the related norepinephrine and dopamine transporters contain 12 
transmembrane domains (TMs), of which TMs 1, 3, 6, and 8 form the majority of the substrate 
permeation pathway as well as key interactions with ions, substrates, and antagonists (Yamashita 
et al. 2005; Penmatsa, Wang, and Gouaux 2013; Field, Henry, and Blakely 2010; Henry et al. 
2003). Species scanning mutagenesis studies of SERT TM domains have identified several well 
conserved residues that are important molecular determinants responsible for high-affinity 
antidepressant binding (Barker et al. 1998; Henry et al. 2006; Andersen, Taboureau, et al. 2009; 
Kumar et al. 2015). For example, the isoleucine at position 172 (I172) in human and mouse 
SERT (hSERT and mSERT, respectively) was shown to mediate high-affinity binding for 
numerous antidepressants as substitution to methionine (the identity of the amino acid at the 
homologous position (M167) in Drosophila SERT) resulted in a dramatic loss in inhibitory 
potencies for the SERT antagonists citalopram, fluoxetine, sertraline, and cocaine. Importantly, 
the I172M substitution does not alter normal 5-HT transport or SERT surface expression 
(Thompson et al. 2011; Henry et al. 2006). The unique properties of this mutation allow for the 
generation of a transporter that has normal 5-HT transport capability but is virtually 
pharmacologically invisible to many antidepressants. In fact, SERT M172 transgenic mice show 
a loss in sensitivity to multiple SSRIs without altering 5-HT transport or synaptic levels of 5-HT 
(Thompson et al. 2011). Notably, the actions of SSRIs in wild-type mice are often compared to 
the SERT null mouse (Bengel et al. 1998), which could be inappropriate due to the 
developmental role of 5-HT in serotonergic and non-serotonergic systems. Chronic loss of 
appropriate serotonergic tone caused by the SERT null genotype results in multiple physiological 
and behavioral phenotypes that make any comparisons to the wild-type mouse during SSRI 
treatment confounding and problematic at best (Holmes, Murphy, and Crawley 2003). The SERT 
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M172 AD-insensitive mouse represents a significant step forward and a powerful new tool to 
define the role of SERT and 5-HT signaling following AD administration. 
In humans and rodents, most SSRIs and SNRIs are metabolized to demethylated forms by 
cytochrome P450 enzymes, found primarily in the liver (Velasquez et al. 2016). Many of these 
demethylated metabolites are active antagonists of SERT mediated 5-HT transport (Sánchez and 
Hyttel 1999). However, the selectivity and potency of these metabolites for mSERT versus 
mSERT M172 has not been evaluated. In this study, we investigate the sensitivity of mSERT 
M172 in midbrain synaptosomes and platelets for antagonism by multiple SSRIs, SNRIs, and 
their metabolites. Furthermore, we look at the generation of the citalopram metabolite 
desmethylcitalopram in serum and brain tissue at 45 min and 2 hr following intraperitoneal 
injections to determine if SSRI chronic treatment regimens could be impacted by bioactive 
metabolites that have equivalent or biologically relevant potencies at SERT and SERT M172. 
This information is critical to ensuring that the physiological and behavioral effects observed 
with AD administration are due to the action of the parent compound and not to metabolites. 
Methods 
Animals  
Serotonin transporter (SERT) M172 knock-in mice were previously generated on a 
129S6 background (Thompson et al. 2011). The M172 knock-in and I172 wild-type littermates 
(8-12 weeks old) from heterozygous breeding litters were used for the ex vivo serotonin transport 
inhibition assays. Age-matched I172 wild-type C57BL/6J (Jackson Laboratory) mice from 
homozygous breeding litters were used for mass spectrometry (MS) analysis. Food and water 
was provided ad libitum and mice were maintained on a 12 hr light/dark schedule. All animal 
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procedures follow approved protocols of the UTHSCSA or IACUC/UNDACC animal use and 
care committees. 
Synaptosome and Platelet-rich Plasma (PRP) Preparations 
Samples were prepared as previously described (Thompson et al. 2011), but adapted to 
obtain both synaptosomes and PRP from the same animal to minimize the number of animals 
used. Briefly, mice were deeply anesthetized using Euthasol (500 µl/animal) (Virbac AH, TX) 
and effectiveness assessed using foot pinch. Following ophthalmectomy for PRP preparation, 
blood was collected and the brain (forebrain and midbrain) dissected on ice for synaptosome 
preparation. 
Brain blocks were homogenized in a buffer solution (containing 0.32 M sucrose and 4.2 
mM HEPES, pH 7.4). Synaptosomal pellets were obtained through two-stage centrifugation: the 
homogenate was spun at 1,500 rpm for 15 min at 4°C and then the supernatant at 1.5 × 10,000 g 
for 15 min at 4°C. Synaptosomal pellets were resuspended with Krebs-Ringer HEPES buffer 
(KRH; 130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.8 g/L 
D-glucose, 10 mM HEPES, pH 7.4, 100 mM pargyline, and 100 mM ascorbic acid). 
Synaptosomal suspensions were assessed for protein content using a spectrophotometer (Thermo 
Scientific, USA) and then diluted to 1,500 µg/µl with KRH buffer. The prepared synaptosomes 
were maintained on ice until dispensed for serotonin transport assays. 
Collected blood was anticoagulated with Acid Citrate Dextrose Solution A (BD Franklin 
Lakes, NJ) at a ratio of 100 µl per 500 µl then centrifuged at 150 × g for 20 min at 22°C to obtain 
PRP (the upper, clear supernatant). The PRP was assessed for platelet counts/µl by using a 
hemocytometer then stored at room temperature, to prevent platelet activation, until use in 
competition 5-HT uptake assays. 
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5-HT Competition Uptake Assays 
Transport of 5-HT was assayed as described previously (Zhu, Blakely, and Hewlett 
2006). Briefly, [3H]5-HT (100 nM) and serial dilutions of SERT inhibitors were prepared 
separately in KRH for synaptosomes or a buffered solution (150 mM NaCl, 50 mM Tris HCl, 25 
mM EDTA, pH 7.4, 100 mM pargyline, and 100 mM ascorbic acid) for platelets. In a final 
volume of 250 µl (150 µl synaptosome or PRP, 50 µl [3H]5-HT, and 50 µl antagonist), the assay 
was initiated by incubation in a water bath for 10 min at 37°C followed by immediate filtration 
over 0.3% polyethylenimine-coated glass fiber filters using a cell harvester. Filter-bound 
radioactivity was quantified by a Beckman LS 6000 liquid scintillation counter. All transport 
assays were performed in duplicate. Radioactivity was normalized as a percentage of inhibition 
and plotted to determine the IC50 of the tested antagonist. 
Animal Injections and Measurement of Brain and Serum Drug Concentrations 
VK05-19.Oxalate S-Citalopram, a gift from Amy Newman (NIH-NIDA), and the 
metabolite (S)-N-Desmethylcitalopram (Toronto Research Chemicals Inc, Cat #D291571) were 
administered via intraperitoneal injection in 0.9% NaCl at 10 mg/kg, 5 ml/kg respectively. For 
mass spectrometry analysis, imipramine was used as an internal standard while citalopram and 
desmethylcitalopram were used as positive controls and were reconstituted in 100% methanol 
with a final concentration of 5 ng. 
Brain Tissue and Serum Preparations  
At 45 minutes and 2 hours post-injection, mice were decapitated. Whole brains were 
frozen and stored in liquid nitrogen (N2). Trunk blood was collected, centrifuged for 10 min at 
4°C, 10,000 rpm and the supernatant transferred to cryovials for storage in N2. Brain tissue was 
pulverized to a fine powder under N2 to allow for a homogeneous mixing of different brain 
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compartments and extracted using a one-step protocol (Brose, Baker, and Golovko 2013). For 
extraction, 10 mg of brain tissue or 10 µL of plasma was mixed with 90 µL of 100% methanol. 
Treated samples were spiked with the internal standard imipramine while positive vehicle 
controls were spiked with imipramine and citalopram, desmethylcitalopram, or both citalopram 
and desmethylcitalopram. The vehicle negative control contained only 100% methanol. Samples 
were briefly sonicated on ice, vortexed and centrifuged for 10 min at 4°C, 10,000 rpm. Collected 
supernatant was diluted 100 fold with 90% methanol in water.   
UPLC-MS/MS Analysis for Citalopram and Desmethylcitalopram 
Compounds were resolved on a Waters ACUITY UPLC HSS T3 column (1.8 µM, 100 Å 
pore diameter, 2.1×150mm, Waters, Milford, MA) with an ACUITY UPLC HSS T3 pre-column 
(1.8 µM, 100 Å pore diameter, 2.1×5mm, Waters) at a temperature of 55°C. Analytes were 
eluted using a Waters ACUITY UPLC pump with a well plate autosampler at 8°C. 10 µL of 
sample was injected on column. 
The separation was based on the previously described method (Brose and Golovko 2013; 
Brose, Golovko, and Golovko 2016). Solvent A was water containing 0.1% formic acid and 
solvent B was acetonitrile with 0.1% formic acid. The flow rate was maintained at 0.45 mL/min. 
The initial conditions of 39% B were held for 0.5 min. Solvent B was increased to 40.5% over 
6.88 min, followed by an increase to 70% over 1.62 min, then increased to 75% over 3 min, and 
further increased to 98 over 1.5 min where it was held for 5.3 min to elute hydrophobic 
molecules from the column. At 20 min, solvent B was returned to initial conditions over 0.2 
minutes to re-equilibrate the column for 2min. 
Compounds were analyzed using a triple quadrupole mass spectrometer (Xevo TQ-S, 
Waters) with electrospray ionization optimized in a positive mode. The capillary voltage was 
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3.29 kV and cone voltage was 14 V. The desolvation temperature was 500°C and the source 
temperature 150°C. The desolvation gas flow was 1000 L/hr, the cone gas flow was 150 L/hr, 
and the nebulizer gas was at 5.0 Bar. The collision gas was set at 0.18 mL/min. MassLynx V4.1 
software (Waters) was used for instrument control, acquisition, and sample analysis. 
Citalopram and desmethylcitalopram were quantified using imipramine as an internal 
standard. Compound’s MS/MS parameters were optimized for multiple reactions monitoring 
(MRM) mode by direct infusion of a standard solution of each analyte. Citalopram was 
quantified using 325.18/109.04 mass transition (collision energy (CE) 14 V) with 325.18/234.14 
conformational ion (CE 24V); desmethylcitalopram was quantified using 311.16/109.04 mass 
transition (CE 14 V) with 311.16/262.15 conformational ion (CE 16V); and imipramine was 
quantified using 281.20/86.09 mass transition (CE 14 V) with 281.20/208.11 conformational ion 
(CE 36V). The mass transitions for analytes and the selection of internal standard were 
consistent with previous reports (Jiang et al. 2010). 
Results and Discussion 
A previous study revealed that in comparison to wild-type mice, the SSRIs citalopram 
and fluoxetine display significantly reduced potencies for inhibition of SERT mediated 5-HT 
uptake in forebrain derived synaptosomes from M172 SERT mice (Thompson et al. 2011). 
Similarly, in this study, the SSRIs citalopram, fluoxetine, and sertraline as well as the SNRI 
venlafaxine showed significant losses in potency for antagonism of M172 synaptosomes, 
reductions ranging from 16-fold (fluoxetine) to 631-fold (citalopram) (Fig. 43, Table 2). As 
multiple SSRIs and SNRIs have active metabolites with half-lives long enough to make them 
biologically relevant (Sánchez and Hyttel 1999), we also characterized the correlate metabolites 
desmethylcitalopram, norfluoxetine, desmethylsertraline, and desvenlafaxine. Comparison of 
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Figure 43. Competition 5-HT uptake analysis in forebrain derived synaptosomes. Forebrain 
derived synaptosomes were prepared from wild-type and M172 mice and utilized to assess the 
ability of multiple SSRI class drugs and their metabolites to compete for [3H]5-HT uptake. All 
SSRIs showed decreased potency in the M172 synaptosomes, while some metabolites showed 
similar potency in both wild-type and M172 synaptosomes. (n = 4-8 per drug; p < 0.05, two-
tailed Student t test). 
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Table 2. Log IC50 values for inhibition of [3H]5-HT uptake. Competition uptake analysis of 
PRP and forebrain derived synaptosomes, derived from wild-type and M172 mice, was 
performed to calculate IC50s for multiple SSRIs and their active metabolites. Fold shift 
compares the rightward shift in potency for inhibiting SERT activity in wild-type and M172. 
 
 Platelets  Synaptosomes  
 Log IC50 Fold Log IC50 Fold 
 WT M172 Shift WT M172 Shift 
Fluoxetine -7.4 ± 0.12 -6.2 ± 0.20 16 -7.0 ± 0.16 -5.8 ± 0.06 16 
Norfluoxetine -7.0 ± 0.06 -6.7 ± 0.13 2 -6.8 ± 0.04 -6.3 ± 0.02 3.2 
Sertraline -8.0 ± 0.05 -6.1 ± 0.18 79 -7.8 ± 0.21 -5.9 ± 0.05 79 
Desmethylsertraline -7.3 ± 0.04 -6.4 ± 0.11 7.9 -6.2 ± 0.13 -5.8 ± 0.08 2.5 
Venlafaxine -6.4 ± 0.12 -3.9 ± 0.12 316 -6.8 ± 0.07 -5.1 ± 0.09 50 
Desvenlafaxine -6.3 ± 0.18 -4.3 ± 0.06 100 -6.8 ± 0.07 -5.1 ± 0.06 50 
Citalopram -7.8 ± 0.07 -5.0 ± 0.06 631 -8.1 ± 0.09 -5.3 ± 0.04 631 
Desmethylcitalopram -7.6 ± 0.25 -5.0 ± 0.06 398 -7.7 ± 0.04 -5.8 ± 0.11 79 
 
potencies of norfluoxetine and desmethylsertraline to inhibit 5-HT uptake of SERT and M172 
SERT containing synaptosomes revealed that the compounds no longer exhibited strong 
selectivity for inhibition of SERT over M172 SERT and showed a fold change in IC50 values of 
3.2- and 2.5-fold, respectively. However, desvenlafaxine and desmethylcitalopram retained 
selectivity for wild-type SERT over M172 SERT (50- and 79-fold, respectively) (Fig. 43, Table 
2). It is important to note that the potency of the metabolite desmethylsertraline to inhibit 5-HT 
uptake in wild-type SERT is decreased 40-fold in reference to its parent compound sertraline, a 
reduction which may be due, in part, to a shift in binding of the metabolite to a lower affinity 
site. Conversely, metabolites norfluoxetine, desvenlafaxine, and desmethylcitalopram inhibit 5-
HT uptake in wild-type SERT at potencies similar to their parent compounds (≤ 2.5-fold 
change). For this reason, it is plausible that these metabolites in particular contribute to 
physiological blockade of transport and have a role in the effects observed following AD 
administration. 
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Figure 44. Competition 5-HT uptake analysis in isolated platelets. Isolated platelet rich 
plasma (PRP), from wild-type and M172 mice, was utilized to assess the ability of multiple SSRI 
class drugs and their metabolites to compete for [3H]5-HT uptake. All SSRIs showed decreased 
potency in the M172 platelets, while some metabolites showed similar potency in both wild-type 
and M172, comparable to what was seen in synaptosomes. (n = 5-7 per drug; p < 0.05, two-tailed 
Student t test).!
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Similar to SERT, NET is a significant target of SNRIs and, though our 5-HT uptake 
assays should not be affected by the presence of NET, we also tested platelets to eliminate any 
contribution of NET. Platelets isolated from whole blood are often used as peripheral markers 
(Oreland and Hallman 1989) in human studies of SERT as they are easily obtained from subjects 
(Yubero-Lahoz et al. 2013). In addition, platelets cannot synthesize 5-HT and are therefore 
entirely dependent on SERT mediated uptake to accumulate 5-HT (Ni and Watts 2006; Berger, 
Gray, and Roth 2009). Our inhibitory data from platelets are consistent with the synaptosomal 
results with respect to the direction of potency changes (Fig. 44, Table 2). However, there were 
some differences in the magnitude of the fold-change of drug potencies between platelets and 
synaptosomes. Platelets likely lack some of the SERT interacting proteins present in neurons, 
which could account for the magnitude differences in potency changes. Nevertheless, the 
identical trends support our conclusions. As we are primarily focused on metabolite action in the 
brain, the following analyses are from synaptosome results.  
Analysis of SERT activity from midbrain synaptosomes derived from the M172 mouse 
reveals that the fluoxetine metabolite norfluoxetine shows a slight decrease in antagonist potency 
for wild-type SERT but gains potency for inhibiting M172 SERT resulting in a significant 
reduction in selectivity (16-fold to 3.2-fold) (Fig. 43, Table 2). Norfluoxetine has been reported 
to return to the brain where it can build up significantly due to its longer half-life compared to 
fluoxetine and is thus likely the major antagonist of 5-HT uptake by SERT in both wild-type and 
M172 SERT mice. Desmethylsertraline, the break-down product of sertraline, also displays 
reduced selectivity for SERT over M172 SERT (79-fold to 2.5 fold) in synaptosomes, but 
importantly is 40-fold less potent than sertraline for inhibiting wild-type SERT and is therefore 
unlikely to significantly contribute to inhibition of 5-HT uptake. Venlafaxine and its metabolite 
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desvenlafaxine have virtually identical potencies for inhibition of SERT and M172 SERT in 
synaptosomes, as each compound exhibits 50-fold selectivity for SERT over M172 SERT. 
Therefore, even if desvenlafaxine can return to the brain, it would inhibit the same as 
venlafaxine. Desmethylcitalopram, the primary metabolite of citalopram, exhibits reduced but 
still robust selectivity for inhibition of SERT over M172 SERT (631-fold to 79-fold). 
 
 
Figure 45. Time course analysis of brain and serum levels of citalopram and the metabolite 
desmethylcitalopram. Age-matched C57BL/6J mice were injected with either citalopram or 
desmethylcitalopram and sacrificed at 45 min or 2 hr post-injection. The analytes were isolated 
from whole brain or serum and detected by LC-MS/MS. In the brain and serum, citalopram 
levels (● Cit) decrease from 45 min to 2 hr, whereas the metabolite desmethylcitalopram (Δ dCit 
from Cit) levels increase only in the brain over time. As a control, mice injected with the 
metabolite desmethylcitalopram (▵ dCit) show an accumulation of the metabolite in the brain, 
when comparing 45 min and 2 hr, but a decreased concentration in the serum, as seen with the 
citalopram derived metabolite. n≥2 mice, unpaired t-test was used to compare 45 min to 2 hr (*, 
p < 0.05). 
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Having established that AD metabolites are capable of antagonizing SERT mediated 5-
HT transport in ex vivo assays, we next determined whether the metabolite desmethylcitalopram 
is capable of crossing the blood brain barrier, as re-entry into the brain following first-pass 
metabolism could contribute to the behavioral effects observed with chronic SSRI treatment. 
Desmethylcitalopram was selected due to its importance in our ongoing studies. Wild-type mice 
injected intraperitoneally with citalopram or its metabolite desmethylcitalopram were sacrificed 
after 45 mins or 2 hr and blood serum or brain tissue extracts analyzed by liquid chromatography 
and mass spectrometry to quantify the parent compounds and metabolites. Comparison of the 45 
min and 2 hr time points revealed that brain and serum citalopram levels decrease over time (Fig. 
45, Table 3). During this period, desmethylcitalopram levels metabolized from citalopram 
increased in the brain, but not in the serum. Likewise, mice directly injected with the metabolite 
itself show an accumulation in the brain over time and a loss over time in the serum. Importantly, 
desmethylcitalopram, unlike norfluoxetine, maintains selectivity for wild-type SERT and is 
therefore not expected to interfere with citalopram treatment studies in the M172 mouse.  
Table 3. LC-MS/MS quantification of citalopram and the metabolite desmethylcitalopram 
in brain and serum. Age-matched C57BL/6J mice were injected with either citalopram or 
desmethylcitalopram and sacrificed at 45 min or 2 hr post-injection. The analytes were isolated 
from whole brain or serum and detected by LC-MS/MS. n≥2 mice, unpaired t-test was used to 
compare 45 min to 2 hr (*, p < 0.05). 
 
 Brain (µM)  Serum (µM)  
 Time  Time  
 45 min 2 hr t test 45 min 2 hr t test 
Citalopram 5.52 ± 0.54 2.85 ± 0.38 * 0.76 ± 0.04 0.42 ± 0.05 * 
Desmethylcitalopram 0.38 ± 0.03 0.73 ± 0.12 * 1.03 ± 0.04 0.51 ± 0.10 * 
Desmethylcitalopram 
from Citalopram 0.14 ± 0.01 0.37 ± 0.05 * 0.33 ± 0.01 0.46 ± 0.09 n.s. 
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In conclusion, synaptosomes and platelets derived from M172 SERT mice show a 
reduced sensitivity to multiple SERT antagonists, as was previously demonstrated (Thompson et 
al. 2011). However, the ability of bioactive metabolites to antagonize 5-HT uptake by the M172 
SERT substitution has not previously been studied. Here we explored the potency of these drugs 
for antagonism of wild-type versus M172 SERT and found that studies using the M172 mouse 
that require selective inhibition of wild-type SERT over M172 SERT need to account for active 
metabolites and determine if there are changes in selectivity, inhibitory potency, and blood brain 
barrier passage and retention. Compounds that loose selectivity but retain similar potencies as the 
parent compound are problematic and should not be used.  
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CHAPTER VII 
AUTISM-LINKED MUTATIONS IN THE HUMAN SEROTONIN TRANSPORTER 
INDUCE DISTINCT STRUCTURAL CHANGES THAT MAY ACCOUNT FOR THE 
ALTERED FUNCTION OF THE TRANSPORTER 
 
Introduction 
Autism spectrum disorder (ASD) is diagnosed in one out of every 68 children in the 
United States (CDC, 2014) and whereas individuals present with a range of behavioral 
manifestations, most share common symptoms including communication and social deficits as 
well as restrictive and repetitive behaviors (American Psychiatric Association, 2013). The varied 
presentations of ASD suggests it is a complex disorder with numerable causes, however, a 
genetic link has been identified in up to 25% of cases (Huguet, Ey, and Bourgeron 2013). 
Furthermore, twin studies have identified concordance rates of up to 92% in identical twins 
supporting that ASD can be heritable and under genetic control (Bailey et al. 1995). 
Early physiological studies revealed that 25-30% of autistic individuals exhibit elevated 
whole blood serotonin (5-HT) levels (Schain and Freedman 1961; Hanley, Stahl, and Freedman 
1977), termed hyperserotonemia, a biomarker that predated the broad acceptance of 5-HT as a 
neurotransmitter (Folk and Long 1988). This biomarker continues to be useful in today’s 
population of ASD individuals (Gabriele, Sacco, and Persico 2014; Muller, Anacker, and 
Veenstra-VanderWeele 2016) and is one of the primary traits most consistently associated with 
the disorder (Cook and Leventhal 1996; Veenstra-VanderWeele and Blakely 2012) suggesting 
that dysregulation of the serotonergic system contributes to biological mechanism and behaviors 
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associated with ASD. Furthermore, this associative link is strengthened by the efficacy of 
selective serotonin-reuptake inhibitors (SSRIs) are used to treat some symptoms of ASD 
(Hollander et al. 2004). SSRIs bind and inhibit the normal activity of the serotonin transporter 
(SERT), an integral membrane protein belonging to the SLC6 family of transporters expressed 
on presynaptic serotonergic neurons (Moore, Halaris, and Jones 1978; Baganz and Blakely 2013) 
and at numerous sites in the periphery including platelets (Qian et al. 1995), which acts in the 
brain to terminate serotonergic signaling by coupling the reuptake of 5-HT from the synapse into 
the presynaptic neuron to the electrochemical gradients of Na+, Cl-, and K+ (Kristensen et al. 
2011; Pramod et al. 2013). Alterations in SERT functional levels have been shown to modulate 
serotonergic tone and are implicated in mood and behavioral disorders (Ramamoorthy et al. 
1993; Barker and Blakely 1995) whereas regulation of SERT activity and trafficking at the 
membrane of platelets modulate blood 5-HT levels, as 5-HT is produced by enterochromaffin 
cells lining the lumen of the gastrointestinal tract (Gershon 2004) and is sequestered inside 
platelets by SERT when they pass through enteric circulation (Anderson, Feibel, and Cohen 
1987).  
Structurally, SERT is composed of twelve transmembrane domains (TMs) related by a 
pseudo-twofold axis in which TMs 1-5 and TMs 6-10 have the same overall internal 
arrangement, but are aligned antiparallel to one another (Coleman, Green, and Gouaux 2016). 
The amino (N) and carboxyl (C) termini, which are located intracellularly, contain multiple sites 
for regulation by phosphorylation (Ramamoorthy et al. 1998; Ramamoorthy et al. 2007) as well 
as mediate protein-protein interactions (Haase et al. 2001; Quick 2003; Carneiro and Blakely 
2006; Carneiro et al. 2008). To date, multiple ASD-linked SERT coding variants (ASVs) have 
been identified including, but not limited to, G56A located on the N terminus, I425L on TM8, 
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Figure 46. Location of autism-associated SERT variants. Variants are overlaid on a 2-D 
representation of SERT. Regulatory domain variants are shaded black whereas the 
transmembrane domain variants are shaded blue.   
 
F465L on TM9, L550V on TM11, and K605N on the C terminus (Fig. 46). Each ASV, with the 
exception of K605N, is significantly associated with phenotypic increases in stereotypic 
utterances, unusual preoccupations, compulsions/rituals, resistance to trivial changes, and 
unusual attachment to objects (Tadevosyan-leyfer et al. 2003; Sutcliffe et al. 2005). Functional 
analyses of these variants indicate an increase in 5-HT transport relative to wild type human 
SERT (hSERT) for all mutants whereas surface expression was elevated only in I425L, F465L, 
and L550V (Prasad et al. 2005; Prasad et al. 2009). The hyperactivity of the cytoplasmic variants 
G56A and K605N has been suggested to result from loss of regulation by phosphorylation due to 
the observation that activators and inhibitors of the cyclic GMP-dependent protein kinase (PKG) 
and the p38 mitogen-activated protein kinase (p38 MAPK) pathways are ineffective in 
modulating the enhanced phosphorylation levels in G56A (Prasad et al. 2005; Veenstra-
VanderWeele et al. 2012). These results reinforce that the gain-of-function of the G56A and 
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K605N variants results from catalytic activation or possible disruptions in phosphatase 
interactions whereas an increase in surface expression impacts 5-HT homeostasis in ASVs 
I425L, F465L, and L550V.  
As the exact mechanism(s) underlying SERT hyperactivity in these ASVs remains 
unclear, it is imperative to understand how mutations in the structural core of the transporter can 
result in the same functional and physiological outcome as mutations in distant regulatory 
termini domains. Here we present structural analyses of the ASVs for the purpose of identifying 
either common or distinct conformational changes, representative of altered tertiary structure, 
that could mediate the observed changes in catalytic activity and surface expression.  
Methodology 
Cell Culture and Site-directed Mutagenesis  
 ASVs were introduced into native or cysteine-reduced SERT backgrounds of pcDNA3-
hSERT using the Stratagene QuikChange® kit and verified by sequencing (Eurofins MWG 
Operon, Huntsville, AL). Analysis of the intracellular Cys-277 probe required introduction of the 
ASVs into the X5C background (C15A, C21A, C109A, C357I, and C622A) (Sato et al. 2004) 
prior to transient expression in HEK-GripTite cells (Invitrogen) using TransIT®-LT1 (Mirus) (1 
µl per 200 ng of DNA). Cells were maintained in a humidified chamber with 5% CO2 at 37°C in 
Dulbecco’s modified Eagle’s medium (DMEM: 10% FBS, 600 µg/ml G418). 
Cysteine Accessibility Analysis 
Conformational changes assessed by rate of inactivation. GripTite cells were plated at 
a density of 10,000 or 50,000 cells/well in 24-well culture plates, incubated for 24 h, and 
transfected with hSERT constructs. Following transfection (24 h), cells were washed with 37°C 
PBS/CM buffer (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, 0.1 mM 
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CaCl2, 1.0 mM MgCl2, pH 7.4) or NMDG-Cl buffer (120 mM NMDG-Cl, 5.4 mM KCl, 1.2 mM 
CaCl2, 10 mM glucose, 7.5 mM HEPES, pH 7.4) and then incubated with 1 mM MTSET, 10 
mM MTSES, or 2 mM MTSEA for 1-10 min at room temperature. Post-treatment, cells were 
washed with PBS/CM or NMDG-Cl buffer and assayed for transport activity by incubation with 
50 nM [3H]5-HT for 5 min at 37°C in MKRHG buffer (5 mM Tris, 7.5 mM HEPES, 120 mM 
NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 10 mM glucose, pH 7.4). Cells were 
dissolved in MicroScint™-20 (PerkinElmer Life Sciences) scintillation fluid and counts/min of 
radioactivity were determined using a TopCount NXT scintillation counter. Specific uptake was 
determined by subtracting uptake observed in nontransfected cells. All experiments were 
repeated in three or more separate assays and data fit to a one phase decay. Half-life values 
estimated from inactivation were analyzed using a one-way ANOVA followed by a post hoc 
Dunnett’s test (GraphPad Software Prism 5).  
Antagonist- or substrate-induced protection of Cys-277. For protection studies, 50,000 
GripTite cells were plated and transfected as described above. 24 h post-transfection, cells were 
pretreated with vehicle, 50 µM 5-HT, or 50 µM cocaine for 10 min at 37°C before addition of 1 
mM MTSEA in PBS/CM buffer for 10 min at room temperature. After washing to remove 
unreacted MTSEA, remaining activity was assayed by [3H]5-HT (50 nM for 5 min at 37°C) in 
MKRHG buffer, radioactivity quantified as above, and data analyzed using a two-way ANOVA 
followed by a post hoc Bonferroni test. 
Cys-277 accessibility in mimicked hyper- or de-phosphorylated SERT. 50,000 
GripTite cells transfected to express ASVs in PKG phosphorylation-dependent (S277C) or 
mimicked hyper- (T276D) and de- (T276A) phosphorylated backgrounds were treated with 
vehicle or 1 mM MTSEA in PBS/CM buffer for 10 min at room temperature. Following 
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treatment, cells were assayed for transport activity by 50 nM [3H]5-HT for 5 min at 37°C in 
MKRHG buffer. Radioactivity was quantified as above, normalized for surface and total SERT 
expression, and data analyzed using a one- or two-way ANOVA followed by a post hoc 
Dunnett’s or Bonferroni test, respectively. 
Protein Expression Analysis 
Surface proteins were biotinylated as previously described (Henry et al. 2003). Briefly, 
surface proteins were biotinylated using 1.5 mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin (Thermo 
Scientific™) in PBS/CM buffer and analyzed via Western blotting. Total protein concentrations 
were determined using the Pierce BCA protein assay kit (Thermo Scientific™) and the resulting 
values used to load equal amounts of protein when conducting SDS-PAGE on 10% gels. Blots of 
total and surface protein were probed with either an N-terminal monoclonal antibody at a 
concentration of 1:1500 (ST51-2, MAb Technologies) or a C-terminal directed polyclonal 
antibody at a concentration of 1:5000 (#48, a gift from Dr. Randy Blakely) followed by 
quantitation of the immunoblot bands using Image Studio (LI-COR). 
Results 
Sensitivity of Cys Probes to MTS Reagents 
Residue Cys-109 (Fig. 47), an endogenous cysteine residue located on the extracellular 
end of transmembrane domain 1 (TM1 or TM1b), and the engineered mutant Cys-277, 
positioned on TM5 proximal to the cytoplasm (Fig. 47), have been shown to exhibit altered 
sensitivity to thiol modifying reagents, including methanethiosulfonates (MTS). This method, 
known as the substituted cysteine accessibility method (SCAM), utilizes the reaction between 
charged, hydrophilic, sulfhydryl reagents and endogenous or engineered cysteine residues to 
elucidate SERT conformational changes induced by mutations and/or antagonist, substrate, or 
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ion binding (Androutsellis-Theotokis, Ghassemi, and Rudnick 2001; Henry et al. 2003; Zhang 
and Rudnick 2006; Forrest et al. 2008; Field, Henry, and Blakely 2010; Henry et al. 2011; Felts 
et al. 2014; Dahal et al. 2014). Recent crystal structures of the homologous bacterial leucine 
transporter (LeuT) and the homologous Drosophila dopamine transporter (dDAT) confirm that 
TM1b and TM5, the respective locations of Cys-109 and Cys-277, undergo significant 
conformational changes during substrate transport (Singh et al. 2008; Krishnamurthy and 
Gouaux 2012; Penmatsa, Wang, and Gouaux 2013). Thus, the sensitivity of Cys probes 109 and 
277 will be assessed in the ASV backgrounds in order to identify conformational changes at the 
extracellular (Cys-109) or cytoplasmic (Cys-277) face of SERT.   
 
 
 
 
Figure 47. Cysteine probes used to assess 
conformational changes through SCAM. 
The extracellular Cys-109 probe (purple 
shaded circle) is located at the extracellular 
end of TM1 (blue cylinder) whereas the 
intracellular Cys-277 probe (purple shaded 
circle) is located at the base of TM5 (green 
cylinder) proximal to the cytoplasm. 
 
 
 
 
The endogenous cysteine residue Cys-109 is responsible for the majority of the 
sensitivity to externally applied MTS reagents (Fig. 48, + Control is Cys-109 and - Control is 
Ala-109) (Chen, Liu-Chen, and Rudnick 1997). Therefore, reactivity of a negatively charged, 
TM1 
TM
5 
109 
277 
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Figure 48. MTSES reactivity at Cys-109 is altered by the regulatory domain variants. HEK-
GripTite cells plated at low- (a) or high-density (b) and transfected to express ASVs were treated 
with 10 mM MTSES in PBS/CM buffer for the indicated time. Following treatment, the cells 
were assayed for [3H]5-HT transport (50 nM for 5 min). Transport activity is plotted as a percent 
of untreated cells and the values represent the mean ± S.E. from three or more independent 
experiments. The t ½ values are estimated from inactivation and analyzed with a one-way 
ANOVA followed by a post hoc Dunnett’s test.  
 
membrane impermeant MTS reagent, MTSES, was evaluated at this location in the ASV 
backgrounds. Furthermore, based on the initial phases of this study that suggested cell density 
impacts the accessibility of a Cys-probe, we tested for Cys reactivity in both low- and high-
density systems, in which cells were plated at a density of 10,000 or 50,000 cells/well. In a low-
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density system, MTSES reactivity at Cys-109 was decreased in the cytoplasmic, regulatory 
domain ASVs G56A and K605N (Fig. 48a). However, in a high-density system, the results were 
inverted as reactivity was increased in G56A and K605N (Fig. 48b), likely resulting from a 
change in cell-cell or protein-protein interactions.     
 
 
Figure 49. Cys-277 is more accessible to MTSEA in ASVs. HEK-GripTite cells plated at low- 
(a) or high-density (b) and transfected to express ASVs in the S277C/X5C background were 
treated with 2 mM MTSEA in PBS/CM buffer for the indicated time. Following treatment, the 
cells were assayed for [3H]5-HT transport (50 nM for 5 min). Transport activity is plotted as a 
percent of untreated cells and the values represent the mean ± S.E. from three or more 
independent experiments. The t ½ values are estimated from inactivation and analyzed with a 
one-way ANOVA followed by a post hoc Dunnett’s test.  
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The intracellular location of the engineered Cys-277 probe requires the use of a 
membrane-permeant MTS reagent, MTSEA, which is (+) charged. Though Cys-109 is the most 
reactive extracellular cysteine to MTS reagents, membrane-permeant reagents can react with the 
several Cys residues on the cytoplasmic face that are accessible to MTS. For this reason, a Cys-
reduced background was engineered such that the primary reactivity of MTSEA occurs at Cys-
277 (Fig. 49, + Control is Cys-277/X5C and - Control is Ser-277/X5C) (Sato et al. 2004). 
Subsequently, each ASV was introduced into the S277C/X5C background and tested in low- and 
high-density cell systems for conformational changes based on changes in reactivity of MTSEA 
at Cys-277. In a low-density system, reactivity of MTSEA was decreased in the cytoplasmic, 
regulatory domain ASVs G56A and K605N (Fig. 49a). Similarly, in a high-density system, 
reactivity was decreased in the ASVs G56A and K605N as well as in the transmembrane domain 
ASVs I425L and L550V, but was unchanged from the positive control in the ASV background of 
F465L (Fig. 49b). 
MTS Reactivity is Cation Dependent         
 Studies have revealed that Cys-109 accessibility is altered in a cation-dependent manner 
(Chen, Liu-Chen, and Rudnick 1997; Felts et al. 2014). Therefore, we chose to replace Na+ in the 
buffer with the large monovalent cation N-methyl-D-glucamine (NMDG+) in order to uncover 
ASV-induced conformational changes in an NMDG+-bound SERT conformation, as NMDG+ 
cannot functionally replace or presumably bind to the highly selective Na+ binding sites in SERT 
(Felts et al. 2014). Reactivity of the large, positively charged, and membrane-impermeant 
MTSET was increased at Cys-109 in the cytoplasmic, regulatory domain ASVs G56A and 
K605N in both low- and high-density systems buffered with NMDG+ (Fig. 50a and 50b, 
respectively, + Control is Cys-109 and - Control is Ala-109).  Furthermore, in a high-density 
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Figure 50. Cys-109 is more accessible to MTSET in sodium-free buffer in ASVs. HEK-
GripTite cells plated at low- (a) or high-density (b) and transfected to express ASVs were treated 
with 1 mM MTSET in NMDG-Cl buffer for the indicated time. Following treatment, the cells 
were assayed for [3H]5-HT transport (50 nM for 5 min). Transport activity is plotted as a percent 
of untreated cells and the values represent the mean ± S.E. from three or more independent 
experiments. The t ½ values are estimated from inactivation and analyzed with a one-way 
ANOVA followed by a post hoc Dunnett’s test.  
 
system, reactivity at Cys-109 was increased in the transmembrane domain ASV backgrounds 
I425L and F465L, but was unchanged from the positive control in the ASV background of 
L550V. Interestingly, MTSEA reactivity at Cys-277 was virtually identical between the ASV 
mutants and the positive control in NMDG+ buffered low- and high-density systems (Fig. 51a 
!!167 
and 51b, respectively, + Control is Cys-277/X5C and - Control is Ser-277/X5C). The similar 
MTSEA sensitivity is consistent with the transporters adopting a shared conformational state in 
the absence of Na+ that is not affected by the mutations. However, we cannot rule out the 
possibility that there are conformational changes in the ASVs that may not be proximal to or 
detected by the Cys-277 residue. 
 
Figure 51. MTSEA reactivity at Cys-109 in sodium-free buffer is unaltered. HEK-GripTite 
cells plated at low- (a) or high-density (b) and transfected to express ASVs in the S277C/X5C 
background were treated with 2 mM MTSEA in NMDG-Cl buffer for the indicated time. 
Following treatment, the cells were assayed for [3H]5-HT transport (50 nM for 5 min). Transport 
activity is plotted as a percent of untreated cells and the values represent the mean ± S.E. from 
three or more independent experiments. The t ½ values are estimated from inactivation and 
analyzed with a one-way ANOVA followed by a post hoc Dunnett’s test.  
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Effect of 5-HT and Cocaine on MTSEA Inactivation 
 In the presence of substrates, SERT undergoes multiple conformational changes while 
mediating substrate translocation (Jardetzky, 1966; Mitchell, 1990). Alternatively, antagonists 
can act by stabilizing occluded, extracellularly-facing, or intracellularly-facing conformations 
(Jacobs et al. 2007; Beuming et al. 2008; Schmitt, Rothman, and Reith 2013; Dahal et al. 2014; 
Wang, Penmatsa, and Gouaux 2015; Coleman, Green, and Gouaux 2016). We hypothesized that 
the ASVs may induce conformational changes that could become more evident with substrate or 
antagonist-bound SERT conformations. Therefore, we assessed how inactivation of transport by 
MTSEA was altered by preincubation with 5-HT or cocaine in the ASVs.  
Addition of 5-HT decreases [3H]5-HT transport (Fig. 52, + Control is Cys-277/X5C and 
- Control is Ser-277/X5C), indicating that 5-HT increases the reactivity of MTSEA at Cys-277 
(Zhang and Rudnick 2006; Jacobs et al. 2007). This result suggests that SERT accumulates in an 
inward-facing conformation when transporting 5-HT, thus increasing the accessibility of Cys-
277 to MTSEA. In fact, a recent study showed that SERT will dwell in the inward-facing 
conformation longer before transitioning outward following addition of substrate, which is 
consistent with increased accessibility of Cys-277 (Zhang, Turk, and Rudnick 2016). 
Conversely, cocaine treatment yields an increase in [3H]5-HT transport (Fig. 52, + Control) 
resulting from a decrease in accessibility of Cys-277 to MTSEA, indicating cocaine induces a 
conformation that protects Cys-277 from MTSEA-induced transport inactivation. In the ASVs, 
accessibility of Cys-277 was unchanged after pretreatment with 5-HT compared to the positive 
control. Interestingly, cocaine protection from inactivation was observed with ASV F465L, but 
not with G56A, I425L, L550V, and K605N (Fig. 52). Importantly, these data are similar to those 
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highlighted in Fig. 49b, where the reactivity of MTSEA at Cys-277 was altered in ASVs G56A, 
I425L, L550V, and K605N, suggestive of a shared conformational change.  
 
 
Figure 52. Cocaine does not protect Cys-277 from MTSEA inactivation in ASVs G56A, 
I425L, L550V, and K605N. HEK-GripTite cells transfected to express ASVs in the S277C/X5C 
background were pretreated with vehicle, 50 µM 5-HT, or 50 µM cocaine for 10 min before 
addition of 1 mM MTSEA in PBS/CM buffer for 10 min. After washing to remove unreacted 
MTSEA, remaining activity was assayed by [3H]5-HT transport (50 nM for 5 min) and plotted as 
a percent of MTSEA-treated cells. ###, p < 0.001 - two-way ANOVA with Bonferroni post-hoc 
comparing treatments to MTSEA and **, p < 0.01; ***, p < 0.001 - two-way ANOVA with 
Bonferroni post-hoc comparing mutants to positive control. Data are the means ± S.E. from three 
or more independent experiments. 
 
PKG-mimicked SERT Phosphorylation Alters MTSEA Reactivity 
 The identification of Thr-276 in TM5 as the site of PKG-dependent phosphorylation 
(Ramamoorthy et al. 2007; Zhang et al. 2007) and the proximity of this residue to Cys-277 led us 
to question the impact of phosphorylation of Thr-276 on SERT conformation in ASV 
backgrounds. Thus, we engineered two backgrounds that would mimic hyper- (T276D) or de- 
(T276A) phosphorylated SERT. These mutants were evaluated for ability to transport 5-HT, the 
values from which were normalized to surface and total SERT expression to account for any 
changes in expression induced by the mutation, and assessed for conformational changes by 
testing for MTSEA reactivity at Cys-277.  
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[3H]5-HT transport in the T276D positive control increased ~600 fold by mimicking a 
hyperphosphorylated, PKG-stimulated transporter (Fig. 53, + Control is Cys-277/X5C), as PKG 
activation stimulates 5-HT transport (Miller and Hoffman 1994; Kilic, Murphy, and Rudnick 
2003; Zhu et al. 2004). The T276A mutant however, which mimics dephosphorylated SERT, did 
not increase [3H]5-HT transport. In the ASVs, T276D increased [3H]5-HT transport in all mutant 
backgrounds, though not to the extent of the positive control, which may be the result of an 
already hyperphosphorylated transporter, whereas T276A in the ASVs only altered transport in 
mutant F465L (Fig. 53). 
 
Figure 53. Transport is blunted in ASVs compared to control in the mimicked 
hyperphosphorylated T276D background. HEK-GripTite cells transfected to express ASVs in 
S277C/X5C PKG phosphorylation-dependent (S277C) or mimicked hyper- (T276D) and de- 
(T276A) phosphorylated backgrounds were assayed for transport activity by [3H]5-HT (50 nM 
for 5 min) and plotted as a percent of the S277C background following normalization to surface 
and total SERT expression. Values represent the mean ± S.E. from three or more independent 
experiments. ##, p < 0.01; ###, p < 0.001 - two-way ANOVA with Bonferroni post-hoc comparing 
T276A and T276D backgrounds to S277C and ***, p < 0.001 - one-way ANOVA with Dunnett's 
post-hoc comparing mutants to positive control. 
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When challenged with MTSEA, [3H]5-HT transport is decreased in the T276D positive 
control pointing to a conformational change effected by the T276D mutation (Fig. 54, + Control 
is Cys-277/X5C). As phosphorylation by protein kinases is believed to occur at a site in an 
extended, not helical, conformation (Knighton et al. 1991; Bose et al. 2006; Goldsmith et al. 
2007), these data and others suggest that the α-helix base of TM5 may unwind in order to 
support phosphorylation thereby increasing MTSEA reactivity at Cys-277 (Zhang et al. 2007; 
Zhang, Turk, and Rudnick 2016). In contrast, T276A results in an increase, or recovery, of 
[3H]5-HT transport, indicating protection of Cys-277 from MTSEA-induced inactivation. 
 
Figure 54. Accessibility of Cys-277 is altered in the ASVs compared to control in the 
mimicked dephosphorylated T276A background. HEK-GripTite cells transfected to express 
ASVs in S277C/X5C PKG phosphorylation-dependent (S277C) or mimicked hyper- (T276D) 
and de- (T276A) phosphorylated backgrounds were treated with 1 mM MTSEA in PBS/CM 
buffer for 10 min. Following treatment, cells were assayed for transport activity by [3H]5-HT (50 
nM for 5 min) and plotted as a percent of the MTSEA-treated S277C background following 
normalization to baseline transport. Values represent the mean ± S.E. from three or more 
independent experiments. #, p < 0.05; ##, p < 0.01; ###, p < 0.001 - two-way ANOVA with 
Bonferroni post-hoc comparing T276A and T276D backgrounds to S277C and **, p < 0.01; ***, 
p < 0.001 - one-way ANOVA with Dunnett’s post-hoc comparing mutants to positive control. 
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Interestingly, addition of Asp-276 in the ASVs equally increased reactivity at Cys-277 compared 
to the positive control, as identified by decreased [3H]5-HT transport (Fig. 54), which suggests 
that a similar conformation is adopted in a mimicked hyperphosphorylated state. In contrast, 
addition of Ala-276 in the ASVs similarily decreased reactivity at Cys-277 compared to the 
positive control only in mutant G56A, as indicated by increased [3H]5-HT transport (Fig. 54), 
whereas reactivity was increased in ASVs I425L, F465L, and L550V, but unchanged in K605N. 
Discussion 
 ASD is a complex neuropsychiatric disorder characterized by social, communication, and 
behavioral abnormalities. Previously, several rare, autism-associated SERT variants (ASVs) 
were identified in a genetic study of 120 families affected with ASD and, when considered 
together, correlated significantly with an elevated severity of rigid-compulsive behaviors 
(Tadevosyan-leyfer et al. 2003; Sutcliffe et al. 2005). Functional analyses of these variants 
indicated a shared increase in 5-HT transport relative to wild type hSERT through either 
increased catalytic activation or elevated surface density (Prasad et al. 2005; Prasad et al. 2009). 
Here, we extend analysis of the ASVs and reveal for the first time that ASVs G56A, I425L, 
F465L, L550V, and K605N induce changes in native SERT tertiary structure.  
In physiologically buffered systems, MTSES reactivity was decreased at Cys-109 in 
ASVs G56A and K605N when cells were plated at a lower density, but the opposite was true in 
the presence of higher cell density, as the same ASVs increased the reactivity of MTSES at Cys-
109. This discrepancy is likely explained by a change in cell-cell or protein-protein interactions 
that affect the accessibility of Cys-109 to MTSES. One possibility is the influence of membrane 
microdomains rich in cholesterol designated as lipid rafts. For example, we found that 5-HT 
transport was increased by ~40% in high cell density systems (data not shown) and, as identified 
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by Chang et al. (Chang et al. 2012; Rudnick et al. 2013), relaxation of the cytoskeletal-associated 
proteins tethering SERT to lipid rafts supports increased transport activity. As such, we propose 
that cell density affects insertion of SERT into lipid rafts through an, as yet, undefined 
mechanism and that accessibility of Cys-109 to MTSES is increased as a result of elevated 
transport activity associated with localization to untethered rafts. When Na+ in the buffer was 
substituted with the larger, monovalent cation NMDG+, MTSET reactivity at Cys-109 was 
increased in ASVs G56A and K605N in both low and high cell density systems whereas an 
increase in reactivity at Cys-109 for variants I425L and F465L was only uncovered when tested 
in higher cell density.   
 Accessibility of Cys-277 to MTSEA in a physiological buffer was similarly decreased in 
ASVs G56A and K605N in a low-density system as well as in a high-density system, at which 
point a decrease in MTSEA reactivity was also observed with variants I425L and L550V.  
Interestingly, protection of Cys-277 by cocaine was identified only in the positive control and the 
ASV F465L whereas cocaine was unable to protect this site in variants G56A, I425L, L550V, 
and K605N, suggestive of a shared conformational change. Furthermore, replacement of Na+ 
with the larger, monovalent cation NMDG+, which was recently shown to increase accessibility 
to Cys-277 by promoting an inward-facing conformation (Zhang, Turk, and Rudnick 2016), 
resulted in unchanged accessibility of Cys-277 to MTSEA in any ASV as compared to the 
positive control in both low and high cell density systems. These data suggest that addition of 
NMDG+ promotes an inward-facing conformation that is similar between hSERT as the ASVs 
and that this conformation is adopted irrespective of cell density. In combination, the majority of 
conditions that tested accessibility of Cys-109 to MTS reagents identified an increase in 
reactivity whereas reactivity at Cys-277 is decreased. Collectively these findings suggest that the 
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ASVs G56A, F465L, and K605N alter SERT tertiary structure by increasing the amount of 
transporters in an outward-facing conformation (Fig. 55). Thus, the elevated transport capacity of 
ASVs may result from an increase in the number of transporters ready to accept substrate or 
through altered accessibility to a kinase or phosphatase that regulates surface expression.  
 
 
Figure 55. ASVs induce an outward-facing conformation. ASVs G56A, F465L, and K605N 
increase reactivity at Cys-109, but decrease reactivity at Cys-277, suggestive of an outward-
facing conformation. These variants are in a conformation ready to accept substrate, which may 
explain the increase in 5-HT transport, or this conformational change may alter regulation on the 
cytoplasmic face by impacting protein-protein interactions.  
 
 Though we have established the ability of ASVs to impact tertiary structure, we have not 
yet identified a direct correlation between altered conformation and elevated 5-HT transport. As 
SERT function and cellular distribution are modified by interacting proteins, including protein 
kinases and phosphatases, a single nucleotide polymorphism at or near a site of interaction would 
certainly provide insight into the mechanism underlying modified SERT structure and function. 
To date, there are no known protein interactions that depend on the ASV residues analyzed here, 
though an ASV-induced change in SERT conformation may ultimately lead to modulation of a 
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protein binding site elsewhere in SERT. For example, Carneiro et al. identified a physical 
association between SERT and the integrin membrane receptor αIIbβ3 at a site in the C-terminus 
(Carneiro et al. 2008), genetic variation of which, like SERT, is associated with elevated whole 
blood 5-HT (Weiss et al. 2004; Weiss et al. 2005; Muller, Anacker, and Veenstra-VanderWeele 
2016). Furthermore, a functional association exists as isoforms of integrin β3 alter SERT 
transport activity, surface trafficking, and subcellular localization (Carneiro et al. 2008). Thus, 
based on the proposed C-terminal interaction of αIIbβ3 with SERT and the location of the ASV 
K605N on the C-terminus, it is plausible that the interactions stabilizing αIIbβ3 and SERT would 
be altered. This hypothesis and others will be assessed in our future studies in order to identify 
specific mechanisms linking the structural and functional effects observed in the ASVs.  
  
!!176 
REFERENCES 
Abramson, J., & Wright, E. M. (2009). Structure and function of Na(+)-symporters with inverted 
repeats. Current Opinion in Structural Biology, 19(4), 425–432. 
Adkins, E. M., Samuvel, D. J., Fog, J. U., Eriksen, J., Jayanthi, L. D., Vaegter, C. B., … Gether, 
U. (2007). Membrane mobility and microdomain association of the dopamine transporter 
studied with fluorescence correlation spectroscopy and fluorescence recovery after 
photobleaching. Biochemistry, 46(37), 10484–10497. 
Agoston, G. E., Vaughan, R., Lever, J. R., Izenwasser, S., Terry, P. D., & Newman, A. H. 
(1997). A novel photoaffinity label for the dopamine transporter based on N-substituted 3α-
[bis(4′-fluorophenyl)methoxy]tropane. Bioorganic & Medicinal Chemistry Letters, 7(23), 
3027–3032. 
Agoston, G. E., Wu, J. H., Izenwasser, S., George, C., Katz, J., Kline, R. H., & Newman, A. H. 
(1997). Novel N-substituted 3 alpha-[bis(4’-fluorophenyl)methoxy]tropane analogues: 
selective ligands for the dopamine transporter. Journal of Medicinal Chemistry, 40(26), 
4329–4339. 
Agoston, G. E., Wu, J. H., Izenwasser, S., George, C., Katz, J., Kline, R. H., & Newman, A. H. 
(1997). Novel N-substituted 3 alpha-[bis(4’-fluorophenyl)methoxy]tropane analogues: 
selective ligands for the dopamine transporter. Journal of Medicinal Chemistry, 40(26), 
4329–4339. 
Amara, S. G., & Kuhar, M. J. (1993). Neurotransmitter Transporters: Recent Progress. Annual 
Review of Neuroscience, 16(1), 73–93. 
Amara, S. G., & Sonders, M. S. (1998). Neurotransmitter transporters as molecular targets for 
addictive drugs. Drug and Alcohol Dependence, 51(1-2), 87–96. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders 
(5th ed.). American Psychiatric Publishing, Arlington, VA. 
Andersen, J., Kristensen, A. S., Bang-Andersen, B., & Strømgaard, K. (2009). Recent advances 
in the understanding of the interaction of antidepressant drugs with serotonin and 
norepinephrine transporters. Chemical Communications , (25), 3677–3692. 
Andersen, J., Taboureau, O., Hansen, K. B., Olsen, L., Egebjerg, J., Strømgaard, K., & 
Kristensen, A. S. (2009). Location of the antidepressant binding site in the serotonin 
transporter: importance of Ser-438 in recognition of citalopram and tricyclic 
antidepressants. The Journal of Biological Chemistry, 284(15), 10276–10284. 
 
!!177 
Anderson, G. M., Feibel, F. C., & Cohen, D. J. (1987). Determination of serotonin in whole 
blood, platelet-rich plasma, platelet-poor plasma and plasma ultrafiltrate. Life Sciences, 
40(11), 1063–1070. 
Androutsellis-Theotokis, A., Ghassemi, F., & Rudnick, G. (2001). A conformationally sensitive 
residue on the cytoplasmic surface of serotonin transporter. The Journal of Biological 
Chemistry, 276(49), 45933–45938. 
Anguelova, M., Benkelfat, C., & Turecki, G. (2003). A systematic review of association studies 
investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective 
disorders. Molecular Psychiatry, 8(6), 574–591. 
Azima, H., & Vispo, R. H. (1958). IMIPRAMINE: A POTENT NEW ANTI-DEPRESSANT 
COMPOUND. The American Journal of Psychiatry, 115(3), 245–246. 
Baganz, N. L., & Blakely, R. D. (2013a). A Dialogue between the Immune System and Brain, 
Spoken in the Language of Serotonin. ACS Chemical Neuroscience, 4(1), 48–63. 
Baganz, N. L., & Blakely, R. D. (2013b). A Dialogue between the Immune System and Brain, 
Spoken in the Language of Serotonin. ACS Chemical Neuroscience, 4(1), 48–63. 
Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., & Rutter, M. 
(1995). Autism as a strongly genetic disorder: evidence from a British twin study. 
Psychological Medicine, 25(1), 63–77. 
Banala, A. K., Zhang, P., Plenge, P., Cyriac, G., Kopajtic, T., Katz, J. L., … Newman, A. H. 
(2013). Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the 
serotonin transporter S1 and S2 binding sites. Journal of Medicinal Chemistry, 56(23), 
9709–9724. 
Barker, E. L., & Blakely, R. D. (1995). Norepinephrine and serotonin transporters: molecular 
targets of antidepressant drugs. Psychopharmacology: The Fourth Generation of Progress, 
28, 321–333. 
Barker, E. L., Moore, K. R., Rakhshan, F., & Blakely, R. D. (1999). Transmembrane domain I 
contributes to the permeation pathway for serotonin and ions in the serotonin transporter. 
The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 19(12), 
4705–4717. 
Barker, E. L., Perlman, M. A., Adkins, E. M., Houlihan, W. J., Pristupa, Z. B., Niznik, H. B., & 
Blakely, R. D. (1998). High affinity recognition of serotonin transporter antagonists defined 
by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates 
species-selective recognition of citalopram and mazindol. The Journal of Biological 
Chemistry, 273(31), 19459–19468. 
Baumann, M. H., Char, G. U., De Costa, B. R., Rice, K. C., & Rothman, R. B. (1994). 
GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the 
rat. The Journal of Pharmacology and Experimental Therapeutics, 271(3), 1216–1222. 
!!178 
Beaulieu, J.-M., & Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of 
dopamine receptors. Pharmacological Reviews, 63(1), 182–217. 
Bengel, D., Murphy, D. L., Andrews, A. M., Wichems, C. H., Feltner, D., Heils, A., … Lesch, 
K.-P. (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-
methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. 
Molecular Pharmacology, 53(4), 649–655. 
Berger, M., Gray, J. A., & Roth, B. L. (2009). The Expanded Biology of Serotonin. Annual 
Review of Medicine, 60(1), 355–366. 
Bergman, J., Madras, B. K., Johnson, S. E., & Spealman, R. D. (1989). Effects of cocaine and 
related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. The 
Journal of Pharmacology and Experimental Therapeutics, 251(1), 150–155. 
Beuming, T., Kniazeff, J., Bergmann, M. L., Shi, L., Gracia, L., Raniszewska, K., … Loland, C. 
J. (2008). The binding sites for cocaine and dopamine in the dopamine transporter overlap. 
Nature Neuroscience, 11(7), 780–789. 
Beuming, T., Shi, L., Javitch, J. A., & Weinstein, H. (2006). A comprehensive structure-based 
alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the 
use of the LeuT structure to probe NSS structure and function. Molecular Pharmacology, 
70(5), 1630–1642. 
Biederman, J., & Spencer, T. (1999). Attention-deficit/hyperactivity disorder (ADHD) as a 
noradrenergic disorder. Biological Psychiatry, 46(9), 1234–1242. 
Bisgaard, H., Larsen, M. A. B., Mazier, S., Beuming, T., Newman, A. H., Weinstein, H., … 
Gether, U. (2011). The binding sites for benztropines and dopamine in the dopamine 
transporter overlap. Neuropharmacology, 60(1), 182–190. 
Björklund, A., & Dunnett, S. B. (2007). Fifty years of dopamine research. Trends in 
Neurosciences, 30(5), 185–187. 
Blakely, R. D., & Edwards, R. H. (2012). Vesicular and plasma membrane transporters for 
neurotransmitters. Cold Spring Harbor Perspectives in Biology, 4(2). 
http://doi.org/10.1101/cshperspect.a005595 
Bloch, M. H., Landeros-Weisenberger, A., Sen, S., Dombrowski, P., Kelmendi, B., Coric, V., … 
Leckman, J. F. (2008). Association of the serotonin transporter polymorphism and 
obsessive-compulsive disorder: Systematic review. American Journal of Medical Genetics. 
Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of 
Psychiatric Genetics, 147(6), 850–858. 
Bohn, L. M., Xu, F., Gainetdinov, R. R., & Caron, M. G. (2000). Potentiated opioid analgesia in 
norepinephrine transporter knock-out mice. The Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience, 20(24), 9040–9045. 
 
!!179 
Boja, J. W., Carroll, F. I., Vaughan, R. A., Kopajtic, T., & Kuhar, M. J. (1998). Multiple binding 
sites for [125I]RTI-121 and other cocaine analogs in rat frontal cerebral cortex. Synapse , 
30(1), 9–17. 
Bose, R., Holbert, M. A., Pickin, K. A., & Cole, P. A. (2006). Protein tyrosine kinase-substrate 
interactions. Current Opinion in Structural Biology, 16(6), 668–675. 
Bossé, R., Fumagalli, F., Jaber, M., Giros, B., Gainetdinov, R. R., Wetsel, W. C., … Caron, M. 
G. (1997). Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine 
transporter. Neuron, 19(1), 127–138. 
Boudker, O., & Verdon, G. (2010). Structural perspectives on secondary active transporters. 
Trends in Pharmacological Sciences, 31(9), 418–426. 
Bowton, E., Saunders, C., Erreger, K., Sakrikar, D., Matthies, H. J., Sen, N., … Galli, A. (2010). 
Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous 
dopamine efflux associated with attention-deficit hyperactivity disorder. The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience, 30(17), 6048–6057. 
Bowton, E., Saunders, C., Reddy, I. A., Campbell, N. G., Hamilton, P. J., Henry, L. K., … Galli, 
A. (2014). SLC6A3 coding variant Ala559Val found in two autism probands alters 
dopamine transporter function and trafficking. Translational Psychiatry, 4, e464. 
Bröer, S. (2006). The SLC6 orphans are forming a family of amino acid transporters. 
Neurochemistry International, 48(6-7), 559–567. 
Bröer, S., & Gether, U. (2012). The solute carrier 6 family of transporters. British Journal of 
Pharmacology, 167(2), 256–278. 
Brose, S. A., Baker, A. G., & Golovko, M. Y. (2013). A fast one-step extraction and UPLC-
MS/MS analysis for E2/D 2 series prostaglandins and isoprostanes. Lipids, 48(4), 411–419. 
Brose, S. A., & Golovko, M. Y. (2013). Eicosanoid post-mortem induction in kidney tissue is 
prevented by microwave irradiation. Prostaglandins, Leukotrienes, and Essential Fatty 
Acids, 89(5), 313–318. 
Brose, S. A., Golovko, S. A., & Golovko, M. Y. (2016). Brain 2-Arachidonoylglycerol Levels 
Are Dramatically and Rapidly Increased Under Acute Ischemia-Injury Which Is Prevented 
by Microwave Irradiation. Lipids, 51(4), 487–495. 
Caplan, D. A., Subbotina, J. O., & Noskov, S. Y. (2008). Molecular mechanism of ion-ion and 
ion-substrate coupling in the Na+-dependent leucine transporter LeuT. Biophysical Journal, 
95(10), 4613–4621. 
Carlsson, A. (1987). Perspectives on the discovery of central monoaminergic neurotransmission. 
Annual Review of Neuroscience, 10, 19–40. 
Carneiro, A. M. D., & Blakely, R. D. (2006). Serotonin-, protein kinase C-, and Hic-5-associated 
redistribution of the platelet serotonin transporter. The Journal of Biological Chemistry, 
281(34), 24769–24780. 
!!180 
Carneiro, A. M. D., Cook, E. H., Murphy, D. L., & Blakely, R. D. (2008). Interactions between 
integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet 
aggregation in mice and humans. The Journal of Clinical Investigation, 118(4), 1544–1552. 
Caron, M. G., & Gether, U. (2016). Structural biology: Antidepressants at work. Nature, 
532(7599), 320–321. 
Carroll, F. I., Blough, B. E., Abraham, P., Mills, A. C., Holleman, J. A., Wolckenhauer, S. A., … 
Forster, M. J. (2009). Synthesis and biological evaluation of bupropion analogues as 
potential pharmacotherapies for cocaine addiction. Journal of Medicinal Chemistry, 52(21), 
6768–6781. 
Carroll, F. I., Gao, Y., Abraham, P., Lewin, A. H., Lew, R., Patel, A., … Kuhar, M. J. (1992). 
Probes for the cocaine receptor. Potentially irreversible ligands for the dopamine 
transporter. Journal of Medicinal Chemistry, 35(10), 1813–1817. 
Carroll, F. I., Gao, Y. G., Rahman, M. A., Abraham, P., Parham, K., Lewin, A. H., … Kuhar, M. 
J. (1991). Synthesis, ligand binding, QSAR, and CoMFA study of 3 beta-(p-substituted 
phenyl)tropane-2 beta-carboxylic acid methyl esters. Journal of Medicinal Chemistry, 
34(9), 2719–2725. 
Carroll, F. I., Mascarella, S. W., Kuzemko, M. A., Gao, Y., Abraham, P., Lewin, A. H., … 
Kuhar, M. J. (1994). Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 
3 beta-(3’-substituted phenyl)-, 3 beta-(4'-substituted phenyl)-, and 3 beta-(3',4'-
disubstituted phenyl)tropane-2 beta-carboxylic acid methyl esters. Journal of Medicinal 
Chemistry, 37(18), 2865–2873. 
Cha, J. H., Zou, M.-F., Adkins, E. M., Rasmussen, S. G. F., Loland, C. J., Schoenenberger, B., 
… Newman, A. H. (2005). Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-
dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine 
transporter. Journal of Medicinal Chemistry, 48(24), 7513–7516. 
Chang, J. C., Tomlinson, I. D., Warnement, M. R., Ustione, A., Carneiro, A. M. D., Piston, D. 
W., … Rosenthal, S. J. (2012). Single molecule analysis of serotonin transporter regulation 
using antagonist-conjugated quantum dots reveals restricted, p38 MAPK-dependent 
mobilization underlying uptake activation. The Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience, 32(26), 8919–8929. 
Chemical Computing Group, Inc. (2012). Molecular Operating Environment, Chemical 
Computing Group Inc., Montreal, Quebec, Canada. 
Chen, F., Larsen, M. B., Sánchez, C., & Wiborg, O. (2005). The S-enantiomer of R,S-
citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric 
mechanism. Comparison with other serotonin transporter inhibitors. European 
Neuropsychopharmacology: The Journal of the European College of 
Neuropsychopharmacology, 15(2), 193–198. 
Cheng, M. H., & Bahar, I. (2015). Molecular Mechanism of Dopamine Transport by Human 
Dopamine Transporter. Structure , 23(11), 2171–2181. 
!!181 
Cheng, M. H., Block, E., Hu, F., Cobanoglu, M. C., Sorkin, A., & Bahar, I. (2015). Insights into 
the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and 
Cocaine Binding. Frontiers in Neurology, 6, 134. 
Chen, J.-G., Liu-Chen, S., & Rudnick, G. (1997). External Cysteine Residues in the Serotonin 
Transporter†. Biochemistry, 36(6), 1479–1486. 
Chen, J. G., Sachpatzidis, A., & Rudnick, G. (1997). The third transmembrane domain of the 
serotonin transporter contains residues associated with substrate and cocaine binding. The 
Journal of Biological Chemistry, 272(45), 28321–28327. 
Chen, N.-H., Reith, M. E. A., & Quick, M. W. (2004). Synaptic uptake and beyond: the sodium- 
and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Archiv: 
European Journal of Physiology, 447(5), 519–531. 
Chen, N., & Reith, M. E. A. (2004). Interaction between dopamine and its transporter: role of 
intracellular sodium ions and membrane potential. Journal of Neurochemistry, 89(3), 750–
765. 
Chen, N., Vaughan, R. A., & Reith, M. E. (2001). The role of conserved tryptophan and acidic 
residues in the human dopamine transporter as characterized by site-directed mutagenesis. 
Journal of Neurochemistry, 77(4), 1116–1127. 
Chen, N., Zhen, J., & Reith, M. E. A. (2004). Mutation of Trp84 and Asp313 of the dopamine 
transporter reveals similar mode of binding interaction for GBR12909 and benztropine as 
opposed to cocaine. Journal of Neurochemistry, 89(4), 853–864. 
Chen, R., Daining, C. P., Sun, H., Fraser, R., Stokes, S. L., Leitges, M., & Gnegy, M. E. (2013). 
Protein kinase C$\beta$ is a modulator of the dopamine D2 autoreceptor-activated 
trafficking of the dopamine transporter. Journal of Neurochemistry, 125(5), 663–672. 
Chen, R., Han, D. D., & Gu, H. H. (2005). A triple mutation in the second transmembrane 
domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and 
methylphenidate. Journal of Neurochemistry, 94(2), 352–359. 
Chen, R., Tilley, M. R., Wei, H., Zhou, F., Zhou, F.-M., Ching, S., … Gu, H. H. (2006). 
Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. 
Proceedings of the National Academy of Sciences of the United States of America, 103(24), 
9333–9338. 
Chi, L., & Reith, M. E. A. (2003). Substrate-induced trafficking of the dopamine transporter in 
heterologously expressing cells and in rat striatal synaptosomal preparations. The Journal of 
Pharmacology and Experimental Therapeutics, 307(2), 729–736. 
Cho, H. J., Meira-Lima, I., Cordeiro, Q., Michelon, L., Sham, P., Vallada, H., & Collier, D. A. 
(2005). Population-based and family-based studies on the serotonin transporter gene 
polymorphisms and bipolar disorder: a systematic review and meta-analysis. Molecular 
Psychiatry, 10(8), 771–781. 
 
!!182 
Choudhury, A., Dominguez, M., Puri, V., Sharma, D. K., Narita, K., Wheatley, C. L., … Pagano, 
R. E. (2002). Rab proteins mediate Golgi transport of caveola-internalized 
glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. The Journal of 
Clinical Investigation, 109(12), 1541–1550. 
Clarke, H., Flint, J., Attwood, A. S., & Munafò, M. R. (2010). Association of the 5- HTTLPR 
genotype and unipolar depression: a meta-analysis. Psychological Medicine, 40(11), 1767–
1778. 
Cline, E. J., Scheffel, U., Boja, J. W., Carroll, F. I., Katz, J. L., & Kuhar, M. J. (1992). 
Behavioral effects of novel cocaine analogs: a comparison with in vivo receptor binding 
potency. The Journal of Pharmacology and Experimental Therapeutics, 260(3), 1174–1179. 
Coccaro, E. F. (1989). Central serotonin and impulsive aggression. The British Journal of 
Psychiatry. Supplement, (8), 52–62. 
Coleman, J. A., Green, E. M., & Gouaux, E. (2016). X-ray structures and mechanism of the 
human serotonin transporter. Nature, 532(7599), 334–339. 
Combs, S. A., DeLuca, S. L., DeLuca, S. H., Lemmon, G. H., Nannemann, D. P., Nguyen, E. D., 
… Meiler, J. (2013). Small-molecule ligand docking into comparative models with Rosetta. 
Nature Protocols, 8(7), 1277–1298. 
Cook, E. H., Jr, Courchesne, R., Lord, C., Cox, N. J., Yan, S., Lincoln, A., … Leventhal, B. L. 
(1997). Evidence of linkage between the serotonin transporter and autistic disorder. 
Molecular Psychiatry, 2(3), 247–250. 
Cook, E. H., & Leventhal, B. L. (1996). The serotonin system in autism. Current Opinion in 
Pediatrics, 8(4), 348–354. 
Cordeiro, Q., Quirino, C., Jacqueline, S.-R., & Homero, V. (2010). Association between the 
SLC6A3 A1343G polymorphism and schizophrenia. Arquivos de Neuro-Psiquiatria, 68(5), 
716–719. 
Cremona, M. L., Matthies, H. J. G., Pau, K., Bowton, E., Speed, N., Lute, B. J., … Yamamoto, 
A. (2011). Flotillin-1 is essential for PKC-triggered endocytosis and membrane 
microdomain localization of DAT. Nature Neuroscience, 14(4), 469–477. 
Dahal, R. A., Pramod, A. B., Sharma, B., Krout, D., Foster, J. D., Cha, J. H., … Henry, L. K. 
(2014). Computational and Biochemical Docking of the Irreversible Cocaine Analog RTI 
82 Directly Demonstrates Ligand Positioning in the Dopamine Transporter Central 
Substrate-binding Site. The Journal of Biological Chemistry, 289(43), 29712–29727. 
Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An NŊ log (N) method for 
Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. 
Daws, L. C., Callaghan, P. D., Morón, J. A., Kahlig, K. M., Shippenberg, T. S., Javitch, J. A., & 
Galli, A. (2002). Cocaine increases dopamine uptake and cell surface expression of 
dopamine transporters. Biochemical and Biophysical Research Communications, 290(5), 
1545–1550. 
!!183 
Daws, L. C., & Gould, G. G. (2011). Ontogeny and regulation of the serotonin transporter: 
Providing insights into human disorders. Pharmacology & Therapeutics, 131(1), 61–79. 
DeFelice, L. J., & Galli, A. (1998). Electrophysiological analysis of transporter function. 
Advances in Pharmacology , 42, 186–190. 
Delano W. L. (2013). The PyMOL Molecular Graphics System, Version 1.6, Schrödinger, LLC, 
New York. 
Desai, R. I., Kopajtic, T. A., Koffarnus, M., Newman, A. H., & Katz, J. L. (2005). Identification 
of a dopamine transporter ligand that blocks the stimulant effects of cocaine. The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience, 25(8), 1889–1893. 
Du, L., Faludi, G., Palkovits, M., Bakish, D., & Hrdina, P. D. (2001). Serotonergic genes and 
suicidality. Crisis, 22(2), 54–60. 
Du, L., Faludi, G., Palkovits, M., Demeter, E., Bakish, D., Lapierre, Y. D., … Hrdina, P. D. 
(1999). Frequency of long allele in serotonin transporter gene is increased in depressed 
suicide victims. Biological Psychiatry, 46(2), 196–201. 
Eiden, L. E., Schäfer, M. K.-H., Weihe, E., & Schütz, B. (2003). The vesicular amine transporter 
family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated 
exocytotic secretion of monoamines and acetylcholine. Pflügers Archiv, 447(5), 636–640. 
Eriksen, J., Bjørn-Yoshimoto, W. E., Jørgensen, T. N., Newman, A. H., & Gether, U. (2010). 
Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and 
dopaminergic neurons. The Journal of Biological Chemistry, 285(35), 27289–27301. 
Eriksen, J., Rasmussen, S. G. F., Rasmussen, T. N., Vaegter, C. B., Cha, J. H., Zou, M.-F., … 
Gether, U. (2009). Visualization of dopamine transporter trafficking in live neurons by use 
of fluorescent cocaine analogs. The Journal of Neuroscience: The Official Journal of the 
Society for Neuroscience, 29(21), 6794–6808. 
Eshleman, A. J., Carmolli, M., Cumbay, M., Martens, C. R., Neve, K. A., & Janowsky, A. 
(1999). Characteristics of drug interactions with recombinant biogenic amine transporters 
expressed in the same cell type. The Journal of Pharmacology and Experimental 
Therapeutics, 289(2), 877–885. 
Eshleman, A. J., Henningsen, R. A., Neve, K. A., & Janowsky, A. (1994). Release of dopamine 
via the human transporter. Molecular Pharmacology, 45(2), 312–316. 
Fabre, V., Beaufour, C., Evrard, A., Rioux, A., Hanoun, N., Lesch, K. P., … Martres, M.-P. 
(2000). Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in 
knock-out mice lacking the 5-HT transporter. The European Journal of Neuroscience, 
12(7), 2299–2310. 
Faham, S., Watanabe, A., Besserer, G. M., Cascio, D., Specht, A., Hirayama, B. A., … 
Abramson, J. (2008). The crystal structure of a sodium galactose transporter reveals 
mechanistic insights into Na+/sugar symport. Science , 321(5890), 810–814. 
!!184 
Felts, B., Pramod, A. B., Sandtner, W., Burbach, N., Bulling, S., Sitte, H. H., & Henry, L. K. 
(2014). The Two Na+ Sites in the Human Serotonin Transporter Play Distinct Roles in the 
Ion Coupling and Electrogenicity of Transport. The Journal of Biological Chemistry, 
289(3), 1825–1840. 
Ferrer, J. V., & Javitch, J. A. (1998). Cocaine alters the accessibility of endogenous cysteines in 
putative extracellular and intracellular loops of the human dopamine transporter. 
Proceedings of the National Academy of Sciences of the United States of America, 95(16), 
9238–9243. 
Field, J. R., Henry, L. K., & Blakely, R. D. (2010). Transmembrane domain 6 of the human 
serotonin transporter contributes to an aqueously accessible binding pocket for serotonin 
and the psychostimulant 3,4-methylene dioxymethamphetamine. The Journal of Biological 
Chemistry, 285(15), 11270–11280. 
Fog, J. U., Khoshbouei, H., Holy, M., Owens, W. A., Vaegter, C. B., Sen, N., … Gether, U. 
(2006). Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate 
amphetamine-induced reverse transport. Neuron, 51(4), 417–429. 
Folk, G. E., Jr, & Long, J. P. (1988). Serotonin as a neurotransmitter: a review. Comparative 
Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology, 91(1), 251–
257. 
Forrest, L. R., & Rudnick, G. (2009). The rocking bundle: a mechanism for ion-coupled solute 
flux by symmetrical transporters. Physiology , 24, 377–386. 
Forrest, L. R., Tavoulari, S., Zhang, Y.-W., Rudnick, G., & Honig, B. (2007). Identification of a 
chloride ion binding site in Na+/Cl -dependent transporters. Proceedings of the National 
Academy of Sciences of the United States of America, 104(31), 12761–12766. 
Forrest, L. R., Zhang, Y.-W., Jacobs, M. T., Gesmonde, J., Xie, L., Honig, B. H., & Rudnick, G. 
(2008). Mechanism for alternating access in neurotransmitter transporters. Proceedings of 
the National Academy of Sciences of the United States of America, 105(30), 10338–10343. 
Foster, J. D., Pananusorn, B., Cervinski, M. A., Holden, H. E., & Vaughan, R. A. (2003). 
Dopamine transporters are dephosphorylated in striatal homogenates and in vitro by protein 
phosphatase 1. Brain Research. Molecular Brain Research, 110(1), 100–108. 
Foster, J. D., Pananusorn, B., & Vaughan, R. A. (2002). Dopamine transporters are 
phosphorylated on N-terminal serines in rat striatum. The Journal of Biological Chemistry, 
277(28), 25178–25186. 
Furman, C. A., Chen, R., Guptaroy, B., Zhang, M., Holz, R. W., & Gnegy, M. (2009). Dopamine 
and Amphetamine Rapidly Increase Dopamine Transporter Trafficking to the Surface: Live-
Cell Imaging Using Total Internal Reflection Fluorescence Microscopy. Journal of 
Neuroscience, 29(10), 3328–3336. 
 
 
!!185 
Gabriele, S., Sacco, R., & Persico, A. M. (2014). Blood serotonin levels in autism spectrum 
disorder: a systematic review and meta-analysis. European Neuropsychopharmacology: The 
Journal of the European College of Neuropsychopharmacology, 24(6), 919–929. 
Gabriel, L. R., Wu, S., Kearney, P., Bellvé, K. D., Standley, C., Fogarty, K. E., & Melikian, H. 
E. (2013). Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: 
differential dependence on dynamin and the actin cytoskeleton. The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience, 33(45), 17836–17846. 
Gabrielsen, M., Ravna, A. W., Kristiansen, K., & Sylte, I. (2012). Substrate binding and 
translocation of the serotonin transporter studied by docking and molecular dynamics 
simulations. Journal of Molecular Modeling, 18(3), 1073–1085. 
Gaffaney, J. D., Shetty, M., Felts, B., Pramod, A.-B., Foster, J. D., Henry, L. K., & Vaughan, R. 
A. (2014). Antagonist-induced conformational changes in dopamine transporter 
extracellular loop two involve residues in a potential salt bridge. Neurochemistry 
International, 73, 16–26. 
Gaffaney, J. D., & Vaughan, R. A. (2004). Uptake inhibitors but not substrates induce protease 
resistance in extracellular loop two of the dopamine transporter. Molecular Pharmacology, 
65(3), 692–701. 
Gainetdinov, R. R., & Caron, M. G. (2003). MONOAMINE TRANSPORTERS: From Genes to 
Behavior. Annual Review of Pharmacology and Toxicology, 43(1), 261–284. 
Gainetdinov, R. R., Sotnikova, T. D., & Caron, M. G. (2002). Monoamine transporter 
pharmacology and mutant mice. Trends in Pharmacological Sciences, 23(8), 367–373. 
Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Levin, E. D., Jaber, M., & Caron, M. G. (1999). 
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 
Science, 283(5400), 397–401. 
Gershon, M. D. (2004). Review article: serotonin receptors and transporters -- roles in normal 
and abnormal gastrointestinal motility. Alimentary Pharmacology & Therapeutics, 20 Suppl 
7, 3–14. 
Gershon, M. D. (2005). Nerves, reflexes, and the enteric nervous system: pathogenesis of the 
irritable bowel syndrome. Journal of Clinical Gastroenterology, 39(5 Suppl 3), S184–93. 
Gether, U., Andersen, P. H., Larsson, O. M., & Schousboe, A. (2006). Neurotransmitter 
transporters: molecular function of important drug targets. Trends in Pharmacological 
Sciences, 27(7), 375–383. 
Geurink, P. P., Prely, L. M., van der Marel, G. A., Bischoff, R., & Overkleeft, H. S. (2012). 
Photoaffinity labeling in activity-based protein profiling. Topics in Current Chemistry, 324, 
85–113. 
Gillman, P. K. (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions 
updated. British Journal of Pharmacology, 151(6), 737–748. 
!!186 
Giros, B., & Caron, M. G. (1993). Molecular characterization of the dopamine transporter. 
Trends in Pharmacological Sciences, 14(2), 43–49. 
Giros, B., el Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., & Caron, M. G. 
(1992). Cloning, pharmacological characterization, and chromosome assignment of the 
human dopamine transporter. Molecular Pharmacology, 42(3), 383–390. 
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996). Hyperlocomotion 
and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. 
Nature, 379(6566), 606–612. 
Glatt, C. E., DeYoung, J. A., Delgado, S., Service, S. K., Giacomini, K. M., Edwards, R. H., … 
Freimer, N. B. (2001). Screening a large reference sample to identify very low frequency 
sequence variants: comparisons between two genes. Nature Genetics, 27(4), 435–438. 
Glowa, J. R., Wojnicki, F. H. E., Matecka, D., & Rice, K. C. (1995). Effects of dopamine 
reuptake inhibitors on food- and cocaine-maintained responding: II. Comparisons with other 
drugs and repeated administrations. Experimental and Clinical Psychopharmacology, 3(3), 
232–239. 
Goldsmith, E. J., Akella, R., Min, X., Zhou, T., & Humphreys, J. M. (2007). Substrate and 
docking interactions in serine/threonine protein kinases. Chemical Reviews, 107(11), 5065–
5081. 
Goodwin, J. S., Larson, G. A., Swant, J., Sen, N., Javitch, J. A., Zahniser, N. R., … Khoshbouei, 
H. (2009). Amphetamine and methamphetamine differentially affect dopamine transporters 
in vitro and in vivo. The Journal of Biological Chemistry, 284(5), 2978–2989. 
Gordon, E. M., Stollstorff, M., Devaney, J. M., Bean, S., & Vaidya, C. J. (2012). Effect of 
dopamine transporter genotype on intrinsic functional connectivity depends on cognitive 
state. Cerebral Cortex , 22(9), 2182–2196. 
Grant, B. D., & Donaldson, J. G. (2009). Pathways and mechanisms of endocytic recycling. 
Nature Reviews. Molecular Cell Biology, 10(9), 597–608. 
Grunhage, F., Schulze, T. G., Muller, D. J., Lanczik, M., Franzek, E., Albus, M., … Others. 
(2000). Systematic screening for DNA sequence variation in the coding region of the human 
dopamine transporter gene. Molecular Psychiatry, 5, 275–282. 
Gu, H. H., Wall, S., & Rudnick, G. (1996). Ion coupling stoichiometry for the norepinephrine 
transporter in membrane vesicles from stably transfected cells. The Journal of Biological 
Chemistry, 271(12), 6911–6916. 
Gu, H., Wall, S. C., & Rudnick, G. (1994). Stable expression of biogenic amine transporters 
reveals differences in inhibitor sensitivity, kinetics, and ion dependence. The Journal of 
Biological Chemistry, 269(10), 7124–7130. 
Haase, J., Killian, A. M., Magnani, F., & Williams, C. (2001). Regulation of the serotonin 
transporter by interacting proteins. Biochemical Society Transactions, 29(Pt 6), 722–728. 
!!187 
Hahn, M. K., & Blakely, R. D. (2007a). The functional impact of SLC6 transporter genetic 
variation. Annual Review of Pharmacology and Toxicology, 47, 401–441. 
Hahn, M. K., & Blakely, R. D. (2007b). The functional impact of SLC6 transporter genetic 
variation. Annual Review of Pharmacology and Toxicology, 47, 401–441. 
Hahn, M. K., Mazei-Robison, M. S., & Blakely, R. D. (2005). Single nucleotide polymorphisms 
in the human norepinephrine transporter gene affect expression, trafficking, antidepressant 
interaction, and protein kinase C regulation. Molecular Pharmacology, 68(2), 457–466. 
Hahn, M. K., Robertson, D., & Blakely, R. D. (2003). A mutation in the human norepinephrine 
transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface 
expression of mutant and wild-type transporters. The Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience, 23(11), 4470–4478. 
Hahn, M. K., Steele, A., Couch, R. S., Stein, M. A., & Krueger, J. J. (2009). Novel and 
functional norepinephrine transporter protein variants identified in attention-deficit 
hyperactivity disorder. Neuropharmacology, 57(7-8), 694–701. 
Halushka, M. K., Fan, J. B., Bentley, K., Hsie, L., Shen, N., Weder, A., … Chakravarti, A. 
(1999). Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure 
homeostasis. Nature Genetics, 22(3), 239–247. 
Hanley, H. G., Stahl, S. M., & Freedman, D. X. (1977). Hyperserotonemia and amine 
metabolites in autistic and retarded children. Archives of General Psychiatry, 34(5), 521–
531. 
Hansen, F. H., Skjørringe, T., Yasmeen, S., Arends, N. V., Sahai, M. A., Erreger, K., … Gether, 
U. (2014). Missense dopamine transporter mutations associate with adult parkinsonism and 
ADHD. The Journal of Clinical Investigation, 124(7), 3107–3120. 
Hastrup, H., Karlin, A., & Javitch, J. A. (2001). Symmetrical dimer of the human dopamine 
transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth 
transmembrane segment. Proceedings of the National Academy of Sciences of the United 
States of America, 98(18), 10055–10060. 
Hastrup, H., Sen, N., & Javitch, J. A. (2003). The human dopamine transporter forms a tetramer 
in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is 
sensitive to cocaine analogs. The Journal of Biological Chemistry, 278(46), 45045–45048. 
Heddiger, M. A. (Ed.). (2013). Molecular aspects of medicine, 34(2-3), 95-752.  
Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2003). 
The ABCs of solute carriers: physiological, pathological and therapeutic implications of 
human membrane transport proteins. Pflügers Archiv, 447(5), 465–468. 
Heikkila, R. E., Cabbat, F. S., & Duvoisin, R. C. (1979). Motor activity and rotational behavior 
after analogs of cocaine: correlation with dopamine uptake blockade. Communications in 
Psychopharmacology, 3(5), 285–290. 
!!188 
Heils, A., Mössner, R., & Lesch, K. P. (1997). The human serotonin transporter gene 
polymorphism--basic research and clinical implications. Journal of Neural Transmission , 
104(10), 1005–1014. 
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996). 
Allelic variation of human serotonin transporter gene expression. Journal of 
Neurochemistry, 66(6), 2621–2624. 
Heim, C., & Nemeroff, C. B. (2001). The role of childhood trauma in the neurobiology of mood 
and anxiety disorders: preclinical and clinical studies. Biological Psychiatry, 49(12), 1023–
1039. 
He, L., Vasiliou, K., & Nebert, D. W. (2009). Analysis and update of the human solute carrier 
(SLC) gene superfamily. Human Genomics, 3(2), 195–206. 
Henry, L. K., Adkins, E. M., Han, Q., & Blakely, R. D. (2003). Serotonin and cocaine-sensitive 
inactivation of human serotonin transporters by methanethiosulfonates targeted to 
transmembrane domain I. The Journal of Biological Chemistry, 278(39), 37052–37063. 
Henry, L. K., Field, J. R., Adkins, E. M., Parnas, M. L., Vaughan, R. A., Zou, M.-F., … Blakely, 
R. D. (2006). Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin 
transporters interact to establish high affinity recognition of antidepressants. The Journal of 
Biological Chemistry, 281(4), 2012–2023. 
Henry, L. K., Iwamoto, H., Field, J. R., Kaufmann, K., Dawson, E. S., Jacobs, M. T., … Blakely, 
R. D. (2011). A Conserved Asparagine Residue in Transmembrane Segment 1 (TM1) of 
Serotonin Transporter Dictates Chloride-coupled Neurotransmitter Transport. The Journal 
of Neuroscience: The Official Journal of the Society for Neuroscience, 286(35), 30823–
30836. 
Henry, L. K., Meiler, J., & Blakely, R. D. (2007). Bound to be different: neurotransmitter 
transporters meet their bacterial cousins. Molecular Interventions, 7(6), 306–309. 
Hess, B., Bekker, H., Berendsen, H. J. C., Fraaije, J. G., & Others. (1997). LINCS: a linear 
constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 
1463–1472. 
Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008). GROMACS 4: Algorithms for 
Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. Journal of Chemical 
Theory and Computation, 4(3), 435–447. 
Hill, E. R., Huang, X., Zhan, C.-G., Ivy Carroll, F., & Gu, H. H. (2011). Interaction of tyrosine 
151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113. 
Neuropharmacology, 61(1-2), 112–120. 
Hiranita, T., Soto, P. L., Newman, A. H., & Katz, J. L. (2009). Assessment of reinforcing effects 
of benztropine analogs and their effects on cocaine self-administration in rats: comparisons 
with monoamine uptake inhibitors. The Journal of Pharmacology and Experimental 
Therapeutics, 329(2), 677–686. 
!!189 
Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, 
R. (2004). A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive 
Behaviors in Childhood and Adolescent Autism. Neuropsychopharmacology: Official 
Publication of the American College of Neuropsychopharmacology, 30(3), 582–589. 
Holmes, A., Murphy, D. L., & Crawley, J. N. (2003). Abnormal behavioral phenotypes of 
serotonin transporter knockout mice: parallels with human anxiety and depression. 
Biological Psychiatry, 54(10), 953–959. 
Holz, R. W., & Coyle, J. T. (1974). The Effects of Various Salts, Temperature, and the Alkaloids 
Veratridine and Batrachotoxin on the Uptake of [3H] Dopamine into Synaptosomes from 
Rat Striatum. Molecular Pharmacology, 10(5), 746–758. 
Hong, W. C., & Amara, S. G. (2013). Differential targeting of the dopamine transporter to 
recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in 
dopamine neurons. The FASEB Journal, 27(8), 2995–3007. 
Huang, X., Gu, H. H., & Zhan, C.-G. (2009). Mechanism for Cocaine Blocking the Transport of 
Dopamine: Insights from Molecular Modeling and Dynamics Simulations. The Journal of 
Physical Chemistry. B, 113(45), 15057–15066. 
Huang, X., & Zhan, C.-G. (2007). How dopamine transporter interacts with dopamine: insights 
from molecular modeling and simulation. Biophysical Journal, 93(10), 3627–3639. 
Huguet, G., Ey, E., & Bourgeron, T. (2013). The Genetic Landscapes of Autism Spectrum 
Disorders. Annual Review of Genomics and Human Genetics, 14(1), 191–213. 
Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: visual molecular dynamics. Journal of 
Molecular Graphics, 14(1), 33–8, 27–8. 
Indarte, M., Madura, J. D., & Surratt, C. K. (2008). Dopamine transporter comparative molecular 
modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. 
Proteins, 70(3), 1033–1046. 
Ingram, S. L., Prasad, B. M., & Amara, S. G. (2002). Dopamine transporter-mediated 
conductances increase excitability of midbrain dopamine neurons. Nature Neuroscience, 
5(10), 971–978. 
Itokawa, M., Lin, Z., Cai, N.-S., Wu, C., Kitayama, S., Wang, J.-B., & Uhl, G. R. (2000). 
Dopamine Transporter Transmembrane Domain Polar Mutants: ΔG and ΔΔG Values 
Implicate Regions Important for Transporter Functions. Molecular Pharmacology, 57(6), 
1093–1103. 
Iversen, L. (2000). Neurotransmitter transporters: fruitful targets for CNS drug discovery. 
Molecular Psychiatry, 5(4), 357–362. 
Iversen, L. L. (1971). Role of transmitter uptake mechanisms in synaptic neurotransmission. 
British Journal of Pharmacology, 41(4), 571–591. 
 
!!190 
Iwasa, H., Kurabayashi, M., Nagai, R., Nakamura, Y., & Tanaka, T. (2001). Genetic variations 
in five genes involved in the excitement of cardiomyocytes. Journal of Human Genetics, 
46(9), 549–552. 
Jaber, M., Jones, S., Giros, B., & Caron, M. G. (1997). The dopamine transporter: a crucial 
component regulating dopamine transmission. Movement Disorders: Official Journal of the 
Movement Disorder Society, 12(5), 629–633. 
Jaber, M., Robinson, S. W., Missale, C., & Caron, M. G. (1996). Dopamine receptors and brain 
function. Neuropharmacology, 35(11), 1503–1519. 
Jacob, G., Shannon, J. R., Costa, F., Furlan, R., Biaggioni, I., Mosqueda-Garcia, R., … 
Robertson, D. (1999). Abnormal norepinephrine clearance and adrenergic receptor 
sensitivity in idiopathic orthostatic intolerance. Circulation, 99(13), 1706–1712. 
Jacobsen, J. P. R., Plenge, P., Sachs, B. D., Pehrson, A. L., Cajina, M., Du, Y., … Caron, M. G. 
(2014). The interaction of escitalopram and R-citalopram at the human serotonin transporter 
investigated in the mouse. Psychopharmacology, 231(23), 4527–4540. 
Jacobs, M. T., Zhang, Y.-W., Campbell, S. D., & Rudnick, G. (2007). Ibogaine, a 
noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing 
state of the transporter. The Journal of Biological Chemistry, 282(40), 29441–29447. 
Jardetzky, O. (1966). Simple allosteric model for membrane pumps. Nature, 211(5052), 969–
970. 
Jiang, T., Rong, Z., Peng, L., Chen, B., Xie, Y., Chen, C., … Chen, H. (2010). Simultaneous 
determination of citalopram and its metabolite in human plasma by LC–MS/MS applied to 
pharmacokinetic study. Journal of Chromatography B, 878(5–6), 615–619. 
Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., & Caron, M. G. (1998). 
Profound neuronal plasticity in response to inactivation of the dopamine transporter. 
Proceedings of the National Academy of Sciences of the United States of America, 95(7), 
4029–4034. 
Just, H., Sitte, H. H., Schmid, J. A., Freissmuth, M., & Kudlacek, O. (2004). Identification of an 
additional interaction domain in transmembrane domains 11 and 12 that supports oligomer 
formation in the human serotonin transporter. The Journal of Biological Chemistry, 279(8), 
6650–6657. 
Kahlig, K. M., Binda, F., Khoshbouei, H., Blakely, R. D., McMahon, D. G., Javitch, J. A., & 
Galli, A. (2005). Amphetamine induces dopamine efflux through a dopamine transporter 
channel. Proceedings of the National Academy of Sciences of the United States of America, 
102(9), 3495–3500. 
Kahlig, K. M., & Galli, A. (2003). Regulation of dopamine transporter function and plasma 
membrane expression by dopamine, amphetamine, and cocaine. European Journal of 
Pharmacology, 479(1-3), 153–158. 
 
!!191 
Kahlig, K. M., Javitch, J. A., & Galli, A. (2004). Amphetamine regulation of dopamine transport. 
Combined measurements of transporter currents and transporter imaging support the 
endocytosis of an active carrier. The Journal of Biological Chemistry, 279(10), 8966–8975. 
Kahlig, K. M., Lute, B. J., Wei, Y., Loland, C. J., Gether, U., Javitch, J. A., & Galli, A. (2006). 
Regulation of dopamine transporter trafficking by intracellular amphetamine. Molecular 
Pharmacology, 70(2), 542–548. 
Kaiser, C., & Setler, P. E. (1981). Antipsychotic agents. Burger’s Medicinal Chemistry, 3, 859–
980. 
Kalivas, P. W. (2007). Neurobiology of cocaine addiction: implications for new 
pharmacotherapy. The American Journal on Addictions / American Academy of 
Psychiatrists in Alcoholism and Addictions, 16(2), 71–78. 
Kanner, B. I., & Zomot, E. (2008). Sodium-coupled neurotransmitter transporters. Chemical 
Reviews, 108(5), 1654–1668. 
Katz, J. L., Agoston, G. E., Alling, K. L., Kline, R. H., Forster, M. J., Woolverton, W. L., … 
Newman, A. H. (2001). Dopamine transporter binding without cocaine-like behavioral 
effects: synthesis and evaluation of benztropine analogs alone and in combination with 
cocaine in rodents. Psychopharmacology, 154(4), 362–374. 
Katz, J. L., Izenwasser, S., & Terry, P. (2000). Relationships among dopamine transporter 
affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology, 148(1), 
90–98. 
Katz, J. L., Kopajtic, T. A., Agoston, G. E., & Newman, A. H. (2004). Effects of N-substituted 
analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. 
The Journal of Pharmacology and Experimental Therapeutics, 309(2), 650–660. 
Katz, J. L., Newman, A. H., & Izenwasser, S. (1997). Relations between heterogeneity of 
dopamine transporter binding and function and the behavioral pharmacology of cocaine. 
Pharmacology, Biochemistry, and Behavior, 57(3), 505–512. 
Kaufmann, K. W., Dawson, E. S., Henry, L. K., Field, J. R., Blakely, R. D., & Meiler, J. (2009). 
Structural determinants of species-selective substrate recognition in human and Drosophila 
serotonin transporters revealed through computational docking studies. Proteins, 74(3), 
630–642. 
Kenna, G. A., Roder-Hanna, N., Leggio, L., Zywiak, W. H., Clifford, J., Edwards, S., … Swift, 
R. M. (2012). Association of the 5-HTT gene-linked promoter region (5-HTTLPR) 
polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. 
Pharmacogenomics and Personalized Medicine, 5, 19–35. 
Khoshbouei, H., Wang, H., Lechleiter, J. D., Javitch, J. A., & Galli, A. (2003). Amphetamine-
induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. 
The Journal of Biological Chemistry, 278(14), 12070–12077. 
 
!!192 
Khoshbouei, H., Wang, H., Lechleiter, J. D., Javitch, J. A., & Galli, A. (2003). Amphetamine-
induced Dopamine Efflux: A VOLTAGE-SENSITIVE AND INTRACELLULAR Na -
DEPENDENT MECHANISM. The Journal of Biological Chemistry, 278(14), 12070–
12077. 
Kilic, F., Murphy, D. L., & Rudnick, G. (2003). A human serotonin transporter mutation causes 
constitutive activation of transport activity. Molecular Pharmacology, 64(2), 440–446. 
Kim, C.-H., Hahn, M. K., Joung, Y., Anderson, S. L., Steele, A. H., Mazei-Robinson, M. S., … 
Kim, K.-S. (2006). A polymorphism in the norepinephrine transporter gene alters promoter 
activity and is associated with attention-deficit hyperactivity disorder. Proceedings of the 
National Academy of Sciences of the United States of America, 103(50), 19164–19169. 
Kim, J. H., & Lawrence, A. J. (2014). Drugs currently in Phase II clinical trials for cocaine 
addiction. Expert Opinion on Investigational Drugs, 23(8), 1105–1122. 
Kimmel, H. L., Negus, S. S., Wilcox, K. M., Ewing, S. B., Stehouwer, J., Goodman, M. M., … 
Howell, L. L. (2008). Relationship between rate of drug uptake in brain and behavioral 
pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacology, 
Biochemistry, and Behavior, 90(3), 453–462. 
Kitayama, S., Shimada, S., Xu, H., Markham, L., Donovan, D. M., & Uhl, G. R. (1992). 
Dopamine transporter site-directed mutations differentially alter substrate transport and 
cocaine binding. Proceedings of the National Academy of Sciences of the United States of 
America, 89(16), 7782–7785. 
Kiyohara, C., & Yoshimasu, K. (2010). Association between major depressive disorder and a 
functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-
analysis. Psychiatric Genetics, 20(2), 49–58. 
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., & Ordway, G. 
A. (1997). Reduced levels of norepinephrine transporters in the locus coeruleus in major 
depression. The Journal of Neuroscience: The Official Journal of the Society for 
Neuroscience, 17(21), 8451–8458. 
Knighton, D. R., Zheng, J. H., Ten Eyck, L. F., Ashford, V. A., Xuong, N. H., Taylor, S. S., & 
Sowadski, J. M. (1991). Crystal structure of the catalytic subunit of cyclic adenosine 
monophosphate-dependent protein kinase. Science, 253(5018), 407–414. 
Koldsø, H., Christiansen, A. B., Sinning, S., & Schiøtt, B. (2013). Comparative modeling of the 
human monoamine transporters: similarities in substrate binding. ACS Chemical 
Neuroscience, 4(2), 295–309. 
Koldsø, H., Noer, P., Grouleff, J., Autzen, H. E., Sinning, S., & Schiøtt, B. (2011). Unbiased 
simulations reveal the inward-facing conformation of the human serotonin transporter and 
Na(+) ion release. PLoS Computational Biology, 7(10), e1002246. 
Koob, G. F., Sanna, P. P., & Bloom, F. E. (1998). Neuroscience of addiction. Neuron, 21(3), 
467–476. 
!!193 
Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology: 
Official Publication of the American College of Neuropsychopharmacology, 35(1), 217–
238. 
Kotzyba-Hibert, F., Kapfer, I., & Goeldner, M. (1995a). Recent trends in photoaffinity labeling. 
Angewandte Chemie International Edition in English, 34(12), 1296–1312. 
Kotzyba-Hibert, F., Kapfer, I., & Goeldner, M. (1995b). Recent trends in photoaffinity labeling. 
Angewandte Chemie International Edition in English, 34(12), 1296–1312. 
Krishnamurthy, H., & Gouaux, E. (2012). X-ray structures of LeuT in substrate-free outward-
open and apo inward-open states. Nature, 481(7382), 469–474. 
Krishnamurthy, H., Piscitelli, C. L., & Gouaux, E. (2009). Unlocking the molecular secrets of 
sodium-coupled transporters. Nature, 459(7245), 347–355. 
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., … 
Gether, U. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. 
Pharmacological Reviews, 63(3), 585–640. 
Kuhar, M. J., Ritz, M. C., & Boja, J. W. (1991). The dopamine hypothesis of the reinforcing 
properties of cocaine. Trends in Neurosciences, 14(7), 299–302. 
Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D. (2003). Design 
of a novel globular protein fold with atomic-level accuracy. Science, 302(5649), 1364–
1368. 
Kuhn, R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). 
The American Journal of Psychiatry, 115(5), 459–464. 
Kumar, V., Yarravarapu, N., Lapinsky, D. J., Perley, D., Felts, B., Tomlinson, M. J., … 
Newman, A. H. (2015). Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin 
Transporter Based on the Selective Serotonin Reuptake Inhibitor ( S )-Citalopram. Journal 
of Medicinal Chemistry, 58(14), 5609–5619. 
Kurian, M. A., Li, Y., Zhen, J., Meyer, E., Hai, N., Christen, H.-J., … Maher, E. R. (2011). 
Clinical and molecular characterisation of hereditary dopamine transporter deficiency 
syndrome: an observational cohort and experimental study. Lancet Neurology, 10(1), 54–
62. 
Lacerda, A. E., Kuryshev, Y. A., Yan, G.-X., Waldo, A. L., & Brown, A. M. (2010). 
Vanoxerine: cellular mechanism of a new antiarrhythmic. Journal of Cardiovascular 
Electrophysiology, 21(3), 301–310. 
Larsen, M. B., Sonders, M. S., Mortensen, O. V., Larson, G. A., Zahniser, N. R., & Amara, S. G. 
(2011). Dopamine transport by the serotonin transporter: a mechanistically distinct mode of 
substrate translocation. The Journal of Neuroscience: The Official Journal of the Society for 
Neuroscience, 31(17), 6605–6615. 
 
!!194 
La Sala, M. S., Hurtado, M. D., Brown, A. R., Bohórquez, D. V., Liddle, R. A., Herzog, H., … 
Dotson, C. D. (2013). Modulation of taste responsiveness by the satiation hormone peptide 
YY. FASEB Journal: Official Publication of the Federation of American Societies for 
Experimental Biology, 27(12), 5022–5033. 
Lawal, H. O., & Krantz, D. E. (2013). SLC18: Vesicular neurotransmitter transporters for 
monoamines and acetylcholine. Molecular Aspects of Medicine, 34(2-3), 360–372. 
Leaver-Fay, A., Tyka, M., Lewis, S. M., Lange, O. F., Thompson, J., Jacak, R., … Bradley, P. 
(2011). ROSETTA3: an object-oriented software suite for the simulation and design of 
macromolecules. Methods in Enzymology, 487, 545–574. 
Lee, S. H., Chang, M. Y., Lee, K. H., Park, B. S., Lee, Y. S., Chin, H. R., & Lee, Y. S. (2000). 
Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-
3beta-(4-fluorophenyl)tropane binding of dopamine transporter. Molecular Pharmacology, 
57(5), 883–889. 
Lesch, K. P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., … Murphy, D. L. 
(1996). Association of anxiety-related traits with a polymorphism in the serotonin 
transporter gene regulatory region. Science, 274(5292), 1527–1531. 
Lever, J. R., Carroll, F., Patel, A., Abraham, P., Boja, J., Lewin, A., & Lew, R. (1993). 
Radiosynthesis of a photoaffinity probe for the cocaine receptor of the dopamine 
transporter: 3$\beta$-(p-chlorophenyl) tropan-2$\beta$-carboxylic acid m-([125I]-iodo)-p-
azidophenethyl ester ([125I]-RTI-82). Journal of Labelled Compounds & 
Radiopharmaceuticals, 33(12), 1131–1137. 
Lever, J. R., Zou, M.-F., Parnas, M. L., Duval, R. A., Wirtz, S. E., Justice, J. B., … Newman, A. 
H. (2005). Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible 
labeling of dopamine transporters: synthesis and covalent binding studies. Bioconjugate 
Chemistry, 16(3), 644–649. 
Li, L.-B., Chen, N., Ramamoorthy, S., Chi, L., Cui, X.-N., Wang, L. C., & Reith, M. E. A. 
(2004). The role of N-glycosylation in function and surface trafficking of the human 
dopamine transporter. The Journal of Biological Chemistry, 279(20), 21012–21020. 
Lindsey, K. P., Wilcox, K. M., Votaw, J. R., Goodman, M. M., Plisson, C., Carroll, F. I., … 
Howell, L. L. (2004). Effects of dopamine transporter inhibitors on cocaine self-
administration in rhesus monkeys: relationship to transporter occupancy determined by 
positron emission tomography neuroimaging. The Journal of Pharmacology and 
Experimental Therapeutics, 309(3), 959–969. 
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015). SLC transporters as therapeutic 
targets: emerging opportunities. Nature Reviews. Drug Discovery, 14(8), 543–560. 
Lin, Z., & Uhl, G. R. (2002). Dopamine transporter mutants with cocaine resistance and normal 
dopamine uptake provide targets for cocaine antagonism. Molecular Pharmacology, 61(4), 
885–891. 
!!195 
Lin, Z., Wang, W., Kopajtic, T., Revay, R. S., & Uhl, G. R. (1999). Dopamine transporter: 
transmembrane phenylalanine mutations can selectively influence dopamine uptake and 
cocaine analog recognition. Molecular Pharmacology, 56(2), 434–447. 
Lin, Z., Wang, W., & Uhl, G. R. (2000). Dopamine transporter tryptophan mutants highlight 
candidate dopamine- and cocaine-selective domains. Molecular Pharmacology, 58(6), 
1581–1592. 
Lodge, D. J., & Grace, A. A. (2011). Developmental pathology, dopamine, stress and 
schizophrenia. International Journal of Developmental Neuroscience: The Official Journal 
of the International Society for Developmental Neuroscience, 29(3), 207–213. 
Loland, C. J., Desai, R. I., Zou, M.-F., Cao, J., Grundt, P., Gerstbrein, K., … Gether, U. (2008). 
Relationship between conformational changes in the dopamine transporter and cocaine-like 
subjective effects of uptake inhibitors. Molecular Pharmacology, 73(3), 813–823. 
Loland, C. J., Mereu, M., Okunola, O. M., Cao, J., Prisinzano, T. E., Mazier, S., … Newman, A. 
H. (2012). R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential 
medication for psychostimulant abuse. Biological Psychiatry, 72(5), 405–413. 
Lucki, I. (1998). The spectrum of behaviors influenced by serotonin. Biological Psychiatry, 
44(3), 151–162. 
Madras, B. K., Miller, G. M., & Fischman, A. J. (2002). The dopamine transporter: relevance to 
attention deficit hyperactivity disorder (ADHD). Behavioural Brain Research, 130(1-2), 
57–63. 
Madras, B. K., Pristupa, Z. B., Niznik, H. B., Liang, A. Y., Blundell, P., Gonzalez, M. D., & 
Meltzer, P. C. (1996). Nitrogen-based drugs are not essential for blockade of monoamine 
transporters. Synapse , 24(4), 340–348. 
Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L., Saha, J. K., & Milius, R. A. 
(1989). Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-
fluorophenyl)tropane. Molecular Pharmacology, 36(4), 518–524. 
Mandell, D. J., Coutsias, E. A., & Kortemme, T. (2009). Sub-angstrom accuracy in protein loop 
reconstruction by robotics-inspired conformational sampling. Nature Methods, 6(8), 551–
552. 
Mattis, J., Tye, K. M., Ferenczi, E. A., Ramakrishnan, C., O’Shea, D. J., Prakash, R., … 
Deisseroth, K. (2012). Principles for applying optogenetic tools derived from direct 
comparative analysis of microbial opsins. Nature Methods, 9(2), 159–172. 
Mazei-Robison, M. S., Bowton, E., Holy, M., Schmudermaier, M., Freissmuth, M., Sitte, H. H., 
… Blakely, R. D. (2008). Anomalous dopamine release associated with a human dopamine 
transporter coding variant. The Journal of Neuroscience: The Official Journal of the Society 
for Neuroscience, 28(28), 7040–7046. 
 
!!196 
Mazei-Robison, M. S., Couch, R. S., Shelton, R. C., Stein, M. A., & Blakely, R. D. (2005). 
Sequence variation in the human dopamine transporter gene in children with attention 
deficit hyperactivity disorder. Neuropharmacology, 49(6), 724–736. 
McElvain, J. S., & Schenk, J. O. (1992). A multisubstrate mechanism of striatal dopamine uptake 
and its inhibition by cocaine. Biochemical Pharmacology, 43(10), 2189–2199. 
Meiergerd, S. M., Patterson, T. A., & Schenk, J. O. (1993). D2 receptors may modulate the 
function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and 
in vivo. Journal of Neurochemistry, 61(2), 764–767. 
Meiler, J., & Baker, D. (2006). ROSETTALIGAND: Protein--small molecule docking with full 
side-chain flexibility. Proteins: Structure, Function, and Bioinformatics, 65(3), 538–548. 
Meltzer, P. C., Liang, A. Y., Blundell, P., Gonzalez, M. D., Chen, Z., George, C., & Madras, B. 
K. (1997). 2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: Potent Non-Nitrogen 
Inhibitors of Monoamine Transporters †. Journal of Medicinal Chemistry, 40(17), 2661–
2673. 
Merchant, B. A., & Madura, J. D. (2012). Insights from molecular dynamics: The binding site of 
cocaine in the dopamine transporter and permeation pathways of substrates in the leucine 
and dopamine transporters. Journal of Molecular Graphics & Modelling, 38, 1–12. 
Miller, K. J., & Hoffman, B. J. (1994). Adenosine A3 receptors regulate serotonin transport via 
nitric oxide and cGMP. The Journal of Biological Chemistry, 269(44), 27351–27356. 
Miranda, M., Wu, C. C., Sorkina, T., Korstjens, D. R., & Sorkin, A. (2005). Enhanced 
ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein 
kinase C. The Journal of Biological Chemistry, 280(42), 35617–35624. 
Missale, C., Castelletti, L., Govoni, S., Spano, P. F., Trabucchi, M., & Hanbauer, I. (1985). 
Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens. Journal 
of Neurochemistry, 45(1), 51–56. 
Mitchell, P. (1957). A general theory of membrane transport from studies of bacteria. Nature, 
180(4577), 134–136. 
Mitchell, P. (1990). Osmochemistry of solute translocation. Research in Microbiology, 141(3), 
286–289. 
Moore, R. Y., Halaris, A. E., & Jones, B. E. (1978). Serotonin neurons of the midbrain raphe: 
ascending projections. The Journal of Comparative Neurology, 180(3), 417–438. 
Morón, J. A., Zakharova, I., Ferrer, J. V., Merrill, G. A., Hope, B., Lafer, E. M., … Shippenberg, 
T. S. (2003). Mitogen-activated protein kinase regulates dopamine transporter surface 
expression and dopamine transport capacity. The Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience, 23(24), 8480–8488. 
Mortensen, O. V., & Amara, S. G. (2003). Dynamic regulation of the dopamine transporter. 
European Journal of Pharmacology, 479(1-3), 159–170. 
!!197 
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016). The serotonin system in 
autism spectrum disorder: From biomarker to animal models. Neuroscience, 321, 24–41. 
Mundorf, M. L., Troyer, K. P., Hochstetler, S. E., Near, J. A., & Wightman, R. M. (2000). 
Vesicular Ca(2+) participates in the catalysis of exocytosis. The Journal of Biological 
Chemistry, 275(13), 9136–9142. 
Murphy, D. L., Wichems, C., Andrews, A. M., Li, Q., Hamer, D., & Greenberg, B. D. (1999). 
CONSEQUENCES OF ENGINEERED AND SPONTANEOUS GENETIC 
ALTERATIONS OF THE 5-HT TRANSPORTER IN MICE, MEN, AND WOMEN. 
Behavioural Pharmacology, 10, S65. 
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000). The human serotonin transporter gene 
linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Molecular Psychiatry, 
5(1), 32–38. 
Navaroli, D. M., Bellvé, K. D., Standley, C., Lifshitz, L. M., Cardia, J., Lambright, D., … 
Corvera, S. (2012). Rabenosyn-5 defines the fate of the transferrin receptor following 
clathrin-mediated endocytosis. Proceedings of the National Academy of Sciences of the 
United States of America, 109(8), E471–80. 
Nemeroff, C. B., & Owens, M. J. (2002). Treatment of mood disorders. Nature Neuroscience, 5 
Suppl, 1068–1070. 
Neubauer, H. A., Hansen, C. G., & Wiborg, O. (2006). Dissection of an allosteric mechanism on 
the serotonin transporter: a cross-species study. Molecular Pharmacology, 69(4), 1242–
1250. 
Newman, A. H., Allen, A. C., Izenwasser, S., & Katz, J. L. (1994). Novel 3 alpha-
(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like 
behavioral profiles. Journal of Medicinal Chemistry, 37(15), 2258–2261. 
Newman, A. H., & Katz, J. L. (2008). Atypical Dopamine Uptake Inhibitors that Provide Clues 
About Cocaine’s Mechanism at the Dopamine Transporter. In Transporters as Targets for 
Drugs (pp. 95–129). Springer Berlin Heidelberg. 
Newman, A. H., Kline, R. H., Allen, A. C., Izenwasser, S., George, C., & Katz, J. L. (1995). 
Novel 4’-Substituted and 4',4''-Disubstituted 3.alpha.-(Diphenylmethoxy)tropane Analogs 
as Potent and Selective Dopamine Uptake Inhibitors. Journal of Medicinal Chemistry, 
38(20), 3933–3940. 
Newman, A. H., & Kulkarni, S. (2002). Probes for the dopamine transporter: New leads toward a 
cocaine-abuse therapeutic—A focus on analogues of benztropine and rimcazole. Medicinal 
Research Reviews, 22(5), 429–464. 
Nieoullon, A. (2002). Dopamine and the regulation of cognition and attention. Progress in 
Neurobiology, 67(1), 53–83. 
 
!!198 
Ni, W., & Watts, S. W. (2006). 5-hydroxytryptamine in the cardiovascular system: focus on the 
serotonin transporter (SERT). Clinical and Experimental Pharmacology & Physiology, 
33(7), 575–583. 
 Obejero-Paz, C. A., Bruening-Wright, A., Kramer, J., Hawryluk, P., Tatalovic, M., Dittrich, H. 
C., & Brown, A. M. (2015). Quantitative Profiling of the Effects of Vanoxerine on Human 
Cardiac Ion Channels and its Application to Cardiac Risk. Scientific Reports, 5, 17623. 
Oreland, L., & Hallman, J. (1989). Blood platelets as a peripheral marker for the central 
serotonin system. Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry, 43(sup20), 
43–51. 
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997). Neurotransmitter Receptor 
and Transporter Binding Profile of Antidepressants and Their Metabolites. The Journal of 
Pharmacology and Experimental Therapeutics, 283(3), 1305. 
Owens, M. J., & Nemeroff, C. B. (1994). Role of serotonin in the pathophysiology of depression: 
focus on the serotonin transporter. Clinical Chemistry, 40(2), 288–295. 
Ozaki, N., Goldman, D., Kaye, W. H., Plotnicov, K., Greenberg, B. D., Lappalainen, J., … 
Murphy, D. L. (2003). Serotonin transporter missense mutation associated with a complex 
neuropsychiatric phenotype. Molecular Psychiatry, 8(11), 933–936. 
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991). Expression Cloning of a Cocaine- and 
Antidepressant-Sensitive Human Noradrenaline Transporter. Nature, 350(6316), 350–354. 
Palmiter, R. D. (2008). Dopamine signaling in the dorsal striatum is essential for motivated 
behaviors: lessons from dopamine-deficient mice. Annals of the New York Academy of 
Sciences, 1129, 35–46. 
Parnas, M. L., Gaffaney, J. D., Zou, M. F., Lever, J. R., Newman, A. H., & Vaughan, R. A. 
(2008). Labeling of dopamine transporter transmembrane domain 1 with the tropane ligand 
N-[4-(4-azido-3-[125I]iodophenyl)butyl]-2beta-carbomethoxy-3beta-(4-
chlorophenyl)tropane implicates proximity of cocaine and substrate active sites. Molecular 
Pharmacology, 73(4), 1141–1150. 
Penmatsa, A., Wang, K. H., & Gouaux, E. (2013). X-ray structure of dopamine transporter 
elucidates antidepressant mechanism. Nature, 503(7474), 85–90. 
Penmatsa, A., Wang, K. H., & Gouaux, E. (2015). X-ray structures of Drosophila dopamine 
transporter in complex with nisoxetine and reboxetine. Nature Structural & Molecular 
Biology, 22(6), 506–508. 
Piccini, J. P., Pritchett, E. L. C., Davison, B. A., Cotter, G., Wiener, L. E., Koch, G., … Dittrich, 
H. C. (2016). Randomized, double-blind, placebo-controlled study to evaluate the safety 
and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent 
onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Heart Rhythm: The 
Official Journal of the Heart Rhythm Society. http://doi.org/10.1016/j.hrthm.2016.04.012 
 
!!199 
Piscitelli, C. L., & Gouaux, E. (2012). Insights into transport mechanism from LeuT engineered 
to transport tryptophan. The EMBO Journal, 31(1), 228–235. 
Piscitelli, C. L., Krishnamurthy, H., & Gouaux, E. (2010). Neurotransmitter/sodium symporter 
orthologue LeuT has a single high-affinity substrate site. Nature, 468(7327), 1129–1132. 
Plenge, P., Gether, U., & Rasmussen, S. G. (2007). Allosteric effects of R- and S-citalopram on 
the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. 
European Journal of Pharmacology, 567(1-2), 1–9. 
Plenge, P., Shi, L., Beuming, T., Te, J., Newman, A. H., Weinstein, H., … Loland, C. J. (2012). 
Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric 
binding of antidepressants to the serotonin transporter. The Journal of Biological Chemistry, 
287(47), 39316–39326. 
Pramod, A. B., Foster, J., Carvelli, L., & Henry, L. K. (2013). SLC6 transporters: structure, 
function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 
34(2-3), 197–219. 
Prasad, B. M., & Amara, S. G. (2001). The dopamine transporter in mesencephalic cultures is 
refractory to physiological changes in membrane voltage. The Journal of Neuroscience: The 
Official Journal of the Society for Neuroscience, 21(19), 7561–7567. 
Prasad, H. C., Steiner, J. A., Sutcliffe, J. S., & Blakely, R. D. (2009). Enhanced activity of 
human serotonin transporter variants associated with autism. Philosophical Transactions of 
the Royal Society of London. Series B, Biological Sciences, 364(1514), 163–173. 
Prasad, H. C., Zhu, C.-B., McCauley, J. L., Samuvel, D. J., Ramamoorthy, S., Shelton, R. C., … 
Blakely, R. D. (2005). Human serotonin transporter variants display altered sensitivity to 
protein kinase G and p38 mitogen-activated protein kinase. Proceedings of the National 
Academy of Sciences of the United States of America, 102(32), 11545–11550. 
Pristupa, Z. B., McConkey, F., Liu, F., Man, H. Y., Lee, F. J., Wang, Y. T., & Niznik, H. B. 
(1998). Protein kinase-mediated bidirectional trafficking and functional regulation of the 
human dopamine transporter. Synapse , 30(1), 79–87. 
Qian, Y., Melikian, H. E., Rye, D. B., Levey, A. I., & Blakely, R. D. (1995). Identification and 
characterization of antidepressant-sensitive serotonin transporter proteins using site-specific 
antibodies. The Journal of Neuroscience: The Official Journal of the Society for 
Neuroscience, 15(2), 1261–1274. 
QUACPAC (2011). OpenEye Scientific Software, Santa Fe, NM. 
Quick, M. W. (2003). Regulating the conducting states of a mammalian serotonin transporter. 
Neuron, 40(3), 537–549. 
Quick, M., Winther, A.-M. L., Shi, L., Nissen, P., Weinstein, H., & Javitch, J. A. (2009). 
Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT 
establishes an inhibitor-bound conformation. Proceedings of the National Academy of 
Sciences of the United States of America, 106(14), 5563–5568. 
!!200 
Quick, M., Yano, H., Goldberg, N. R., Duan, L., Beuming, T., Shi, L., … Javitch, J. A. (2006). 
State-dependent conformations of the translocation pathway in the tyrosine transporter 
Tyt1, a novel neurotransmitter: sodium symporter from Fusobacterium nucleatum. The 
Journal of Biological Chemistry, 281(36), 26444–26454. 
Ralph, R. J., Paulus, M. P., Fumagalli, F., Caron, M. G., & Geyer, M. A. (2001). Prepulse 
inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: 
differential effects of D1 and D2 receptor antagonists. The Journal of Neuroscience: The 
Official Journal of the Society for Neuroscience, 21(1), 305–313. 
Ramamoorthy, S., Bauman, A. L., Moore, K. R., Han, H., Yang-Feng, T., Chang, A. S., … 
Blakely, R. D. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: 
molecular cloning, expression, and chromosomal localization. Proceedings of the National 
Academy of Sciences of the United States of America, 90(6), 2542–2546. 
Ramamoorthy, S., Cool, D. R., Mahesh, V. B., Leibach, F. H., Melikian, H. E., Blakely, R. D., & 
Ganapathy, V. (1993). Regulation of the human serotonin transporter. Cholera toxin-
induced stimulation of serotonin uptake in human placental choriocarcinoma cells is 
accompanied by increased serotonin transporter mRNA levels and serotonin transporter-
specific ligand binding. The Journal of Biological Chemistry, 268(29), 21626–21631. 
Ramamoorthy, S., Giovanetti, E., Qian, Y., & Blakely, R. D. (1998). Phosphorylation and 
regulation of antidepressant-sensitive serotonin transporters. The Journal of Biological 
Chemistry, 273(4), 2458–2466. 
Ramamoorthy, S., Samuvel, D. J., Buck, E. R., Rudnick, G., & Jayanthi, L. D. (2007). 
Phosphorylation of threonine residue 276 is required for acute regulation of serotonin 
transporter by cyclic GMP. The Journal of Biological Chemistry, 282(16), 11639–11647. 
Ramamoorthy, S., Shippenberg, T. S., & Jayanthi, L. D. (2011). Regulation of monoamine 
transporters: Role of transporter phosphorylation. Pharmacology & Therapeutics, 129(2), 
220–238. 
Rao, A., Simmons, D., & Sorkin, A. (2011). Differential subcellular distribution of endosomal 
compartments and the dopamine transporter in dopaminergic neurons. Molecular and 
Cellular Neurosciences, 46(1), 148-158.  
Rasmussen, S. G. F., & Gether, U. (2005). Purification and fluorescent labeling of the human 
serotonin transporter. Biochemistry, 44(9), 3494–3505. 
Reith, M. E. A. (2002). Neurotransmitter transporters: structure, function, and regulation. 
Humana Press. 
Reith, M. E. A., Blough, B. E., Hong, W. C., Jones, K. T., Schmitt, K. C., Baumann, M. H., … 
Katz, J. L. (2015). Behavioral, biological, and chemical perspectives on atypical agents 
targeting the dopamine transporter. Drug and Alcohol Dependence, 147, 1–19. 
 
 
!!201 
Reith, M. E., Berfield, J. L., Wang, L. C., Ferrer, J. V., & Javitch, J. A. (2001). The uptake 
inhibitors cocaine and benztropine differentially alter the conformation of the human 
dopamine transporter. The Journal of Biological Chemistry, 276(31), 29012–29018. 
Retz, W., Freitag, C. M., Retz-Junginger, P., Wenzler, D., Schneider, M., Kissling, C., … Rösler, 
M. (2008). A functional serotonin transporter promoter gene polymorphism increases 
ADHD symptoms in delinquents: interaction with adverse childhood environment. 
Psychiatry Research, 158(2), 123–131. 
Rickhag, M., Owens, W. A., Winkler, M.-T., Strandfelt, K. N., Rathje, M., Sørensen, G., … 
Gether, U. (2013). Membrane-permeable C-terminal dopamine transporter peptides 
attenuate amphetamine-evoked dopamine release. The Journal of Biological Chemistry, 
288(38), 27534–27544. 
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987). Cocaine receptors on dopamine 
transporters are related to self-administration of cocaine. Science, 237(4819), 1219–1223. 
Robertson, D. (1999). The epidemic of orthostatic tachycardia and orthostatic intolerance. The 
American Journal of the Medical Sciences, 317(2), 75–77. 
Rothman, R. B. (1990). High affinity dopamine reuptake inhibitors as potential cocaine 
antagonists: a strategy for drug development. Life Sciences, 46(20), PL17–21. 
Rothman, R. B., & Baumann, M. H. (2003). Monoamine transporters and psychostimulant drugs. 
European Journal of Pharmacology, 479(1-3), 23–40. 
Rothman, R. B., Baumann, M. H., Prisinzano, T. E., & Newman, A. H. (2007). Dopamine 
transport inhibitors based on GBR12909 and benztropine as potential medications to treat 
cocaine addiction. Biochemical Pharmacology. http://doi.org/10.1016/j.bcp.2007.08.007 
Rothman, R. B., Baumann, M. H., Prisinzano, T. E., & Newman, A. H. (2008). Dopamine 
transport inhibitors based on GBR12909 and benztropine as potential medications to treat 
cocaine addiction. Biochemical Pharmacology, 75(1), 2–16. 
Rothman, R. B., Mele, A., Reid, A. A., Akunne, H. C., Greig, N., Thurkauf, A., … Pert, A. 
(1991). GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of 
dopamine. Pharmacology, Biochemistry, and Behavior, 40(2), 387–397. 
Rudnick, G. (1998). Bioenergetics of neurotransmitter transport. Journal of Bioenergetics and 
Biomembranes, 30(2), 173–185. 
Rudnick, G. (2006). Serotonin transporters--structure and function. The Journal of Membrane 
Biology, 213(2), 101–110. 
Rudnick, G., & Clark, J. (1993). From synapse to vesicle: the reuptake and storage of biogenic 
amine neurotransmitters. Biochimica et Biophysica Acta, 1144(3), 249–263. 
Rudnick, G., Krämer, R., Blakely, R. D., Murphy, D. L., & Verrey, F. (2013). The SLC6 
transporters: perspectives on structure, functions, regulation, and models for transporter 
dysfunction. Pflügers Archiv - European Journal of Physiology, 466(1), 25–42. 
!!202 
Runyon, S. P., & Carroll, F. I. (2008). Tropane-based dopamine transporter-uptake inhibitors. 
Trudell ML SI (ed) Dopamine Transporters, Chemistry, Biology, and Pharmacology. Wiley, 
New York, 125–170. 
Saha, K., Sambo, D., Richardson, B. D., Lin, L. M., Butler, B., Villarroel, L., & Khoshbouei, H. 
(2014). Intracellular methamphetamine prevents the dopamine-induced enhancement of 
neuronal firing. The Journal of Biological Chemistry, 289(32), 22246–22257. 
Sakrikar, D., Mazei-Robison, M. S., Mergy, M. A., Richtand, N. W., Han, Q., Hamilton, P. J., … 
Blakely, R. D. (2012). Attention deficit/hyperactivity disorder-derived coding variation in 
the dopamine transporter disrupts microdomain targeting and trafficking regulation. The 
Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(16), 
5385–5397. 
Sánchez, C., & Hyttel, J. (1999). Comparison of the effects of antidepressants and their 
metabolites on reuptake of biogenic amines and on receptor binding. Cellular and 
Molecular Neurobiology, 19(4), 467–489. 
Sarker, S., Weissensteiner, R., Steiner, I., Sitte, H. H., Ecker, G. F., Freissmuth, M., & Sucic, S. 
(2010). The high-affinity binding site for tricyclic antidepressants resides in the outer 
vestibule of the serotonin transporter. Molecular Pharmacology, 78(6), 1026–1035. 
Sato, Y., Zhang, Y.-W., Androutsellis-Theotokis, A., & Rudnick, G. (2004). Analysis of 
transmembrane domain 2 of rat serotonin transporter by cysteine scanning mutagenesis. The 
Journal of Biological Chemistry, 279(22), 22926–22933. 
Saunders, C., Ferrer, J. V., Shi, L., Chen, J., Merrill, G., Lamb, M. E., … Galli, A. (2000). 
Amphetamine-induced loss of human dopamine transporter activity: an internalization-
dependent and cocaine-sensitive mechanism. Proceedings of the National Academy of 
Sciences of the United States of America, 97(12), 6850–6855. 
Schain, R. J., & Freedman, D. X. (1961). Studies on 5-hydroxyindole metabolism in autistic and 
other mentally retarded children. The Journal of Pediatrics, 58, 315–320. 
Schloss, P., & Henn, F. A. (2004). New insights into the mechanisms of antidepressant therapy. 
Pharmacology & Therapeutics, 102(1), 47–60. 
Schmitt, K. C., & Reith, M. E. A. (2010). Regulation of the dopamine transporter: aspects 
relevant to psychostimulant drugs of abuse. Annals of the New York Academy of Sciences, 
1187, 316–340. 
Schmitt, K. C., & Reith, M. E. A. (2011). The atypical stimulant and nootropic modafinil 
interacts with the dopamine transporter in a different manner than classical cocaine-like 
inhibitors. PloS One, 6(10), e25790. 
Schmitt, K. C., Rothman, R. B., & Reith, M. E. A. (2013). Nonclassical pharmacology of the 
dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. The 
Journal of Pharmacology and Experimental Therapeutics, 346(1), 2–10. 
 
!!203 
Schmitt, K. C., Zhen, J., Kharkar, P., Mishra, M., Chen, N., Dutta, A. K., & Reith, M. E. A. 
(2008). Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-
type and mutant human dopamine transporters: molecular features that differentially 
determine antagonist-binding properties. Journal of Neurochemistry, 107(4), 928–940. 
Schultz, W. (2007). Multiple dopamine functions at different time courses. Annual Review of 
Neuroscience, 30, 259–288. 
Seeger, G., Schloss, P., & Schmidt, M. H. (2001). Functional polymorphism within the promotor 
of the serotonin transporter gene is associated with severe hyperkinetic disorders. Molecular 
Psychiatry, 6(2), 235–238. 
Sen, N., Shi, L., Beuming, T., Weinstein, H., & Javitch, J. A. (2005). A pincer-like configuration 
of TM2 in the human dopamine transporter is responsible for indirect effects on cocaine 
binding. Neuropharmacology, 49(6), 780–790. 
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007). Meta-analysis of serotonin 
transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin 
reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry, 12(3), 247–257. 
Shannon, J. R., Flattem, N. L., Jordan, J., Jacob, G., Black, B. K., Biaggioni, I., … Robertson, D. 
(2000). Clues to the origin of orthostatic intolerance: a genetic defect in the cocaine-and 
antidepressant sensitive norepinephrine transporter. The New England Journal of Medicine, 
342, 541–549. 
Shen, K., & Meyer, T. (1999). Dynamic control of CaMKII translocation and localization in 
hippocampal neurons by NMDA receptor stimulation. Science, 284(5411), 162–166. 
Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A., & Farid, R. (2006). Novel procedure for 
modeling ligand/receptor induced fit effects. Journal of Medicinal Chemistry, 49(2), 534–
553. 
Shih, J. C., Chen, K., & Ridd, M. J. (1998). Role of MAO A and B in neurotransmitter 
metabolism and behavior. Polish Journal of Pharmacology, 51(1), 25–29. 
Shi, L., Quick, M., Zhao, Y., Weinstein, H., & Javitch, J. A. (2008). The mechanism of a 
neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by 
substrate in a second binding site. Molecular Cell, 30(6), 667–677. 
Shimada, S., Kitayama, S., Lin, C. L., Patel, A., Nanthakumar, E., Gregor, P., … Uhl, G. (1991). 
Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. 
Science, 254(5031), 576–578. 
Singh, S. K. (2008). LeuT: a prokaryotic stepping stone on the way to a eukaryotic 
neurotransmitter transporter structure. Channels , 2(5), 380–389. 
Singh, S. K., Piscitelli, C. L., Yamashita, A., & Gouaux, E. (2008). A competitive inhibitor traps 
LeuT in an open-to-out conformation. Science , 322(5908), 1655–1661. 
 
!!204 
Singh, S. K., Yamashita, A., & Gouaux, E. (2007). Antidepressant binding site in a bacterial 
homologue of neurotransmitter transporters. Nature, 448(7156), 952–956. 
Sitte, H. H., Farhan, H., & Javitch, J. A. (2004). Sodium-dependent neurotransmitter 
transporters: oligomerization as a determinant of transporter function and trafficking. 
Molecular Interventions, 4(1), 38–47. 
Sitte, H. H., Huck, S., Reither, H., Boehm, S., Singer, E. A., & Pifl, C. (1998). Carrier-mediated 
release, transport rates, and charge transfer induced by amphetamine, tyramine, and 
dopamine in mammalian cells transfected with the human dopamine transporter. Journal of 
Neurochemistry, 71(3), 1289–1297. 
Sonders, M. S., Zhu, S. J., Zahniser, N. R., Kavanaugh, M. P., & Amara, S. G. (1997). Multiple 
ionic conductances of the human dopamine transporter: the actions of dopamine and 
psychostimulants. The Journal of Neuroscience: The Official Journal of the Society for 
Neuroscience, 17(3), 960–974. 
Sorkina, T., Doolen, S., Galperin, E., Zahniser, N. R., & Sorkin, A. (2003). Oligomerization of 
dopamine transporters visualized in living cells by fluorescence resonance energy transfer 
microscopy. The Journal of Biological Chemistry, 278(30), 28274–28283. 
Sorkina, T., Hoover, B. R., Zahniser, N. R., & Sorkin, A. (2005). Constitutive and protein kinase 
C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent 
mechanism. Traffic , 6(2), 157–170. 
Sorkina, T., Richards, T. L., Rao, A., Zahniser, N. R., & Sorkin, A. (2009). Negative Regulation 
of Dopamine Transporter Endocytosis by Membrane-Proximal N-Terminal Residues. The 
Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 29(5), 1361–
1374. 
Spielewoy, C., Roubert, C., Hamon, M., Nosten-Bertrand, M., Betancur, C., & Giros, B. (2000). 
Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter 
knockout mice. Behavioural Pharmacology, 11(3-4), 279–290. 
Stahl, S. M. (1998). Mechanism of action of serotonin selective reuptake inhibitors: Serotonin 
receptors and pathways mediate therapeutic effects and side effects. Journal of Affective 
Disorders, 51(3), 215–235. 
Stoops, W. W., Lile, J. A., Glaser, P. E. A., Hays, L. R., & Rush, C. R. (2012). Influence of acute 
bupropion pre-treatment on the effects of intranasal cocaine. Addiction , 107(6), 1140–1147. 
Subach, F. V., Patterson, G. H., Manley, S., Gillette, J. M., Lippincott-Schwartz, J., & 
Verkhusha, V. V. (2009). Photoactivatable mCherry for high-resolution two-color 
fluorescence microscopy. Nature Methods, 6(2), 153–159. 
Sulzer, D., Sonders, M. S., Poulsen, N. W., & Galli, A. (2005). Mechanisms of neurotransmitter 
release by amphetamines: a review. Progress in Neurobiology, 75(6), 406–433. 
 
!!205 
Sutcliffe, J. S., Delahanty, R. J., Prasad, H. C., McCauley, J. L., Han, Q., Jiang, L., … Blakely, 
R. D. (2005). Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers 
susceptibility to autism and rigid-compulsive behaviors. American Journal of Human 
Genetics, 77(2), 265–279. 
Tadevosyan-leyfer, O., Dowd, M., Mankoski, R., Winklosky, B., Putnam, S., McGrath, L., … 
Folstein, S. E. (2003). A Principal Components Analysis of the Autism Diagnostic 
Interview-Revised. Journal of the American Academy of Child and Adolescent Psychiatry, 
42(7), 864–872. 
Tanda, G., Li, S. M., Mereu, M., Thomas, A. M., Ebbs, A. L., Chun, L. E., … Katz, J. L. (2013). 
Relations between stimulation of mesolimbic dopamine and place conditioning in rats 
produced by cocaine or drugs that are tolerant to dopamine transporter conformational 
change. Psychopharmacology, 229(2), 307–321. 
Tanda, G., Newman, A. H., & Katz, J. L. (2009). Discovery of Drugs to Treat Cocaine 
Dependence: Behavioral and Neurochemical Effects of Atypical Dopamine Transport 
Inhibitors. In S.J. Enna and Michael Williams (Ed.), Advances in Pharmacology (Vol. 
Volume 57, pp. 253–289). Academic Press. 
Tang, W., Kang, J., Wu, X., Rampe, D., Wang, L., Shen, H., … Garyantes, T. (2001). 
Development and evaluation of high throughput functional assay methods for HERG 
potassium channel. Journal of Biomolecular Screening, 6(5), 325–331. 
Tarnok, Z., Ronai, Z., Gervai, J., Kereszturi, E., Gadoros, J., Sasvari-Szekely, M., & Nemoda, Z. 
(2007). Dopaminergic candidate genes in Tourette syndrome: Association between tic 
severity and 3′ UTR polymorphism of the dopamine transporter gene. American Journal of 
Medical Genetics, 144B(7), 900–905. 
Tate, C. G., Haase, J., Baker, C., Boorsma, M., Magnani, F., Vallis, Y., & Williams, D. C. 
(2003). Comparison of seven different heterologous protein expression systems for the 
production of the serotonin transporter. Biochimica et Biophysica Acta, 1610(1), 141–153. 
Tavoulari, S., Margheritis, E., Nagarajan, A., DeWitt, D. C., Zhang, Y.-W., Rosado, E., … 
Rudnick, G. (2015). Two Na+ Sites Control Conformational Change in a Neurotransmitter 
Transporter Homolog. The Journal of Biological Chemistry, jbc.M115.692012. 
Tella, S. R. (1995). Effects of monoamine reuptake inhibitors on cocaine self-administration in 
rats. Pharmacology, Biochemistry, and Behavior, 51(4), 687–692. 
Thakur, G. A., Grizenko, N., Sengupta, S. M., Schmitz, N., & Joober, R. (2010). The 5-HTTLPR 
polymorphism of the serotonin transporter gene and short term behavioral response to 
methylphenidate in children with ADHD. BMC Psychiatry, 10, 50. 
Thapar, A., O’Donovan, M., & Owen, M. J. (2005). The genetics of attention deficit 
hyperactivity disorder. Human Molecular Genetics, 14 Spec No. 2, R275–82. 
 
 
!!206 
Thompson, B. J., Jessen, T., Henry, L. K., Field, J. R., Gamble, K. L., Gresch, P. J., … Blakely, 
R. D. (2011). Transgenic elimination of high-affinity antidepressant and cocaine sensitivity 
in the presynaptic serotonin transporter. Proceedings of the National Academy of Sciences, 
108(9), 3785–3790. 
Torres, G. E., & Amara, S. G. (2007). Glutamate and monoamine transporters: new visions of 
form and function. Current Opinion in Neurobiology, 17(3), 304–312. 
Torres, G. E., Gainetdinov, R. R., & Caron, M. G. (2003). Plasma membrane monoamine 
transporters: structure, regulation and function. Nature Reviews. Neuroscience, 4(1), 13–25. 
Uhl, G. R., & Lin, Z. (2003). The top 20 dopamine transporter mutants: structure–function 
relationships and cocaine actions. European Journal of Pharmacology, 479(1–3), 71–82. 
Ukairo, O. T., Bondi, C. D., Newman, A. H., Kulkarni, S. S., Kozikowski, A. P., Pan, S., & 
Surratt, C. K. (2005). Recognition of benztropine by the dopamine transporter (DAT) 
differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and 
mazindol as a function of a DAT transmembrane 1 aspartic acid residue. The Journal of 
Pharmacology and Experimental Therapeutics, 314(2), 575–583. 
Vaughan, R. A. (1995). Photoaffinity-labeled ligand binding domains on dopamine transporters 
identified by peptide mapping. Molecular Pharmacology, 47(5), 956–964. 
Vaughan, R. A., Agoston, G. E., Lever, J. R., & Newman, A. H. (1999). Differential binding of 
tropane-based photoaffinity ligands on the dopamine transporter. The Journal of 
Neuroscience: The Official Journal of the Society for Neuroscience, 19(2), 630–636. 
Vaughan, R. A., & Foster, J. D. (2013). Mechanisms of dopamine transporter regulation in 
normal and disease states. Trends in Pharmacological Sciences, 34(9), 489–496. 
Vaughan, R. A., Gaffaney, J. D., Lever, J. R., Reith, M. E., & Dutta, A. K. (2001). Dual 
incorporation of photoaffinity ligands on dopamine transporters implicates proximity of 
labeled domains. Molecular Pharmacology, 59(5), 1157–1164. 
Vaughan, R. A., & Kuhar, M. J. (1996). Dopamine transporter ligand binding domains. 
Structural and functional properties revealed by limited proteolysis. The Journal of 
Biological Chemistry, 271(35), 21672–21680. 
Vaughan, R. A., Sakrikar, D. S., Parnas, M. L., Adkins, S., Foster, J. D., Duval, R. A., … Hauck-
Newman, A. (2007). Localization of cocaine analog [125I]RTI 82 irreversible binding to 
transmembrane domain 6 of the dopamine transporter. The Journal of Biological Chemistry, 
282(12), 8915–8925. 
Vaughan, R. A., Uhl, G., & Kuhar, M. J. (1993). Recognition of dopamine transporters by 
antipeptide antibodies. Molecular and Cellular Neurosciences, 4(2), 209–215. 
Veenstra-VanderWeele, J., & Blakely, R. D. (2012). Networking in autism: leveraging genetic, 
biomarker and model system findings in the search for new treatments. 
Neuropsychopharmacology: Official Publication of the American College of 
Neuropsychopharmacology, 37(1), 196–212. 
!!207 
Veenstra-VanderWeele, J., Muller, C. L., Iwamoto, H., Sauer, J. E., Owens, W. A., Shah, C. R., 
… Blakely, R. D. (2012). Autism gene variant causes hyperserotonemia, serotonin receptor 
hypersensitivity, social impairment and repetitive behavior. Proceedings of the National 
Academy of Sciences of the United States of America, 109(14), 5469–5474. 
Velasquez, J. C., Goeden, N., Herod, S. M., & Bonnin, A. (2016). Maternal Pharmacokinetics 
and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy. ACS Chemical 
Neuroscience. http://doi.org/10.1021/acschemneuro.5b00287 
Velázquez-Sánchez, C., Ferragud, A., Murga, J., Cardá, M., & Canales, J. J. (2010). The high 
affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor 
stimulation and sensitization. European Neuropsychopharmacology: The Journal of the 
European College of Neuropsychopharmacology, 20(7), 501–508. 
Vernier, P., Moret, F., Callier, S., Snapyan, M., Wersinger, C., & Sidhu, A. (2004). The 
degeneration of dopamine neurons in Parkinson’s disease: insights from embryology and 
evolution of the mesostriatocortical system. Annals of the New York Academy of Sciences, 
1035, 231–249. 
Vocci, F. J., Acri, J., & Elkashef, A. (2005). Medication development for addictive disorders: the 
state of the science. The American Journal of Psychiatry, 162(8), 1432–1440. 
Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Ding, Y. S., Logan, J., … Lieberman, J. 
(1996). Relationship between psychostimulant-induced“ high” and dopamine transporter 
occupancy. Proceedings of the National Academy of Sciences, 93(19), 10388–10392. 
Vosburg, S. K., Hart, C. L., Haney, M., Rubin, E., & Foltin, R. W. (2010). Modafinil does not 
serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence, 106(2-3), 233–236. 
Wall, S. C., Innis, R. B., & Rudnick, G. (1993). Binding of the cocaine analog 2 beta-
carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: 
different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-
[125I]iodophenyl)tropane binding. Molecular Pharmacology, 43(2), 264–270. 
Wang, H., Elferich, J., & Gouaux, E. (2012). Structures of LeuT in bicelles define conformation 
and substrate binding in a membrane-like context. Nature Structural & Molecular Biology, 
19(2), 212–219. 
Wang, H., Goehring, A., Wang, K. H., Penmatsa, A., Ressler, R., & Gouaux, E. (2013). 
Structural basis for action by diverse antidepressants on biogenic amine transporters. 
Nature, 503(7474), 141–145. 
Wang, K. H., Penmatsa, A., & Gouaux, E. (2015). Neurotransmitter and psychostimulant 
recognition by the dopamine transporter. Nature, 521(7552), 322–327. 
Watanabe, A., Choe, S., Chaptal, V., Rosenberg, J. M., Wright, E. M., Grabe, M., & Abramson, 
J. (2010). The mechanism of sodium and substrate release from the binding pocket of 
vSGLT. Nature, 468(7326), 988–991. 
!!208 
Weiss, L. A., Abney, M., Cook, E. H., Jr, & Ober, C. (2005). Sex-specific genetic architecture of 
whole blood serotonin levels. American Journal of Human Genetics, 76(1), 33–41. 
Weiss, L. A., Veenstra-Vanderweele, J., Newman, D. L., Kim, S.-J., Dytch, H., McPeek, M. S., 
… Abney, M. (2004). Genome-wide association study identifies ITGB3 as a QTL for whole 
blood serotonin. European Journal of Human Genetics: EJHG, 12(11), 949–954. 
Wei, Y., Williams, J. M., Dipace, C., Sung, U., Javitch, J. A., Galli, A., & Saunders, C. (2007). 
Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a 
Ca2+/calmodulin-dependent kinase II-dependent mechanism. Molecular Pharmacology, 
71(3), 835–842. 
Wilbrandt, W., & Rosenberg, T. (1961). The concept of carrier transport and its corollaries in 
pharmacology. Pharmacological Reviews, 13, 109–183. 
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001). Dopaminergic 
role in stimulant-induced wakefulness. The Journal of Neuroscience: The Official Journal 
of the Society for Neuroscience, 21(5), 1787–1794. 
Wolters, J. P., & Hellstrom, W. J. G. (2006). Current concepts in ejaculatory dysfunction. 
Reviews in Urology, 8 Suppl 4, S18–25. 
Wong, D. T., & Bymaster, F. P. (1995). Development of antidepressant drugs. Fluoxetine 
(Prozac) and other selective serotonin uptake inhibitors. Advances in Experimental 
Medicine and Biology, 363, 77–95. 
Wong, D. T., & Bymaster, F. P. (2002). Dual serotonin and noradrenaline uptake inhibitor class 
of antidepressants potential for greater efficacy or just hype? Progress in Drug Research. 
Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques, 58, 
169–222. 
Wong, M.-L., & Licinio, J. (2001). Research and Treatment Approaches to Depression. Nature 
Reviews. Neuroscience, 2(5), 343–351. 
Woodward, J. J., Wilcox, R. E., Leslie, S. W., & Riffee, W. H. (1986). Dopamine uptake during 
fast-phase endogenous dopamine release from mouse striatal synaptosomes. Neuroscience 
Letters, 71(1), 106–112. 
Wu, X., & Gu, H. H. (2003). Cocaine affinity decreased by mutations of aromatic residue 
phenylalanine 105 in the transmembrane domain 2 of dopamine transporter. Molecular 
Pharmacology, 63(3), 653–658. 
Xu, F., Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Bohn, L. M., Miller, G. W., … Caron, 
M. G. (2000). Mice lacking the norepinephrine transporter are supersensitive to 
psychostimulants. Nature Neuroscience, 3(5), 465–471. 
Yamashita, A., Singh, S. K., Kawate, T., Jin, Y., & Gouaux, E. (2005). Crystal structure of a 
bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature, 
437(7056), 215–223. 
!!209 
Yubero-Lahoz, S., Robledo, P., Farré, M., & de laTorre, R. (2013). Platelet SERT as a peripheral 
biomarker of serotonergic neurotransmission in the central nervous system. Current 
Medicinal Chemistry, 20(11), 1382–1396. 
Zahniser, N. R., & Sorkin, A. (2004). Rapid regulation of the dopamine transporter: role in 
stimulant addiction? Neuropharmacology, 47 Suppl 1, 80–91. 
Zahniser, N. R., & Sorkin, A. (2009). Trafficking of dopamine transporters in psychostimulant 
actions. Seminars in Cell & Developmental Biology, 20(4), 411–417. 
Zdravkovic, I., Zhao, C., Lev, B., Cuervo, J. E., & Noskov, S. Y. (2012). Atomistic models of 
ion and solute transport by the sodium-dependent secondary active transporters. Biochimica 
et Biophysica Acta, 1818(2), 337–347. 
Zhan, C.-G., Deng, S.-X., Skiba, J. G., Hayes, B. A., Tschampel, S. M., Shields, G. C., & 
Landry, D. W. (2005). First-principle studies of intermolecular and intramolecular catalysis 
of protonated cocaine. Journal of Computational Chemistry, 26(10), 980–986. 
Zhang, F., Vierock, J., Yizhar, O., Fenno, L. E., Tsunoda, S., Kianianmomeni, A., … Deisseroth, 
K. (2011). The microbial opsin family of optogenetic tools. Cell, 147(7), 1446–1457. 
Zhang, Y.-W., Gesmonde, J., Ramamoorthy, S., & Rudnick, G. (2007). Serotonin transporter 
phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with 
obsessive compulsive disorder. The Journal of Neuroscience: The Official Journal of the 
Society for Neuroscience, 27(40), 10878–10886. 
Zhang, Y.-W., & Rudnick, G. (2006). The cytoplasmic substrate permeation pathway of 
serotonin transporter. The Journal of Biological Chemistry, 281(47), 36213–36220. 
Zhang, Y.-W., Turk, B. E., & Rudnick, G. (2016). Control of serotonin transporter 
phosphorylation by conformational state. Proceedings of the National Academy of Sciences 
of the United States of America. http://doi.org/10.1073/pnas.1603282113 
Zhao, C., Stolzenberg, S., Gracia, L., Weinstein, H., Noskov, S., & Shi, L. (2012). Ion-controlled 
conformational dynamics in the outward-open transition from an occluded state of LeuT. 
Biophysical Journal, 103(5), 878–888. 
Zhao, Y., Terry, D. S., Shi, L., Quick, M., Weinstein, H., Blanchard, S. C., & Javitch, J. A. 
(2011). Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter 
homologue. Nature, 474(7349), 109–113. 
Zhong, H., Hansen, K. B., Boyle, N. J., Han, K., Muske, G., Huang, X., … Sánchez, C. (2009). 
An allosteric binding site at the human serotonin transporter mediates the inhibition of 
escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL–SI/TT mutant. 
Neuroscience Letters, 462(3), 207–212. 
Zhou, Z., Zhen, J., Karpowich, N. K., Goetz, R. M., Law, C. J., Reith, M. E. A., & Wang, D.-N. 
(2007). LeuT-desipramine structure reveals how antidepressants block neurotransmitter 
reuptake. Science, 317(5843), 1390–1393. 
!!210 
Zhou, Z., Zhen, J., Karpowich, N. K., Law, C. J., Reith, M. E. A., & Wang, D.-N. (2009). 
Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. 
Nature Structural & Molecular Biology, 16(6), 652–657. 
Zhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006). The proinflammatory cytokines 
interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. 
Neuropsychopharmacology: Official Publication of the American College of 
Neuropsychopharmacology, 31(10), 2121–2131. 
Zhu, C.-B., Hewlett, W. A., Feoktistov, I., Biaggioni, I., & Blakely, R. D. (2004). Adenosine 
receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-
regulation of serotonin transporters involves both transporter trafficking and activation. 
Molecular Pharmacology, 65(6), 1462–1474. 
Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: a fast force field 
generation tool for small organic molecules. Journal of Computational Chemistry, 32(11), 
2359–2368. 
Zomot, E., Bendahan, A., Quick, M., Zhao, Y., Javitch, J. A., & Kanner, B. I. (2007). 
Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature, 
449(7163), 726–730. 
Zou, M. F., Kopajtic, T., Katz, J. L., Wirtz, S., Justice, J. B., Jr, & Newman, A. H. (2001). Novel 
tropane-based irreversible ligands for the dopamine transporter. Journal of Medicinal 
Chemistry, 44(25), 4453–4461. !
